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Sphingolipids (SL) are essential structural components of membranes found 
in all eukaryotes and have also been identified in some bacteria. The first step of the 
SL biosynthetic pathway across all species is catalysed by serine 
palmitoyltransferase (SPT), a member of the alpha-oxoamine synthase (AOS) family 
of pyridoxal 5’- phosphate (PLP)-dependent enzymes. AOS enzymes are involved in 
the biosynthesis of a range of important natural products such as heme, vitamins and 
antibiotics where they catalyse the reaction between amino acid and acyl-thioester 
substrates. Substrate specificity across the family is of great importance, as human 
mutant SPTs shift the substrate specificity from L-serine to glycine or L-alanine that 
lead to production of deoxy-sphingolipids that are toxic to mammalian cells. PLP, a 
form of vitamin B6, is one of nature’s most versatile catalysts and is involved in over 
160 enzymes that carry out diverse reactions on amine-containing substrates. This 
work probes the functional role of the phosphate group of PLP, usually housed in a 
phosphate binding cup (PBC) and investigates the need for a novel and unexpected 
H-bond between the hydroxyl group of the L-serine substrate and the 5’-phosphate 
group of PLP in SPT. In this study, the PLP cofactor was removed from SPT with 
amino-thiol substrates which act as mechanism-based inhibitors of SPT via 
production of a thiazolidine adduct. Replacement of natural PLP with the 
dephosphorylated form of the cofactor, pyridoxal, allowed a study on the importance 
of the PLP phosphate:L-serine H-bond on substrate specificity and optimal SPT 
activity. Furthermore, analysis of the phosphate binding cup of the 
ALAS:PLP:glycine external aldimine, a related AOS family member; revealed an 
important residue that could possibly be involved in determining substrate specificity 
of different members of the AOS family. PBC analysis also expanded, with a 
detailed and interesting study of a novel SPT:PLP:myriocin inhibitor complex. 
Human SPT is a heterodimeric, membrane-bound enzyme composed of two 
subunits (hLCB1/hLCB2) which is thought to contain a single PLP-containing active 
site. Mutations in human hLCB1 have been linked to the rare sphingolipid metabolic 
disease hereditary sensory neuropathy I (HSAN1). Recent studies identified three 
heterozygous missense mutations in the second human SPT subunit hLCB2 that 
 
ii 
show a significant loss in SPT activity. The three human SPT mutations V359M, 
G385V and I504F were mapped onto the bacterial S. paucimobilis SPT as V246M, 
G268V and G385F. These bacterial SPT mutant mimics reveal that the amino acid 
changes have varying impacts; they perturb the PLP cofactor binding, reduce the 
affinity for both substrates, decrease the enzyme activity, and, in the most severe 
case, cause the protein to be expressed in an insoluble form. 
SPTs and most of the other members of the AOS family utilise an acyl-CoA 
thioester substrate. In contrast, a sphingolipid-producing bacterium, S. wittichii, is 
thought to use a small type II acyl carrier protein (ACP) to deliver the acyl chain to 
its homodimeric SPT target. Converting the unmodified apo-ACP to the activated 
“substrate” acyl-ACP, has proven difficult and amino acid sequence alignment, 
combined with modelling studies revealed an unusual tryptophan residue that could 
prevent modification to the acyl-ACP form. In this study a double mutant ACP 
E36G/W37A has been prepared and characterised. Both wild-type and mutant S. 
wittichii ACP are expressed in the recombinant E. coli host in their inactive apo-
form. The transfer of a phosphopantethiene (4’PP) linker by a specific PPTase (also 
known as an acyl carrier protein synthase (AcpS)) has been successful in modifying 
the mutant form of ACP to its holo-form but could not transfer a palmitoyl group 
(C16).  
E.coli ACP has been successfully expressed, purified and characterised in this 
study. For the first time, ion mobility mass spectromerty (IM-MS) has been used on 
this protein to gain structural insight into the different forms of ACP. Collisional 
cross section (CCS) distributions have been calculated for different acylated states of 
the ACP concluding that the protein exists in equilibrium between two states: a 
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1.1 Introducing Sphingolipids  
1.1.1 Structural and Functional Diversity of Sphingolipids 
Lipids are a large and diverse group of naturally occurring organic compounds 
catalogued into eight categories based on the LIPID MAPS classification system
1
. 
Sphingolipids (SLs) are one of the eight classes regarded as a family of 
phospholipids and glycolipids found in almost all eukaryotes and some prokaryotes 
and viruses
2
. They were first isolated in crystallised ethanolic brain extracts in 1800’s 
by the German biochemist Johann Thudichum. SLs are distinguished from other 
lipids due to their chemical structure. Early pioneering work by Thudichum, 
followed by work from  Carter
3
 and co-workers has provided the basic long chain 
base (LCB) chemical structure upon which all SLs are created (Fig. 1.1). There are 
three major types of sphingoid bases, D-erythro-sphingosine, D-erythro-
dihydrosphingosine and phytosphingosine. The main LCB in mammals is 
sphingosine, whereas in fungi phytosphingosine is found. Sphingoid bases are 
connected to fatty acid chains through an N-acyl linkage to give the ceramide class 
of lipids (Fig. 1.1 (R)). This structure encompasses a wide array of 2-amino-1,3-
dihydroxyalkanes or –enes with (2S, 3R)-erythro stereochemistry and alkyl chain 




Figure 1.1: General structure of ceramide molecule. The D-erythro-sphingosine (2S, 3R) LCB 
skeleton is coloured purple, the fatty acid group is blue and the variable head group (R) is in 
red. 
 
The structural diversity of SLs can be altered with variations in sphingosine chain 
length, head group and the degree of saturation
5
. Variations at the 1-hydroxy position 
(Fig. 1.1 (R)) range in complexity from a simple H in ceramide to more complex 
phospho- and glycosphingolipids
2




are ceramide 1-phosphate (Cer1P), sphingomyelins (SM) and ceramide 
phosphoethanolamines (CerPE)
6
. The GSLs are divided into glucose ceramides and 
galactose ceramides
6
 and are discussed further in chapter 1.1.3.  
Such variations in the chemical structure of SLs allow them to play diverse 
roles in cellular metabolism
7
. SLs are important structural components for eukaryotic 
membranes, where they can be organised as small aggregates referred to as ‘lipid 
rafts’
8, 9
. These rafts are rich in ceramide, cholesterol and sphingomylelin and are 
involved in signalling, while changes in raft thickness and composition affects 
membrane transport
10
. Ceramide, sphingosine and sphingosine-1-phosphate (S1P) 
are the most important bioactive lipids. Simpler SLs such as sphingosine and its 
related sphingoid bases have been shown to be involved in regulating the cell cycle 
and apoptosis
11
. SLs and ceramides also mediate the cell-stress response such as the 
regulation of apoptosis
12
 and cell senescence
13
. The phosphorylated LCB, S1P is an 
important mediator in cell signalling, playing crucial roles in cell survival, 
inflammation and cell migration
14
. Accumulating evidence suggests that alterations 
in SLs and their metabolizing enzymes are linked to many cancers. For example, 







1.1.2 The de novo Sphingolipid Biosynthetic Pathway 
Following the preliminary theory that serine and palmitic acid possibly act as 





 to discover that the SL biosynthetic pathway originates with the “claisen” 
condensation of palmitoyl-CoA and L-serine to form 3-keto-dihydrosphingosine 
(KDS). This rate limiting step is catalysed by the pyridoxal-5’-phosphate (PLP)-
dependent enzyme serine palmitoyltransferase (SPT) (Fig. 1.2). Despite SL diversity 
in all organisms, SPT is responsible for the initial step of ubiquitous synthesis in all 
SL biosynthetic pathways. KDS is subsequently reduced to form dihydrosphingosine 
(DHS) by 3-keto-dihydrosphingosine reductase (KDSR) and at this stage the 
eukaryotic pathways diverge. This is a complex, multi-enzyme pathway each with 
multiple isoforms. The initial steps of SL biosynthesis are carried out in the 
endoplasmic reticulum (ER) and the further metabolism of ceramide to 
sphingomyelin and more complex GSLs takes place in the Golgi apparatus
18
 , thus 
producing a complex library of structurally essential lipids which collectively have 
been termed the “sphingolipidome”
19
. Eukaryotic SL pathways (Fig. 1.2) have been 
comprehensively studied and most of the enzymes and intermediates of the 
mammalian and fungal pathway are known, however, insight into the bacterial 


























































1.1.3 Bacterial Glycosphingolipids 
Lipopolysaccharides (LPSs) were thought to be the major component of the 
outer membrane of Gram negative bacteria. Unexpectedly, some gram negative 
bacteria named “Sphingomonads” were proven to have membranes that lack 3-
hydroxy fatty acids and instead are composed of GSLs. The chemical structure of 
GSLs isolated from Sphingomonas paucimobilis was first elucidated by Kawahara
20
 
in 1991. They contained three dihydrosphingosines, a ceramide portion shown to be 
2-hydroxy-myristic acid and two types of glycolipid moiety: GSL-1 common to all 
sphingomonas bacteria and GSL-4A
20, 21
. GSL-1 contains only glucuronic acid 
(GlcA), whereas GSL-4A is composed of mannose (Man), galactose (Gal), 
glucosamine (GlcN) and glucuronic acid (GlcA) (Fig. 1.3). More recently, the GSLs 
from Sphingomonas wittichii have been determined
22
 to have two 
dihydrosphingosines and the fatty acid portion contains myristic acid or 2-hydroxy-
myristic acid. As well as containing GSL-1, S. wittichii also contains GSL-1’ which 
is composed of galacturonic acid (GalA) (Fig. 1.3). 
 




However, variations in SL composition are observed between bacterial species. In 
contrast to S. paucimobilis and S. wittichii, Porphyromonas gingivalis is a dental 
pathogen that is composed of very unusual isobranched sphinganine bases
23
. Since S. 
paucimobilis and S. wittichii are SL producing organisms, investigation of their 
genomes reveals they encode an SPT homolog. An important breakthrough was the 





1.2 Serine Palmitoyltransferase (SPT) 
The wide variety of SL-containing organisms that encode a gene for SPT 
accentuates the ubiquitous nature of the enzyme which has been extensively 
reviewed
25
. In all pathways SPT catalyses the first and rate limiting condensation of 










1.2.1 Eukaryotic SPT 
Eukaryotic SPT is a membrane-bound enzyme which contains two core 
subunits, LCB1 and LCB2 in yeast
26-28
 and SPTLC1 and SPTLC2/3 in mammals
29-31
. 
For clarity we have adopted the nomenclature hLCB1, hLCB2a/b for the human 
subunits
32
. The hLCB1 and hLCB2 subunits display relatively high sequence 
homology to each other, but a comparison with other PLP-binding enzymes revealed 
that only the hLCB2a contains key catalytic residues including the lysine that binds 
PLP
33, 34
 (Fig. 1.5).  
 
 
Figure 1.5: Sequence alignment of several different SPTs. Human SPT, hLCB2a, (O15270), 
yeast SPT, yLCB2 (P40970), viral, vSPT (AET42601.1) and bacterial, bSPT (Q93UV0). The 
highly conserved active site lysine is annotated in yellow and the strictly conserved residues 
involved in PLP binding are annotated in pink. Other highly conserved residues are 
annotated in cyan. The sequence alignment was prepared using CLUSTALW2.  
 
In contrast, hLCB1 lacks these residues but contains other residues predicted to 
be involved in catalysis, leading to the working hypothesis that the hLCB1/hLCB2a 
heterodimer has a single active site. Hornemann and colleagues suggested that the 
eukaryotic SPT may in fact be a higher order complex
35
 and indeed recent results 
lend weight to that hypothesis. Also, the same group recently identified a second 
hLCB2 isoform, hLCB2b, also known as SPTLC3 with 68% sequence identity to 
hLCB2a that is predominantly expressed in the placenta and prefers shorter chain 
acyl-CoAs (C12 and C14) to generate short chain SLs
36




identified two highly-related isoforms of a third “small subunit” in humans (ssSPTa 
and ssSPTb) which were shown to be crucial for maximal enzyme activity
32
. These 
are functionally orthologous to a previously characterised small subunit (Tsc3p) 
discovered in yeast
37
. These ssSPTs can increase the catalytic activity of the 
hLCB1/hLCB2 complex up to 100 fold, and also influence the chain length 
specificity of the acyl-CoA substrate, and, thus, impact directly on the concentrations 
and chemical nature of the SL pool. This complexity was further increased by the 
recent discovery of other components of a so-called SPOTS complex in yeast that is 
composed of LCB1/LCB2/Tsc3p, an ORM protein(s), and a phosphoinositide 
phosphatase, Sac1
38, 39
. These ORM and Sac1 components are thought to play a role 





1.2.2 Viral SPT 
A group of marine viruses of the genus Coccolithovirus have shown to infect 
the marine algae Emiliania huxleyi which play important roles in controlling the 
carbon cycle and are responsible for large algal blooms. Over five years ago, the 
genome of this viral genus was sequenced
43
. This was shown to contain a cluster of 
sphingolipid biosynthetic genes, possibly suggesting that sphingolipids could play a 
role in controlling algal blooms that have also been proposed to influence global 
climate
43
. Within the sphingolipid gene cluster, the single open reading frame (ORF) 
ehv050 was shown to have a similar sequence to both subunits (LCB 1 and LCB2) of 
the eukoryotic-like SPT (Fig. 1.5). The ehv050 gene was expressed and characterized 
in Saccharomyces cerevisiae by Dunn and colleagues and demonstrated that the 
encoded protein was indeed a functional endoplasmic reticulum-localized SPT
43
. In 
contrast to eukaryotic-SPT, the novel single chain viral SPT domains are linked 
together as a “fusion” (Fig. 1.6). The C-terminal domain is correlated to the LCB1 
subunit and the N-terminal domain is correlated to the LCB2 C-terminal domain 
(Fig. 1.6) and lacks the N-terminal membrane binding domain observed in the human 
and yeast enzymes. Interestingly, viral SPT was shown to differ from eukaryotic SPT 








Figure 1.6: Subunit composition of SPT isozymes. 
 
1.2.3 Bacterial SPT 
Unlike eukaryotic SPT which is membrane associated adding severe technical 
difficulties when studying this enzyme, bacterial SPTs from S. paucimobilis and S. 
wittchii are water soluble homodimeric enzymes
24, 44
. Both bacterial SPTs are used as 
a focus of this study due to the vast amount of information on both enzymes already 
available. The X-ray crystal structures and catalytic mechanisms of SPT from S. 
paucimobilis and S. wittichii have been published in a collaborative project between 
the Campopiano (Edinburgh) and Naismith (St. Andrews) groups
44-46
. Ikushiro and 
co-workers have isolated and purified bacterial SPTs from Sphingobacterium 
multivorum, Sphingobacterium spiritivorum and Bdellovibrio stolpii
47
. A putative 
SPT gene has also been identified in the gut-dwelling bacterium Bacteroides 
fragilis
48
 and studies in our laboratory confirm the purified recombinant version of 
this enzyme has SPT activity (Campopiano, unpublished). Bacterial SPT display 




therefore knowledge gained from bacterial SPTs sheds some light on the more 
complex mammalian systems. 
 
1.2.4 Substrate Selectivity of SPT 
Mammalian SPT has high selectivity for palmitoyl-CoA in vitro
49, 50
 and 
displays a stronger preference for odd chain pentadacanoyl (C15) and heptadecanoyl 
(C17) CoAs over even chain myristoyl (C14) and stearoyl (C18) CoA’s. Amino acid 
substrate specificity of SPT is also restricted to L-serine. Different amino-acid 
substrates were tested by monitoring the formation of the condensation product. 
Neither, L-alanine, L-serinamide, L-serinol or L-serine methyl ester were able to 
produce the condensation product, highlighting the requirement of the amino, 
carboxyl and hydroxyl groups of L-serine for substrate specificity of SPT
33
. The 
orientation of both the carboxyl and hydroxyl groups of serine is important. In 
contrast to L-serine acting as a substrate for SPT, D-serine has been shown to be an 
inhibitor
33
. More promiscuous amino acid selectivity would result in the formation of 
deoxysphingoid bases (deoxy-LCBs) from the condensation of L-alanine and glycine 
with palmitoyl-CoA. Indeed, such deoxy-SLs have been observed in human 
metabolic disease models, detailed in section 1.3. Bacterial SPT from S. paucimobilis 
also has acyl-CoA specificity for palmitoyl CoA but can also readily accept stearoyl 
and myristoyl
46
. Similar thioester substrate specificities are also seen in SPT from S. 




1.2.5 Crystal structures of SPT 
The first X-ray crystal structure of bacterial SPT from S. paucimobilis
45
 was 
solved in our group over 6 years ago and confirmed what we expected to observe 
after comparison against structures of related AOS enzymes
51, 52
; a homodimer 
consisting of three domains (N-terminal, central catalytic and C-terminal) and two 
active sites which lie at the dimer interface. Important residues involved in PLP 






Table 1.1:  Important PLP binding residues of Sp SPT. 
 
In 2009, the S. paucimobilis PLP:L-serine:external aldimine structure was solved
46
 
and has deepened our knowledge into the role of important residues for catalysis and 
intermediate stabilisation. This structure led to the possible hypothesis that the 
hydroxyl group of L-serine is needed to make a key hydrogen bond interaction with 
the phosphate group of PLP (Fig. 1.7-D) to allow for optimum SPT activity and has 
paved the way for the work detailed here. A comparison of the structures of the 
internal and external aldmine reveals that most of the key interactions between the 
enzyme and the PLP cofactor are unchanged. Figure 1.7-C and D highlights that in 
both the internal and external aldmine, His
234
 hydrogen bonds to the hydroxyl of 
PLP, Asp
231
 hydrogen bonds to the protonated nitrogen of the pyridine ring and 
Arg
390 
is a key active site residue. By forming the SPT:PLP:L-serine external 






 residue that has been displaced with L-serine adopts a different conformation, 
now making a hydrogen bond with the L-serine hydroxyl. His
159
 is still involved in 
π-stacking with the PLP ring as in the internal aldimine, but in the external aldimine 
also hydrogen bonds to the carboxylate group of L-serine (Fig. 1.7-D). Interestingly, 
Arg
378
 swings into the active site in the SPT:PLP:L-serine external aldimine structure 
to make a salt bridge with the carboxylate group of L-serine (Fig. 1.7).  
 
Figure 1.7: (A) residues involved in PLP binding of the Sp SPT internal aldimine. The Arg
378
 
residue is shown in the swung out conformation. (B) residues involved in PLP binding of the 
Sp SPT external aldimine. The Arg
378
 residue is shown in the swung in conformation. (C) 
structure of Sp SPT:PLP internal aldimine (PDB: 2JG2) created using using the PyMol 
Software
172
. (D) structure of the Sp SPT:PLP:L-serine external aldmine (PDB: 2W8J) created 




Expanding our knowledge, in 2010, the structure of SPT from S. wittichii
44
 was 
solved by our group. In the Sw SPT:PLP internal aldimine structure the residue  








similar to that observed in the Sp SPT:PLP internal aldimine structure. It is thought 
that this residue will therefore play the same role as in Sp SPT and swing into the 
active site upon L-serine substrate binding. Interestingly, in the Sw SPT structure two 









 in Sp SPT) appear to be too far away (3.2 and 3.1 Å respectively) to form 
interactions with the pyridine nitrogen of PLP (Fig. 1.8). These residues are 
conserved amongst all SPTs and AOS members and play a role in PLP stabilization 
in the active site (Table 1.1). Furthermore, the entrance to the active site situated at 
the ‘top’ of Sw SPT is wider than that of Sp SPT which could possibly suggest 
binding of bulkier substrates, possibly acyl-ACP instead of acyl-CoA thioesters. This 
is discussed further in chapter 3.5.  
 
Figure 1.8: Active site overlay of Sw SPT (2XDU) and Sp SPT (2JG2) showing only subtle 
differences. The black lettering and numbering represents Sp SPT and the red lettering and 
numbering represents Sw SPT. Sw SPT Asp
211 
is shown to be too far from the pyridine 
nitrogen of PLP to hydrogen bond as observed in Sp SPT with Asp
231
. This figure has been 
taken from reference 
44
. 
1.2.6 Inhibitors of SPT 
There are a few naturally occurring inhibitors (Fig. 1.9-A) of SPT and their 
inhibitory properties can be rationalized due to their high structural similarity to 
substrates or biosynthetic reaction intermediates. Despite the importance of both PLP 
enzymes and SPT in particular, only a small number of SPT-specific inhibitors have 
been discovered and their mode of inhibition well understood. The L-serine 
analogue, β-chloro-L-alanine (βCA) (Fig. 1.9-A) is a known “suicide” SPT inhibitor 
which irreversibly inactivates SPT by producing a PLP:βCA adduct
53, 54




at the PLP active site, βCA can also act as a broad spectrum PLP inhibitor. A study 
carried out by our group on inhibition of SPT by L-cycloserine (Fig. 1.9-A) revealed 
an exciting twist and surprise. Instead of forming an irreversible PLP:3-
hydroxyisoxazole adduct at the active site, as previously observed in other PLP-
dependent enzymes, incubation with SPT instead resulted in the formation of 
pyridoxamine 5'-phosphate (PMP) and a small aldehyde product, β-amino-
oxyacetaldehyde
55
 (Fig. 1.9-B). Myriocin (Fig. 1.9-A) is indisputably the best known 
SPT inhibitor and is widely used in SL research as a ‘blocker’ of the biosynthetic 
pathway. However, up until recently, very little has been made clear about its mode 
of action. Wadsworth et al.  revealed an unexpected and completely unprecedented 
enzyme-catalyzed myriocin degradation mechanism that generates a second species 
which acts as a suicide inhibitor of its enzyme target
56
. Myriocin first binds to the 
enzyme active site and is then broken down to generate a reactive long chain 
aldehyde which acts as a suicide inhibitor by covalently modifying the key active site 
lysine residue in all SPTs. Furthermore, this reactive aldehyde is structurally similar 
to the long chain aldehyde produced by sphingosine 1’-phosphate lyase (S1PL), 
which could suggest a possible feedback mechanism in the SL biosynthetic pathway, 
whereby hexadecenal, the end product, may regulate SL biosynthesis by inhibiting 
SPT. This is a starting point for future studies based around this encouraging and 
stimulating hypothesis.  
 
Figure 1.9: (A) Chemical structure of SPT inhibitors, β-Chloro-L-Alanine, Myriocin and L-





1.3 Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1) 
There are a few very rare gain-of-function SPT mutations that have been 
identified and their genetic lineage has been studied
57-61
. These mutations lead to 
hereditary sensory neuropathies (HSAN1) whose clinical outcomes include 
progressive distal sensory loss and severe ulcerations of the limbs. What causes the 
neuronal breakdown has been the subject of a long-standing and interesting debate. 
As well as having an impact on the basal SPT activity, a new hypothesis suggests 
that the SPT mutations associated with HSAN1 lead to an enzyme lacking exquisite 
substrate specificitcy for L-serine. Penno and colleagues discovered that tissue from 
HSAN1 patients contains high levels of L-alanine and glycine derived deoxy-SLs, 
that have shown to be toxic to HEK293 cells
60
. The HSAN1 locus was initially  
mapped to chromosome 9 (9q22.1-9q22.3)
62, 63
. Linkage analysis of patients/families 
with HSAN1 and the gene defects linked to these chromosomes led to the 
identification of disease-causing mutations in the hLCB1 subunits of SPT. Four 
missense mutations in the hLCB1 subunit associated with HSAN1 (C133W, C133Y, 
V144D, and G387A) were among the first to be identified (Table 1.2) and have 
shown to have a negative effect on the SPT enzyme and SL production
57, 58, 64, 65
. 
Patients with the hLCB1 C133W/C133Y mutations generate deoxy-SLs (1-deoxy 
and 1-deoxymethyl, Fig. 1.10) that are present in high concentrations compared to 
normal individuals.  
 
Figure 1.10: Deoxyshpingolipds formed by the condensation of palmitoyl-CoA and (A) L-




This was subsequently confirmed in mouse models of the disease
60, 66
. It is thought 
that these neurotoxic deoxy-SLs build up over time to such concentrations that they 
lead to nerve damage and breakdown. Since these deoxy-SLs cannot be 
phosphorylated (to sphingosine 1-phosphate, S1P), they cannot be degraded by the 
S1P lyase and accumulate in cells. Another mutation at residue Cys
133
 (C133R) was 




 The multisubunit, membrane-bound nature of the eukaryotic SPT has 
prevented a detailed structural and mechanistic analysis of the impact of the HSAN1 
causing mutations on the enzyme. To gain insight into and explore the molecular 
basis of the HSAN1 genotype we have used the S. paucimobilis (Sp) SPT isoform as 
a model system. Both cysteine mutations were previously engineered into the Sp SPT 
(as N100W and N100Y) in our group
46
. These mutations result in a compromised 
SPT enzyme, severely impacting PLP binding, reducing affinity for the L-serine 
substrate, and causing catastrophic effects on catalytic activity. More recently, two 
more hLCB1 mutations (S331F and A352V) were identified downstream of the 
previously characterised HSAN1 mutations. The S331F mutation is thought to be a 
result of spontaneous mutation, as it is not carried by the parents of the child who has 
the disease and resulted in symptoms far more severe than those associated with the 
more common HSAN1 mutations. Furthermore, a second mutation at amino acid 
position Ser
331
 (S331Y) is linked to a distinct syndrome phenotype
68, 69
 . 
Interestingly, for the first time, three different mutations (V359M, G382V, and 
I504F) were recently identified in the hLCB2a subunit by Rotthier et al.
70
. They 
found that each mutation lowered the activity of the hLCB1/hLCB2a heterodimer 








Mutant Sp SPT 
residue 
Location in  
Sp SPT 
Clinical features Ref 
hSPT1      
C133Y N100 Active site Sensory neuropathy, ulcer 
mutilations, lancinating pains. 
57, 58
 
C133W N100 Active site Sensory neuropathy, ulcer 
mutilations, lancinating pains. 
57, 58
 
C133R N100 Active site Sensory neuropathy 67 
V144D D121 Surface-exposed Sensory neuropathy, ulcer 
mutilations, lancinating pains. 
57
 
S331F H278 Surface-exposed Ulcerations, mental 
retardation, hypotonia, severe 
growth and mental retardation, 




S331Y H278 Surface-exposed As S331F  68 
A352V S308 Not-surface exposed Sensory neuropathy, ulcer 
mutilations, lancinating pains. 
61, 68
 
G387A E343 Surface-exposed Not disease associated. 71, 72 
hSPT2     













A182P T79 Not surface-exposed Sensory neuropathy 73 
Table 1.2: Overview of hLCB1 and hLCB2a mutations linked to HSAN1 and their related 








1.4  Pyridoxal 5’-Phosphate 
1.4.1 Background of vitamin B6  
Vitamin B6 is a generic term referring to three pyridine derived vitamers; 
pyridoxal (PL), pyridoxine (PN) and pyridoxamine (PM) and their 5’phosphorylated 
forms pyridoxal 5’-phosphate (PLP), pyridoxine 5’-phosphate (PNP) and 
pyridoxamine 5’-phosphate (PMP) (Fig. 1.11). These differ from each other in 
structure due to the chemical group present at the 4’ position. The importance of 
vitamin B6 was first demonstrated by Snell almost 60 years ago, producing an 
enzymatic transamination reaction by heating pyridoxal with several amino acids. 
Since then, PLP has been the subject of extensive research as it represents one of 
nature’s most versatile cofactor
74, 75
. The natural forms of vitamin B6 are precursors 
of the biologically activated compound PLP, which is a cofactor for over 160 





Figure 1.11: Structures of the six B6 vitamers with carbon atom numbering shown on the 
pyridoxal structure. 
 
The ubiquitous nature of PLP has received great interest as it is one of the few 
cofactors whose biosynthetic pathway has been extensively characterised. Although 




microorganisms are able to synthesise it de novo
78
. Two distinct pathways are 
known; the deoxyxylulose 5’-phosphate (DXP) dependent pathway and the D-ribose 
5-phosphate (R5P) pathway
79
. Both pathways contain highly conserved genes, but 
there are large differences in amino acid sequences with comparison of the encoded 
proteins, suggesting that both pathways diverged during evolution. The ‘DXP 
dependent pathway’ was the first to be discovered and even though it has been 
broadly studied its detail remains to be fully elucidated, requiring a total of seven 
enzymes (GapB, PdxB, PdxF (SerC), PdxA, DXS, PdxJ and PdxH) which has 
recently been reviewed by Begley et al.
80
. DXP is condensed with 3-hydroxy-1-
aminoacetone phosphate producing PNP, which is then oxidised to PLP by PdxH. 
The ‘R5P pathway’ or the ‘DXP-independent pathway’ uses Pdx1 and Pdx2, directly 
condensing glutamine and gluteraldehyde 3’-phosphate to form PLP. This pathway is 
more broadly circulated than the first discovered, being found in archaea, fungi, 
plants and most bacteria
78
. The crystal structures of many of the enzymes involved in 
the biosynthesis of vitamin B6 have aided in giving a broader understanding into the 
complexity of both pathways
81-88
. In contrast to bacteria, mammals obtain PLP from 
the three B6 vitamers, which are taken up from the environment and recycled in a 
“salvage pathway”. In the liver all B6 vitamers are phosphorylated by an ATP-
dependent pyridoxal kinase (PLK), which is hydrolysed by a non-specific alkaline 
phosphatase before being delivered to the tissue. A specific PLK targets PL and other 




1.4.2 The chemistry of PLP 
All enzymes that use PLP as a cofactor (with exception of glycogen 
phosphorylase) act upon amino acid substrates and share the same first common 
step– Schiff’s base exchange. The PLP cofactor is covalently bound to an active site 
lysine residue by forming a Schiff’s base (imine). This “internal aldimine” exists in 
two tautomeric forms; an enolimine when the oxygen is protonated and a 
ketoenamine when the imine nitrogen is protonated. An incoming amino acid 
substrate displaces the active site lysine residue via a transaldimination reaction 




aldimine is thought to occur via a geminal diamine intermediate
89
 (Fig. 1.12) 
analogous to that observed in serine-glyoxylate aminotransferase (SGAT). The 
external aldimine intermediate is the starting point for breaking one of the three 
bonds attached to the Cα of the amino acid external aldimine, resulting in diverse 
reactions such as transamination, decarboxylation, racemisation and replacement 
reactions. 
 
Figure 1.12: The typical structure of a PLP enzyme. The first step in the SPT mechanism is 
binding of amino acid substrate L-serine via a transaldimination reaction forming a germinal 
diamine intermediate. Displacement of the active site lysine residue forms the external 
aldimine. 
 
The diversity of PLP-catalysed reactions has been extensively reviewed
74, 75, 90, 91
. 
The reaction specificity is determined by the three possible “leaving groups” relative 
to the plane of the pyridine ring. It was proposed over 40 years ago by Dunathan
92
 
that the bond being broken must be in a plane perpendicular to the   orbitals of the 
PLP electron sink (Fig. 1.13-A) in order for the necessary orbital overlap to occur. 
PLP acts as an electron sink as it is extremely efficient at delocalizing, the excess 
electron density on the deprotonated α-carbon of the reaction intermediate The 
“Dunathan hypothesis” explains the steroelectronic control that the cofactor provides 
during PLP-dependent catalysis. The three conformations shown in Fig. 1.13-B 
would yield different types of reaction linked by rotation around Cα-N bond in 120° 
intervals: (I) activates Cα-H bond and leads to transamination, α,β- elimination, β,γ- 
elimination and β-decarboxylation. (II) leads to Cα-R bond cleavage and (III) leads 




specificity is enabled by the electron sink properties of the pyridine ring of PLP, 
stabilising the formation of a carbanion/quinonoid species (Fig. 1.14). Reaction 
diversity is due to the different routes to this important quinonoid species. In addition 
to the above described reactions, PLP has also been shown to participate in radical 
mediated reactions
93
,  function as an oxygen scavenger
94





Figure 1.13: (A) The Dunathan stereoelectronic hypothesis. The bond being broken must be 
in a plane perpendicular to the pyridoxal imine  -system. The p-orbital is aligned with the 
pyridine ring  -system for maximal overlap, lowering the energy of the transition state and 
increasing the rate of reaction. (B) The three possible conformations of the external aldimine 






Figure 1.14: Principle resonance forms obtained after external aldimine deprotonation. 
 
1.4.3 PLP Classification 
Dunathan and Voet proposed that all B6 enzymes arise from common 
ancestry
96
 however, sequence similarity between PLP-dependent enzymes were too 
removed to establish shared lineage. Owing to the wide variety and vast diversity of 
PLP-dependent enzyme-catalysed reactions, the first classification of PLP enzymes 
was suggested by Christian et al.
97
 in 1994. This initial classification divided the 
PLP-enzymes into three distinct classes: α, β and γ. Each class is distinguished from 
each other by their different regiospecificity and is therefore dependent upon the 
carbon atom that is involved in the chemistry. As the number of PLP enzyme 
structures in the database grew, a second classification was proposed by Goldsmith et 
al.
98
 a year later. This allowed the enzymes to be categorized into five fold-types, 
based upon their sequence and three-dimensional structure. This classification 
includes: the aspartate aminotransferase family (fold type I), the tryptophan synthase 
β family (fold type II), the alanine racemase family (fold type III), the D-amino acid 
aminotransferase family (fold type IV) and the glycogen phosphorylase family (fold 






The aspartate aminotransferase family (fold type I) 
The aspartate aminotransferase (AAT) super family is the largest of the five and the 
most structurally characterized and diverse. This family is further divided into six 
subclasses dependent on the structure of the N-terminal part of the protein, defined 
by Metha et al
99
. There is high structural conservation within this fold type and the 
three dimensional structure reveals them to be homodimers consisting of three 
domains, a short N-terminal domain, a central core and a C-terminal domain. The 
two active sites lie at the dimer interface and residues from both domains and 
subunits are involved in cofactor binding. The PLP moiety is attached covalently to a 
conserved lysine residue at the N-terminal of one helix and the phosphate group of 
PLP is anchored to the N-terminal of another helix. The aspartate aminotransferases 
catalyse the amino transfer between and amino acid and an oxo-acid substrate in two 
half-reactions. SPT is a member of this family. 
The tryptophan synthase β family (fold type II) 
This family are characterised by three different 3D structures: tryptophan synthase β, 
threonine deaminase and O-acetylserine sulfhydrylase. Tryptophan synthase forms a 
α2β2 tetramer where β contains the catalytically active PLP binding site and α is 
thought to be the regulatory domain. Threonine deaminase is a dimer of a dimer 
forming a α4 tetramer. It has one regulatory domain at the C-terminal and one PLP 
binding catalytic domain located at the N-terminal of the protein. Lastly, O-
acetylserine sulfhydrylase is a α2 dimer consisting of a PLP-binding domain but has 
no regulatory domain. The PLP cofactor is bound in the same orientation as the 
aspartate aminotransferases. 
The alanine racemase family (fold type III) 
This family is a group of homodimers in which each monomer contains two 
domains. These domains consist of an 8 stranded α/β barrel and a domain mainly 
consisting of β strands. Only one molecule of PLP is bound at the cleft between both 
domains via an active-site lysine residue situated at the C-terminal. The phosphate 




The D-amino acid aminotransferase family (fold type IV) 
Enzymes of this group consist of two identical subunits that form a catalytically 
active dimer and are similar to fold type I and II. This fold type contains two 
domains and the active site is located at the domain interface. Residues from both 
subunits make up the catalytic site. PLP is bound to the active site via an aldimine 
linkage to a lysine residue located at the C-terminal and the phosphate interacts with 
the N-terminus of the α helix of the same domain. 
 
The glycogen phosphorylase family (fold type V) 
This family of proteins differs from the other family members as the phosphate group 
of PLP participates in proton transfer instead of acting as an electrophilic catalyst. 
However, since PLP is used catalytically it can be included in the superfamily. These 
enzymes are multidomain proteins. PLP is bound at the C-terminal domain and the 
phosphate group of PLP binds at the N-terminal of the α helix that holds the active 










Figure 1.15: Crystal structure of members of different PLP-dependent enzyme fold types 
created using using the PyMol Software
172
. A: Fold-type I, serine palmitoyltransferase, 2JG2 
B: Fold type II, serine racemase, 3HMK. C: Fold-type III, alanine racemase, 2RJG. D: Fold-






1.4.4  The functional groups of PLP 
The PLP cofactor contains five functional groups of interest; aldehyde, 
hydroxyl, methyl, pyridine and phosphate (Fig. 1.16). The essentiality of the C4 
aldehyde group is well established throughout literature for ‘classic’ PLP dependent 
enzymes, forming an imine/Schiff base linkage with an active site lysine side chain 
on the enzyme. This has become the paradigm for all PLP-catalysed reactions (with 
the exception of glycogen phosphorylase). The C2 methyl of PLP is important for 
cofactor binding, having a spatial role in the interaction with the PLP binding site. 
Alterations at C2 lead more to changes in conformation rather than playing a 
catalytic role
100
. The significance of the electron sink properties of the protonated 
pyridine nitrogen is accepted throughout the field as being essential for stabilizing 
the negative charge that develops at Cα by delocalization through the π system of 
PLP. The reaction specificity of PLP, focussing on stereoelectronics, the protonation 
state of the external aldimine and the pyridine nitrogen on carbanion stabilisation 
have been discussed in reviews by Toney
101, 102
. Crystallography has shown that 
residue Asp
222 
in aspartate aminotransferase protonate the pyridine nitrogen in the 
internal aldimine form
103
. In contrast, the crystal structure of alanine racemase 
showed there to be no aspartate amino group in a location able to protonate the 
pyridine nitrogen of PLP
104
. Important work by Toney et al.
105
 has finally challenged 
the accepted dogma that all PLP dependent enzymes equally require the electron sink 
properties of the protonated pyridine nitrogen of PLP. The carbocyclic analogue of 
PLP, 1-deazapyridoxal 5’phosphate (deazaPLP) (Fig. 1.16) was synthesised in 7 
steps
106
 and used to replace the natural PLP cofactor in three different enzymes from 
three different fold types; aspartate aminotransferase (AAT), alanine racemase (AR) 








These enzymes belong to three different fold-types, therefore covering large 
variations in the environment of the pyridine nitrogen. AAT is in the same AOS fold 
type classification as SPT (fold type I) and carries out transamination reactions 
whereby the PLP nitrogen has to be in its protonated form. Changing the PLP 
nitrogen to a carbon resulted in a massive loss in activity and was shown to cause 
more disruptive impact on the enzyme than a mutation of the general base catalyst 
and active site lysine residue in AAT. Indeed, Toneys work demonstrates deazaPLP 
to be a poor substitute for the natural cofactor of this enzyme and thus, presumably 
for this fold-type. However, it was established that the protonated pyridine nitrogen 
was not essential to stabilise the carbanion formation of the PLP-substrate aldimine 
in AR and OASS. It should be considered that the protonation state of the PLP 
nitrogen should be expected to vary in different PLP dependent enzymes as the 
acidity of the side chain functional group interacting with it varies (Fig. 1.17). With 
this assumption the nitrogen is likely to be in a neutral state in AR and OASS. 
Indeed, racemisation with AR was still able to occur, albeit at a reduced rate. More 
significantly, β-elimination reactions of both AR and OASS displayed very good 
activity. These results have shed a new light on how we consider the functional 
groups of PLP to be equally important in different enzymes and in various reactions 
and indeed challenge the idea of the electron sink properties of the pyridine nitrogen 
being considered to be the “hallmark” of PLP catalyzed reaction. 
 
Figure 1.17: The protonation state of the pyridine nitrogen varying with acidity of the amino 
acid reidue interacting with it.  Aspartate aminotransferase is fully protonated with Asp
222
, 
whereas Alanine racemase and O-acetylserine sulfhyrylase are likey to maintain the nitrogen 








While the roles of the pyridine nitrogen and aldehyde group of PLP are well 
established, the role of the hydroxyl (C3) and phosphate group (C5) have been less 
well studied. The attention on the catalytic importance of the C3 hydroxyl of PLP 
was first studied in the 1950s by Snell using various C3 derivatives which which 
resuted in an inactive enzyme
107
. Following this, the electronics of PLP has been 
extensively studied with the current hypothesis that the C3 hydroxyl hydrogen is 
needed to bond to the imine nitrogen of PLP
108
. It is surprising that the literature 
conveys little work on probing the role of the phosphate group of PLP. The 
phosphate moiety acts as an anchor by making a number of interactions with residues 
from the enzyme which together makes up a ‘phosphate binding cup’ (PBC). The 
concept of this cup was proposed by Denesyuk et al. in 2002 after analysis of X-ray 
structures from five different fold types
109, 110
. Older studies established by Snell in 
1972 had looked at whether a sulphate at the 5’-position of pyridoxal could replace 
the phosphate
111
. Of the three enzymes tested, only arginine decarboxylase was 
active with this modified cofactor (23% activity compared with the PLP-containing 
enzyme) which initially emphasised an importance for the 5’phosphate in catalysis. 
However, effects of replacing the phosphate group seemed to show no general 
pattern from one enzyme to another. In contrast to ‘classic’ PLP dependent enzymes, 
modifying PLP in every position around the ring of glycogen phosphorylase have 
been extensively studied
112-114
. In contrast to other PLP-dependent enzymes, this 
homodimeric enzyme utilized the phosphate group on PLP to perform its reaction by 
donating a proton to an inorganic phosphate molecule. Further studies based on 
probing the important functional groups of the PLP cofactor in several enzymes has 






P NMR technique is 
useful, since it places a probe that can relay information on the chemistry of the 
cofactor in the active site. 
 
1.5 α-Oxoamine Synthase Family (AOS) 
1.5.1 Mechanism and Importance 
As well as being a member of the fold-type I family, SPT is also a member of 




the Claisen-like condensation reaction of an amino acid substrate with a thioester 
(Fig. 1.18). Each AOS enzyme member catalyses a unique transformation which is 
specific to the biosynthetic pathway in which it plays the key first step (Table. 1.2). 
However, at present the origin of substrate specificity for each enzyme is unclear. 
 
 
Figure 1.18: Claisen like condensation reaction carried out by AOS members, where R= 
varying amino acid side chain and R’=varying thioester chains. 
 
The AOS family is ever expanding with there currently being 12 members (Table. 
1.3). Along with SPT, other well characterised members include; 5-aminolevulinate 
synthase (ALAS), 8-amino-7-oxononanoate synthase (AONS), 2-amino-3-
ketobutyrate CoA ligase (KBL) and Cholerae CAI-1 synthase (CqsA) all with 
relatively high sequence homology (Fig. 1.19). SPT, AONS and ALAS all catalyse 
decarboxylation reactions of amino acids whereas KBL is unique, catalysing the 
condensation between an acyl-CoA thioester and an amino acid producing a 
carboxylated product. Both ALAS and AONS play fundamental roles in the 
biosynthesis of prosthetic groups essential for biochemical processes. 
5-aminolevulinic acid (ALA) is the universal precursor for the synthesis of 
tetrapyrroles such as heme (Figure 1.20-A) which is absolutely vital for oxygen 
transport. There are two distinct and unrelated PLP dependent pathways known for 
the synthesis of ALA; The ‘C5 pathway’ and the ‘Shemin pathway’
119
. The ‘C5 
pathway’ is found in plants, algae and bacteria and utilises the C5 of glutamate 
alongside two enzymes. In contrast the ‘Shemin pathway’ found in animals, fungi 
and some bacteria requires ALAS, providing the rate-limiting condensation of 
succinyl CoA and glycine, producing ALA, CoA and CO2
119, 120
. Biotin, (Figure 
1.20-B) also known as vitamin H or B7, is essential for all living organisms and is a 




AONS catalyses the first step of the biotin pathway from pimeloyl-CoA and 
L-alanine
51, 121, 122
. Pimeloyl-CoA is the common precursor in biotin biosynthesis, 





Figure 1.19: Sequence alignment of well characterised AOS members. Completely 
conserved residues are shown in green and residues involved in PLP binding and 











































KBL plays an essential role in the threonine degradation pathway. L-threonine is 
converted into L-2-amino-3-ketobutyrate which acts as a substrate for KBL, 
catalysing the conversion of 2-amino-3-ketobutyrate into glycine and acetyl-CoA in 
the presence of CoA. The sequence homology between E. coli and the human 
enzyme is 54%, emphasising the strong conservation of KBL during evolution
52
. 
CqsA is involved in the biosynthesis of the strongest autoinducer involved in 
quorum sensing by Vibrio cholera autoinducer-1 (CAI-1). Quorum sensing is a 
bacterial mechanism of cell-cell communication which results in the production, 
release and detection of signalling molecules called autoinducers,
123
 controlling 
biofilm production and virulence factors. Until recently, the substrates utilised by 
CqsA were unclear. The chemical structure of CAI-1 suggested decanoyl-CoA as a 
possible substrate and other hypothesised substrates included L-threonine and L-2-
aminobutyric acid
124
. However, recently it was reported that (S)-adenosylmethionine 
(SAM) and decanoyl-CoA are the in vivo substrates for CqsA
125
. The CqsA 
mechanism is unique by combining two enzymatic transformations, β,γ-elimination 
of SAM and an acyltransferase reaction
125
. 
More recently, the family has expanded with the addition of LqsA, PigH-
SerT, Fum8, SxtA, Orf34 and TamD. The CqsA homolog, LqsA from Legionella 
pneumophila is also involved in quorum sensing, producing a similar autoinducer 
LAI-1, however, the substrates are not clear at this moment
126
. The activity of both 
CqsA and LqsA was eliminated upon mutation of the conserved lysine residue 
needed for PLP binding, placing both enzymes in the AOS superfamily of PLP 
dependent enzymes. Most recently, a CqsA and LqsA homologue was identified in 
the Jathinobacterium HH01 genome annotated as JqsA producing the novel 
autoinducer JAI-1
127
. Studies have shown its involvement in the regulation and 
expression of violacein biosynthesis genes. The SerT domain of PigH (a 
multidomain NRPS-PKS protein) is involved in the prodigiosin biosynthetic 
pathway. Prodiginine (Fig. 1.20-C) class of natural products are a family of 
tripyrrole, red pigments produced by Serratia marcescens which are attracting 
increasing interest because of their immunosuppressive and anticancer activities. 




from L-proline and connected by a bipyrrole unit to ring B, which is derived from L-
serine. Ring C originates from glycine, and both rings B and C have methylene 
bridging
128
 (Fig. 1.20-D). SerT catalyses the condensation between L-serine and 
pyrrolyl-β-ketoacid-S-ACP forming 4-hydroxy-2,2’-bipyrrole-5-methanol (HBM)
129
. 
The functions of the first five proteins involved in the Seratia prodigiosin pathway 
are established
129
. Also involved in the synthesis of pyrrole intermediates, RedN
128
 is 
a PLP-dependent amino transferase which is part of the undecylprodigiosin 
biosynthetic pathway. Fum8 is involved in the fumonisin biosynthetic pathway in 
Filimentous verticillioides, catalysing the condensation of L-alanine and stearoyl-
ACP forming fumonisin intermediates. The mechanism involves release of the C18 
chain from stearoyl-ACP and incorporates two carbons and one amino group from L-




 from Lyngbya wollei was 
identified in the saxitoxin biosynthetic pathway. Saxitoxin (Fig. 1.20-E) and its 
derivative paralytic shellfish toxins (PST) are neurotoxic alkaloids which bind and 
block sodium channels resulting in sever disruption of nerve channels. SxtA 
catalyses the reaction of propionyl-ACP with arginine initiated by a PKS, which 
performs a methylation of acetate and a Claisen condensation of arginine. The 5-
aminolevulinate synthase, ORF34
132
 from E. coli is a bifunctional enzyme which has 
just recently joined the AOS family. ORF34 catalyses the production of ALA by the 
condensation of succinyl-CoA and glycine. ALA is then transformed to ALA-CoA 
through an ALA-AMP intermediate by an acyl-CoA ligase, ORF35. ORF34 plays a 
duel role, then cyclizing ALA-CoA to 2-amino-3-hydroxycyclopent-2-enone 
polyketide (C5N). Lastly, the seryl transferase (TamD)
133
 from Pseudoalteromonas 
tunicata is involved in the biosynthesis of an antifungal and bioactive pyrollic 
compound, tambjamine (Fig. 1.20-F). TamD catalyses the reaction of malonyl-CoA 
with L-serine to produce a tambjamine derivitative that TamJ and TamP work on to 





Figure 1.20: Important condensation and natural products derived from AOS biosynthetic 
pathways. 
 
Two mechanisms were initially proposed for the formation of the PLP:amino 
acid carbanion equivalent carried out by the AOS family
49
; (A) decarboxylation of 
the substrate amino acid forming the PLP-stabilised carbanion followed by acylation 
(B) removal of the α-hydrogen atom of the substrate amino acid forming a carbanion 
followed by acylation and decarboxylation. The latter pathway was supported by 
studies showing the exchange of the α-hydrogen atom of the amino acid substrate in 
SPT, ALAS and AONS with deuterium (from D2O)
134-136
. Strong sequence 
homology amongst these AOS members therefore suggests a common general 
mechanism 
49, 122, 137, 138
 involving: displacement of the lysine-PLP internal aldimine 
by an incoming amino acid substrate to form the external aldimine; formation of the 
proposed ‘Dunathan intermediate’ by abstraction of the α-proton from the PLP-
amino acid external aldimine, formation of the substrate quinonoid/carbanion 
intermediate; a Claisen-like condensation with the fatty acid-CoA thioester substrate, 




intermediate; decarboxylation to form the product quinonoid; reprotonation of the 
product quinonoid to form the product external aldimine; regeneration of the PLP-





















































1.5.2 Structural insights into the AOS family 
The three-dimensional structures are available for five members of the AOS 
family (SPT, AONS, ALAS, KBL and CqsA) from various species. Each are 
homodimers and each monomer contains 3 domains (central catalytic domain, C-
terminal domain and a short N-terminal domain) and a unique and conserved PLP 
binding site (Fig. 1.22). Both PLP binding sites are located at the dimer interface and 
key residues are responsible for stabilisation of the PLP cofactor; lysine, histidine 
and aspartic acid, (Fig. 1.22-F). In each of these known structures, the pyridine ring 
of PLP is superimposable and the residues required for cofactor stabilisation are 
absolutely conserved. For brevity, S. paucimobilis SPT residue numbering is used 
when describing the above residues involved in stabilising PLP in the active site of 
the AOS family. His
159
 is located in a three residue motif that is conserved 






) and stacks directly above one 
face of the PLP ring. Studies based upon mutating His
159 
in Sp SPT indicated the 
absolute necessity of the residue for not only anchoring the amino acid substrate but 





is perfectly conserved within the AOS family; the 
carboxylic acid group of the aspartate forms a salt bridge with the protonated 
pyridine nitrogen of PLP aiding stabilisation
45, 51, 52, 140
. Mutating the essential lysine 
residue inhibits both PLP binding and activity of the enzyme, (Wadsworth, PhD 
Thesis 2014). The second histidine residue, His
234
 makes polar contact with the PLP 







































































































































































































































































































































1.6 Acyl Carrier Proteins (ACP) 
ACPs are small (~80 amino acids), acidic, dynamic and highly conserved 
globular proteins. They are integral components of the fatty acid synthases (FAS) 
which are divided into two major classes; in yeast and mammals ACPs exist as part 
of a large, multi-domain enzyme and are classified as type I and in bacteria they exist 
as distinct proteins, encoded by distinct genes, and are known as type II. ACPs are 
also involved in a large diversity of natural product biosynthesis, functioning in 
polyketide synthase (PKS) and non-ribosomal synthase (NRPS) systems. Although 
the role of the carrier protein in each of the three broad classes is the same, distinct 
modes of interaction are found in different systems
141
. The main role of the ACP in 
all three systems is to shuttle a growing acyl chain as a thioeseter between 
biosynthetic enzymes. ACPs are modified and activated by the covalent addition of a 
4’-phosphopantetheinyl (4’-PP) group to the hydroxyl group of a specific serine 
residue. This 4’-PP post-translational modification (PTM) is catalysed by a specific 
phosphopantetheinyl transferase enzyme (PPTase, also known as an ACP synthase, 
AcpS) and is derived from coenzymeA (CoA). This converts an ACP from its 
inactive apo from to its active holo form. 
 
1.6.1 Fatty Acid Synthase (FAS) 
1.6.1.1 Type I FAS 
De novo biosynthesis of FAs occurs via a conserved set of reactions that are 
essentially the same regardless of the organism, involving stepwise elongation of 
activated precursors by two-carbon units
142, 143
. Type I FAS systems are found in 
bacteria, fungi, and eukaryotes
144
. They consist of small catalytic domains that 
transfer acetyl and malonyl substrates from CoA. The active domains are covalently 
linked to make large multi-modular proteins 
[83]
 and include a β-ketosynthase (KS), 
acyl transferase (AT), dehydratase (DH), enoylreductase (ER), β-ketoreductase (KR), 
ACP and thioesterase (TE). The ACP domain is a crucial unit of the type I FAS and 
shuttles a growing acyl chain amongst the active sites of the other catalytic modules. 
The remarkable X-ray structure of the porcine type I FAS was solved by Maier et 
al.
143




observed with exception of the ACP and the TE domain, presumably due to their 
characteristic flexibility. The same group published the structure of fungal FAS
145
 
which was shown to be a multi-meric protein containing six reaction chambers. 
Again, similar to the mammalian FAS, the ACP domain could not be observed. 
Unlike the type II FAS, the ACP structures of the type I FAS are limited
142
 (Table. 
1.4). The structures of both rat
146
 and human ACP (in complex with AcpS)
147
 were 
solved as discrete proteins, detached from the large multifunctional construct it is 
usually part of. Interestingly, unlike type II FAS ACPs, the type I rat FAS ACP was 
shown not to sequester long hydrophobic chains from aqueous bulk solvent. The type 
I system is formed by a series of active sites that may partially shield the acyl chain 
from oxidation or hydrolysis, unlike in the type II FAS system where the chain is 
buried and protected inside the protein hydrophobic cavity. In contrast, the X-ray 
structure of yeast holo-ACP was determined and locked in position at the KS active 




1.6.1.2 Type II FAS 
Type II FAS systems are typically found in bacteria and are functionally 
analogous to the type I systems
144
, whereby the ACP shuttles the growing acyl chain 
among enzymes within the FAS complex. The discernible feature of the type II 
system is that each FAS component is an individual protein that is encoded by a 
discrete gene. The first ACP structure from E. coli was reported 25 years ago. Since 
then the conservation of the 3D-stucture of ACPs is becoming more apparent due to 
the number of solved NMR and X-ray crystal structures now available
142
 (Table. 
1.4). A highly conserved Asp-Ser-Leu (DSL) motif (Fig. 1.23) is consistent 
throughout various ACPs from different organisms where the 4’-PP prosthetic group 
derived from CoA (Fig. 1.24-B) is attached to the central serine residue. The 
secondary structural elements are all analogous, containing four major α-helices, 
namely, helix I, II and IV (Fig. 1.24-A). Helix I is the most flexible region and is 
anti-parallel to helix II. These are bridged by a long structured loop. Helix II is 




‘recognition’site that interacts with partner enzymes of the FAS complex. Helix III 
varies in orientation and is the shortest that links helix II and IV.  
 
 
Figure 1.23: Sequence alignment of several FAS ACPs; E.coli (YP_489362.1), P. 
aeruginosa (NP_251656.1), V. harveyi (2L0Q_A), B. subtilis (YP_005556718) and S. wittichii 
(YP_001264382). Highly conserved residues are annotated in yellow and the conserved 
‘DSL’ motif is annotated in cyan. The sequence alignment was prepared using CLUSTALW2. 
 
Figure 1.24: (A) ACP type II structure from E. coli (PDB: 2K92) created using using the 
PyMol Software
172






In 2002, the first acylated ACP structure was published
149
 showing the butyryl C4 
group buried within a flexible hydrophobic cavity inside the protein. The X-ray 
structure suggested that for longer acyl chains, only the reactive part of the acyl chain 
is buried within the ACP due to the limited size of the hydrophobic cavity. Five years 
later, the same group published the X-ray structures of hexanoyl (C6), heptanoyl 
(C7) and decanoyl (C10) ACP from E. coli 
150
. Interpretation of these structures 
reveals that the hydrophobic cavity can in fact expand to accommodate longer acyl 
chains without causing major changes to the protein fold. A model that places the 
acyl chain buried within a hydrophobic cavity poses the problem of how does the 
chain grow (by 2 carbons) during successive rounds of fatty acid biosynthesis? The 
proposed ‘switchblade’ model suggests that the acyl chain is flicked in and out of the 
respective active sites of the FAS complex in a mechanism that is still unclear (Fig. 
1.25). Earlier NMR studies of E. coli, Plasmodium falciparum and spinach ACPs 
suggest that the ACP can exist in equilibrium between two conformations
142, 146, 151
. 
Molecular dynamic analysis has proposed that the acyl chain spends a portion of the 
time associated with one of the loops between helices
152
. An interesting hypothesis is 
that this observed two-state equilibrium will change depending on the length of the 






Figure 1.25: Structures of (A) type II hexanoyl E. coli ACP (PDB: 2FAC) and (B) type II 
decanoyl E. coli ACP (PDB: 2FAE) showing the growing acyl chain inside the hydrophobic 
cavity. Figures made using the PyMol Software
172
 (C) Schematic showing ‘switchblade’ 
mechanism of a C6 chain buried inside the hydrophobic cavity before flicking out, enabling 
the chain to grow by 2 carbons. The chain flicks back inside the hydrophobic cavity to 











Organism Acylation state PDB file 
FAS   
Type I Proteins   
Human Apo-in complex with AcpS 2CG5 
Rat Apo 2PNG 




E.coli Apo 1ACP, 1T8K, 2K92 
E.coli Holo 2K93 
E.coli Butyryl  1L0I, 1L0H, 2K94 
E.coli Hexanonyl  2FAC 
E.coli Heptanonoyl  2FAD 
E.coli Decanoyl  2FAE 
E.coli Trans-2-Dodecenoyl-in complex with FabI 2FHS 
S. oleracea Decanoyl  2FVF, 2FVE 
S. oleracea Octadecanoyl 2FVA, 2AVA 
P. falciparum Holo 2FQ0, 2FQ2 
M. tuberculosis Holo 1KLP 
B. subtilis Apo 1HY8 
B. subtilis Holo-in complex with AcpS 1F8O 
B. subtilis Malonyl 2X2B 







1.6.2 Polyketide Synthase (PKS) and Non-ribosomal Peptide 
Synthetase (NRPS) 
The modular megasynthase proteins (~200-2000kDa) responsible for 
polyketide (PK) and non-ribosomal peptide (NRP) biosynthesis are known as 
polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS). PK and 
NRP are a class of natural products assembled by the elongation of acyl-CoA and 
amino acid building blocks
153, 154
. Despite these two classes differing in overall 
structure and mechanism of biosynthesis, there are remarkable similarities in the 
organization and function of the biosynthetic machinery, by which both families are 
assembled
154
. PKS are involved in the synthesis of C-C bonds, much like the FAS 
systems, whereas NRPS are involved in peptide bond formation. Enzymes are 
organized in assembly lines and the specific and coordinated action of these enzymes 
result in the unique structures of PK and NRP that arise. The identity and order of 
each enzyme domain within the assembly line displays
155
: (i) the sequence of the 
activated monomer units, (ii) the chemistry that occurs at that position of the 
assembly line, and (iii) the length and function of the product released from the 
assembly line. Both PKS and NRPS modules are made up of three core domains; two 
are catalytic and one acts as a carrier (ACP in PKS and peptide carrier protein (PCP) 
in NRPS). The contrast to the FAS system, the PKS and NRPS can contain several 
carrier proteins required for chain elongation via a condensation reaction. Auxiliary 
domains are also present that mediate reduction, dehydration and methylation of the 
polyketide/polypeptide chain
154
. PKS are subdivided into three classes; type I PKS is 
the multidomain protein, type II involves discrete proteins and type III that utilizes 
an acyl- CoA as activated monomer in place of an ACP
153, 156
. In contrast, NRPS 
only function as type I megasynthases. Many NRPS PCP and PKS ACP structures 
have been determined (Table. 1.5) as distinct stand-alone proteins
142
 and possess the 
same helical bundle arrangement as seen in ACP from the FAS system. In contrast to 
the observed E. coli ACP structure, the NMR structure of PKS Streptomyces 
coelicolor (S. coelicolor) acylated ACP suggests that 4’PP arm and acyl chain lies on 
the outside of the protein structure instead of being buried inside a hydrophobic 





Organism Acylation state PDB file 
PKS   
Type II Proteins   
S. coelicolor Apo 2AF8, 2K0Y 
S. coelicolor Holo 2K0X 
S. coelicolor Acetyl 2KG6 
S. coelicolor Malonyl 2KG8 
S. coelicolor 3-Oxobutyl 2KGD 
S. coelicolor 3,4-Dioxobutyl 2KGE 
S. coelicolor Butyryl 2KG9 
S. coelicolor Hexanonyl 2KGA 
S. coelicolor Octanonyl 2KGC 
S. rimosus Apo 1NQ4 
S. roseofulvus Holo 1OR5 
S. erythraea Apo 2JU1, 2JU2 
A. parasiticus Holo 2KR5 
NRPS   
E. coli Apo 2FQ1 
B. brevis Apo 2GDY 
B. brevis Holo 1DNY 
B. brevis Apo/Holo 2GDW 









Figure 1.26: NMR resolved structures of (A) S. coelicolor PKS hexanonyl ACP (PDB: 2KGA) 
showing the C6 chain on the outside of the protein and (B) FAS E. coli hexanonyl ACP 





1.6.3 Acyl Carrier Protein Synthase (AcpS) and Molecular Basis of 
ACP-AcpS interaction 
As previously discussed, ACPs must be modified to their active form by the 
addition of a 4’-PP group from CoA. The 4’-PP group is attached covalently by a 
phosphate ester bond to the hydroxyl group of a conserved serine residue and is 
necessary for activity of ACPs. PTM is catalysed by a specific AcpS or PPTase (Fig 
1.27-A) but can also be directly acylated in one step (Fig 1.27-B). Furthermore, 
another soluble cytosolic enzyme, acyl-ACP synthetase (AasS) is able to ligate free 





Figure 1.27: (A) Conversion of apo-ACP to holo-ACP (B) Conversion of apo-ACP directly to 
acyl-ACP (C) Conversion of holo-ACP to longer-chain acyl-ACP. 
Sequence alignments of ACPs from various organisms have revealed that many 
anionic residues in helix II are conserved and thought to play a role in interacting 
with other enzymes
142
. Indeed, the first  Bacillus subtilis ACP-AcpS structure solved 
by Parris et al.
157
 confirmed helix II as being the central recognition and interaction 
site. AcpS exists as a trimer forming three active sites at the subunit interface and 
forms electrostatic interactions with acidic helix II
144
. The most important of the 
interactions involve conserved residue Arg
14 









 of AcpS is thought play an important role in activation of the 
ACP serine residue. The significance of certain residues of Vibrio harveyi ACP has 
also been studied by mutagenesis
158
, also revealing an important role for helix II and 







The overall aim of this thesis is to explore the PLP dependent enzyme Serine 
palmitoyltransferase (SPT) in order to gain insight into substrate selectivity, 
inhibition and the role of the cofactor. The main goals are as follows: 
 Explore the mechanism based inhibition of Sphingomonas paucimobilis (Sp) 
SPT with the amino containing substrates; L-penicillamine and L-cysteine via 
production of a thiazolidine adduct. 
 Develop a gentle method to remove the natural PLP cofactor from SPT using 
the above amino-thiol substrates. 
 Probe the role of the phosphate group of PLP in Sp SPT by replacing it with the 
dephosphorylated form, pyridoxal. Use the phosphate binding cup analysis to 
gain insight into a novel SPT:PLP:myriocin complex as well as using it as a 
tool to investigate substrate specificity of other AOS members. 
 Investigate the effect of Sp SPT mutations that cause the human genetic disease 
HSAN1 in a bacterial mimic. Analysis of how these mutations have impact on 
substrate binding, ability to form key intermediates and overall structure. 
 
The second part of the thesis investigates the possibility that a bacterial SPT from 
Sphingomonas wittichii utilises an acyl carrier protein (ACP) to deliver the acyl 
chain moiety to the enzyme instead of a palmitoyl-CoA substrate. This work is 
studied by: 
 Preparation of a double mutant Sw ACP E36G/W37A with aims of 
converting the unmodified apo-ACP to the activated “substrate” C16-ACP. 
 Purification of different PPTases and creating different constructs to try and 
allow for the conversion of apo-ACP to C16-ACP. 
 
The final part of this thesis involves expression and purification of ACPs from 
different organisms with the main goal to gain structural insight on the apo, holo and 














2.1 Media and Supplements 
2.1.1 Cell lines 
 
Species Cell  line Genotype Application 




























thi-1 gyrA96 relA1 
Transformation – host for 
plasmid storage. 














expression host.  
E. coli C2987 
NEB  
fhuA2Δ(argF-lacZ)U169 
phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
Transformation of 
ligations and PCR. 





2.1.2 Sterile procedure 
All liquid and solid media, flasks, tips, eppendorfs were sterilized before use to 
avoid contamination. The sterilizing process was performed using LTE touchclave 
lab autoclave set to 120 °C, 1 atm for 20 mins.  
 
2.1.3  Culture Media 
Growth media was dissolved in distilled water and pH adjusted to pH 7.5. 
Antibiotic of the desired concentration was added on cooling.  
Luria Bertani (LB): Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride (10 
g/L) 
Super optimal broth (SOC): Tryptone (20 g/L), yeast extract (5 g/L), sodium 
chloride (10 mM), potassium chloride (2.5 mM), magnesium chloride (10 mM), 
magnesium sulphate (10 mM), glucose (2 % w/v) – filter sterilized. 
 
2.1.4 Agar 
Agar was dissolved in distilled water and melted by autoclaving. All plates 
were stored at 4 ˚C and used within 1 week of preparation. 
LB: Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride (5 g/L), Agar (15 g/L)  
 
2.1.5 Antibiotics 
All stocks were prepared using distilled water, and filter sterilized through a 
0.22 m filter. All antibiotics were stored at 4 °C and used within 1 week of 
preperation. 
Ampicillin: A 100 mg/mL stock solution was made. The required volume was added 
to media to give a final concentration of 100 μg/mL. 
Kanamycin: A 30 mg/mL stock solution was made. The required volume added to 




2.1.6 Protein expression and induction 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was used to a final concentration 
described at section 2.5.2. A 100 mM stock solution was prepared on the same day as 
usage and stored at 4 ˚C. 
 
2.2 Materials and Reagents 
 All reagents, chemicals and media were purchased from Sigma-Aldrich, 
Fisher or Biorad unless otherwise stated. Palmitoyl-CoA was from Avanti Lipids. 
The thioester analogue of palmitoyl-CoA, S-(2-oxoheptadecyl)-CoA, was 
synthesised by John Wadsworth, as described
134
 with modifications inspired by 
Gerson and Schlenk
159
. CoA and derivatives were purchased from Sigma-Aldrich. 
All chromatography columns were from GE Healthcare. All plasmids were available 
from the lab prior to this work unless otherwise stated. The plasmids encoding the E. 
coli ACP (ACP/pET22b) was a generous gift from Prof. Mike Burkhart (University 
of California, San Diego). The synthetic DNA construct for S. wittichii AcpS was 






All bufferes were made by dissolving the components in sterile water. All 
buffers were filtered and degassed prior to chromataography and stored at 4 ºC. 
 
Stock solution: 0.5 M potassium phosphate (KPhos), pH 7.5. Dibasic KPhos, 
K2HPO4 (0.470 moles/L), monobasic potassium phosphate, KH2PO4 (0.0299 
moles/L). 
Buffer A: 20 mM KPhos pH 7.5, 150 mM NaCl, 10 mM imidazole, 25 μM PLP 
Buffer B: 20 mM KPhos pH 7.5, 150 mM NaCl, 50 mM imidazole, 25 μM PLP 
Buffer C: 20 mM KPhos pH 7.5, 150 mM NaCl, 300 mM imidazole, 25 μM PLP 
Buffer D: 20 mM Tris pH 7.5, 150 mM NaCl, 100 μM PLP 
Buffer E: 20 mM KPhos pH 7.5 
Buffer F: 20 mM KPhos pH 7.5, 1 M KCl 
Buffer G: 20 mM KPhos pH 7.5, 150 mM NaCl 
Buffer H: 20 mM KPhos pH 7.9, 0.5 mM NaCl, 5 mM imidazole, 10% glycerol 
Buffer I: 20 mM KPhos pH 7.9, 0.5 mM NaCl, 500 mM imidazole, 10% glycerol 
Buffer J: 50 mM Tris.HCl pH 8.0, 10 mM imidazole 
Buffer K: 50 mM ammonium acetate pH 8.0, 50 mM imidazole 
Buffer L: 50 mM ammonium acetate pH 8.0, 150 mM imidazole 
Buffer M: 50 mM ammonium acetate pH 8.0, 300 mM imidazole 
Buffer N: 50 mM ammonium acetate pH 8.0 
Buffer O: 20 mM Tris pH 7.5, 10 mM imidazole, 10% glycerol, 1 mM EDTA, 0.1 
mM DTT  
Buffer P: 20 mM Tris pH 7.5, 20 mM imidazole, 10% glycerol, 1 mM EDTA, 0.1 
mM DTT  
Buffer Q: 20 mM Tris pH 7.5, 250 mM imidazole, 10% glycerol, 1 mM EDTA, 0.1 
mM DTT pH 7.5 
Buffer R: 20 mM Tris pH 7.5, 10% glycerol, 1 mM EDTA, 0.1 mM DTT, 0.002% 




2.3  Molecular Biology Methods 
2.3.1 Polymerase Chain Reaction (PCR) Primers 
Primers were designed (Table. 2.2) to facilitate directional cloning. Primers 
were designed to be roughly 20 base pairs long, with minimizing GC content and 
ending (3') in a G or C to increase efficiency of priming. Primer oligonucleotides 
were purchased from Sigma Aldrich and stored at -20 °C as 10 μM stocks.  
 
Oligonucleotide Sequence (5’-3’) 
Sp SPT V246M for CGGCATGTACGAGGCGCAAG 
Sp SPT V246M rev TCGTACATGCCGCGCCCGTTG 
Sp SPT G268V for GGTCGTCACAGTCGGCGGCTTC 
Sp SPT G268V rev ACTGTGACGACCGATTTGGAG 
 Sp SPT G385F for CGGCCTTCACCTTCCTGCTG 
Sp SPT G385F rev AAGGTGAAGGCCGGGGTC 
Sp SPT A295T for CACCACCTCGCTGCCGCCCTC 
Sp SPT A295T rev GCGAGGTGGTGAAGATGTACGGAC 
Sp SPT A295S for CACCTCCTCGCTGCCGCCCTC 
Sp SPT A295S rev GCGAGGAGGTGAAGATGTACGGAC 
Ec ACP Stop for TCGAGTAGCACCACCACCACCAC 
Ec ACP Stop rev GGTGCTACTCGAGCGCCTGGTGG 
Table 2.2: Oligonucleotides used for molecular cloning and PCR. 
 
 
2.3.2 Polymerase Chain Reaction: QuickChange® Site-Directed 
Mutagenesis (Stratagene) 
Thermostable Turbo Pfu polymerase was used for this PCR reaction as it 
exhibits a high fidelity 3’-5’ proof reading ability that minimizes the number of PCR 
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induced mutations. The following PCR cycle (Fig. 2.1) and mix were used: Pfu 10x 
buffer (5 μl), dNTP mix (1 μl), turbo cloned Pfu polymerase (1 μl), forward and 
reverse primer (2.5 μl) and template DNA (2 μl) was made up to 50 μl with dH20. 
After completion of the PCR cycle DnpI mix (1 μl) and DnpI buffer (5 μl) was added 
and left to incubate at 37 ˚C for 1 hour to destroy template DNA. The ligation 








Figure 2.1: PCR cycle conditions. 
 
2.4 DNA manipulation, purification and analysis 
2.4.1 Restriction enzyme digest 
Restriction enzyme digests were carried out using the appropriate restriction 
enzymes and specified DNA template. Generally, a double digest contained the 
following; the DNA to be cut (60 μl), both specified restriction enzymes (1.5 μl) and 
corresponding buffer (10 x) (7 μl). The reaction mixture was left to incubate at 37 ˚C 
overnight and terminated by the addition of DNA loading dye (2 μL, 5x, Novagen). 
The digestion mixture was analysed by agarose gel as described in section 2.4.5. 
 
2.4.2 Gel Extraction QIAquick® Gel extraction Kit (QIAGEN) 
Gel extraction was carried out following the Qiagen QIAquick 
®
 gel extraction 
kit protocol. The DNA fragment of interest was excised from the agarose gel with a 
clean scalpel. Depending on the size/wet weight of the gel slice, an appropriate 
2 min/ kb @ 
68˚C 
Extension 





95˚C 30sec @ 
TmAnneal 
Annealing 







volume of QG buffer was added, (300 μl-1 mL). The gel slice was completely 
dissolved by incubation at 50 ˚C for 10 minutes. Isopropanol was added to the 
sample and mixed (1 gel volume), before being transferred to a QIAquick spin 
column 2 mL collection tube. The sample was centrifuged for 1 minute at 13,000 
rpm to bind the DNA. The flow through was discarded and buffer QG (0.5 mL) was 
added to the reaction mixture and centrifuged for another minute. This removed all 
traces of agarose. To wash, buffer PE (0.75 mL) was added and centrifuged as before 
for 1 minute. The flow through was discarded and the sample centrifuged for another 
minute. The QIAquick column was transferred to a 1.5 mL microcentrifuge tube and 
DNA was eluted with buffer EB (50 μl) and centrifuged for 1 minute. DNA was 
stored at -20 ˚C until further use. 
 
2.4.3 DNA ligation 
Generally, insert DNA (2 μl), vector DNA (2 μl), ligation buffer (2x) (5 μl), 
and T4 ligase (2 μl) were mixed by gentle pipetting and incubated at room 
temperature for 2 hours for maximum efficiency. The reaction mixture was 
transformed into C2987 E. coli competent cells (25 μL) as described in section 2.5.1. 
 
2.4.4 Mini-prep: QIAprep® Spin Miniprep Kit (QIAGEN) 
The mini-prep procedure was carried out according to QIAprep Spin 
protocol. Overnight LB cultures (5 mL) were centrifuged for 10 minutes at 3,000 
rpm. The bacterial cell pellet was resuspended in buffer P1 (250 μl) until no cell 
clumps were visible and transferred to a micro-centrifuge tube. Buffer P2 was then 
added (250 μl) and mixed by inverting 4-6 times until solution became viscous and 
slightly clear. Buffer N3 was added (350 μl) and mixed immediately to avoid 
precipitation, again by inverting 4-6 times. The reaction mixture was centrifuged for 
10 minutes at 13,000 rpm, and the supernatants applied to QIAprep spin columns. 
The sample mixture was centrifuged for another 1 minute and the flow through 
discarded. The QIAprep spin column was washed by the addition of buffer PB (0.5 
mL) and centrifuged for 1 minute. The flow through was discarded and the reaction 
mixture was washed again by the addition of buffer PE (0.75 mL) and centrifuged as 
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before for a further 1 minute. The flow through was again discarded and the column 
was spun for an additional 1 minute to remove residual wash buffer. This step is 
important as residual ethanol from buffer PE can inhibit subsequent enzymatic 
reactions. The QIAprep column was placed in a 1.5 mL microcentrifuge tube and 
buffer EB (50 μl) was addd to elute DNA. The column was allowed to stand for 1 
minute before being spun for another 1 minute.  
 
2.4.5 Gel Electrophoresis  
Agarose (1 g) was added to TAE buffer (100 mL) and boiled until the agarose 
had completely dissolved. The solution was allowed to cool and Gel Red was added 
to a final concentration of 0.5 μg/mL. The solution was mixed to ensure homogeneity 
and cast to the desired thickness. The gel was immersed in TAE buffer and a 
constant voltage (100 volts) was applied for approximately 1 hour until good 
separation between bands could be seen. Sample DNA (2 μl) was added to (5x) DNA 
loading buffer (8 μl) for sample preparation. 4 μl of MWM was used. 
 
2.4.6 Sequencing PCR 
Sequencing reactions consisted of 24 cycles: 94 ˚C for 30 seconds, 50 ˚C for 
20 seconds and 60 ˚C for 4 minutes. The reaction mixture contained 5 μl of DNA, 1 
μl primer, (Table. 2.3), 2 μl (5x) sequencing buffer terminator and 2 μl of Big Dye 
version 3.1. Samples were then given to the GenePool at the Ashworth Building, The 




Table 2.3: pET forward and reverse primer sequence 5’-3’. 
 
2.5 Protein overexpression 
2.5.1 Transformation of E. coli 
Plasmid DNA (2 μl) was added to competent E. coli cells (25 μl) and left 
incubating on ice for 20 minutes. Cells were then heat shocked at 42 ˚C for 40 
seconds. These were again placed on ice for a further 5 minutes before 80 μl of SOC 
media was added. These were then incubated at 37 ˚C for 1 hour with shaking. This 
solution was spread evenly using sterile technique, on LB Agar plates containing the 
appropriate antibiotic, and incubated overnight at 37°C. 
 
2.5.2 Protein Expression 
After successful transformation a single colony was used to inoculate LB broth 
(500 mL) containing the appropriate antibiotic and grown overnight at 37 °C with 
shaking (250 rpm). This was then sub-cultured into LB broth (5 litres) and grown to 
an OD600 of 0.6, at 37 °C. These were then induced with IPTG. IPTG concentration 
and incubation conditions requied for optimum expression are shown in table 2.4. 
The cells were then harvested by centrifugation at 6, 000 rpm for 10 minutes at 4 °C. 
The supernatant was discarded and the pellet was frozen at -20 °C. 
  
Primer Plasmid Sequence (5’- 3’) 
pET forward pET TTAATACGACTCACTATAGGG 













 C-term His-tag 
HMS 174 
(DE3) 
2YT 0.1 30 5 
Sp SPT/pET28a all mutants BL21 
(DE3) 





2YT 0.1 30 5 
Sw ACP-SPT/pET28a BL21 
(DE3) 
2YT 0.1 30 5 
Sw ACP-SPT/pET28a mutant BL21 
(DE3) 
2YT 0.1 30 5 



















LB 0.1 30 3 
Ec ACP/pET22b 
 C-term His-tag 
BL21 
(DE3) 
LB 0.1 32 3 
Ec ACP/pET22b 
 No His-tag 
BL21 
(DE3) 
LB 0.1 32 3 
Vh AasS/pET16b-  BL21 
(DE3) 





LB 1 32 3 
Rat ACP/pET28a 
No His tag- 
BL21 
(DE3) 
LB 0.1 30 3 
Table 2.4: Optimum conditions for protein expression. 
2.5.3 Cell lysis by sonication 
All cells were thawed on ice before being resuspended in lysis buffer and one 
EDTA-free protease inhibitor cocktail tablet. Sonication was carried out on ice using 
a 30 second on/off cycle for 15 minutes disrupted the cells. The suspension was 
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centrifuged (30 minutes, 13,000 rpm, 4 °C) to precipitate cell debris and insoluble 
material.  
 
2.6 Protein purification 
2.6.1 Purification of S. wittichii and S.paucimobilis SPT wild type and 
mutants 
Ni-NTA agarose 
The supernatant from centrifugation was filtered through a 0.45 μm filter 
(Sartorins). Ni-NTA beads (QIAgen) were equilibrated with buffer A by mixing and 
centrifuging. The equilibrated gel was added to the filtered supernatant and incubated 
with rotation for 1 hour at 4 °C. The beads were washed with 40 column volumes of 
buffer B and the protein eluted with 7 mL of buffer C. All KPhos buffers were 
replaced with 20 mM Tris.HCl buffer (pH 7.5) for work on the replacement of PLP 
with pyridoxal to eliminate exogenous phosphate. 
 





 S-200 High Resolution (120 mL) size 
exclusion column was pre-equilibrated with 1 column volume of buffer D. 5 mL 
concentrated sample was loaded onto the column and eluted over 1 column volume 
collecting 10 mL fractions. The approximate mass of the purified protein could be 
calculated using a calibration curve of known molecular weights. All KPhos buffers 
were replaced with 20 mM Tris.HCl buffer (pH 7.5) for work on the replacement of 
PLP with pyridoxal to eliminate exogenous phosphate. 
 
2.6.2 Purification of S. wittichii ACP 
Anion Exchange Chromatography 
A HiLoad
TM
 16/10 Q Sepharose
TM
 High Performance (20 mL) anion 
exchange column was washed and recharged with 4 column volumes of buffer E 
followed by 1 column volume of buffer F. The column was again pre-equilibrated 
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with 2 column volumes of buffer E. CFE containing recombinant Sw ACP was 
loaded onto the column and washed with 2 column volumes of buffer F. The protein 
eluted with a linear salt gradient (0-1M KCl) over 20 column volumes. 
 





 75 prep grade (120 mL) size exclusion 
column was pre-equilibrated with 1 column volume of buffer G. 1 mL concentrated 
sample was loaded onto the column and eluted over 1 column volume collecting 5 











 75 calibration curve. 
 





 HP (5 mL) column was washed with 10 column volumes of 
buffer H and recharged with 5 column volumes of buffer I. The column was then 
equilibrated with 10 column volumes of buffer H. The CFE was loaded onto the 
column and washed with 20 column volumes of buffer H. The protein eluted using a 
linear gradient of 5-500 mM imidazole over 30 column volumes.  
 
Log MW
























Size Exclusion Chromatography of S. wittichii AcpS and S. coelicolor AcpS 





75 prep grade (120 mL) size exclusion column. 
Purification was carried out as described for ACP using the same buffer. 
2.6.4 Purification of E. coli ACP 
Ni-NTA Agarose 
The supernatant from centrifugation was filtered through a 0.45 μm filter 
(Sartorins). Ni-NTA beads (QIAgen) were equilibrated with buffer J by mixing and 
centrifuging. The equilibrated gel was added to the filtered supernatant and incubated 
with rotation for 1 hour at 4 °C. The beads were washed with 40 column volumes of 
buffer K and the protein eluted with 7 mL of buffers L and M.  
 





 75 prep grade (120 mL) size exclusion column 
was pre-equilibrated with 1 column volume of buffer N. 1 mL concentrated sample 
was loaded onto the column and eluted over 1 column volume collecting 5 mL 
fractions. 
 
2.6.5 Purification of V. harveyi AasS 
Ni-NTA Agarose 
The supernatant from centrifugation was filtered through a 0.45 μm filter 
(Sartorins). Ni-NTA beads (QIAgen) were equilibrated with buffer O by mixing and 
centrifuging. The equilibrated gel was added to the filtered supernatant and incubated 
with rotation for 1 hour at 4 °C. The beads were washed with 40 column volumes of 






2.6.6  Purification of Rat and S.coelicolor ACP 
Nucleic Acid and Protein Precipitation 
Streptomycin sulfate dissolved in H2O (2g per 100ml of CFE) was added to 
the CFE on ice with rapid stirring for 10 seconds. The nucleic acids were harvested 
by centrifugation (8,000 rpm, 20 minutes, 4 
o
C) and the supernatant retained. A 60% 
ammonium sulfate fractional cut was performed on the supernatant and the solution 
was stirred rapidly at 4
o
C for 2 hours. The protein precipitate was removed by 
centrifugation (8,000 rpm, 20 minutes, 4 
o
C) and a 90% ammonium sulfate fractional 
cut was performed on the resulting supernatant with rapid stirring at 4 
o
C for 2 hours. 
The pH of the solution was adjusted to 3.4 by the addition of HCl (1M) and the 
solution was left to settle for 24 hours at 4
o
C. The protein precipitate was then 
harvested by centrifugation (16, 000 rpm, 30 minutes, 4 
o
C) and resuspended in a 
minimum amount of buffer E. 
 
Anion Exchange Chromatography 
A HiLoad
TM
 16/10 Q Sepharose
TM
 High Performance (20 mL) anion 
exchange column was washed and recharged with 4 column volumes of buffer E 
followed by 1 column volume of buffer F. The column was again pre-equilibrated 
with 2 column volumes of buffer E. CFE containing recombinant ACP was loaded 
onto the column and washed with 2 column volumes of buffer E. The protein eluted 
with a linear salt gradient (0-1M KCl) over 20 column volumes. 
 





 75 prep grade (120 mL) size exclusion column 
was pre-equilibrated with 1 column volume of buffer E. 1 mL concentrated sample 





2.7 Protein quantification 
2.7.1 SDS-PAGE 
Protein indentification was analysed under denaturing conditions using SDS-
PAGE. SDS loading buffer was added into the protein solution and boiled for 5 
minutes to denature the protein then centrifuged for 5 minutes at 13, 000 rpm. Each 
gel consisted of a 15% acrylamide running gel and a 4% stacking gel (Table. 2.5). 
The gel was run at 200 V, 180 mA for 50 minutes. LMW markers (GE Health Care) 
were used to detect approximate molecular weights. Visualisation of the protein 
bands were carried out using a solution containing Coomasie blue (H2O, 0.1% w/v 
Coomassie brilliant blue R250, 40% v/v methanol and 10% v/v acetic acid) at 37 ºC 
for 15 mins and destained with water in the microwave for 10 minutes. 
 15% running gel 4% stacking gel 
dH20 5.7 ml 2.9 ml 
40% acrylamide 6 ml 0.75 ml 
1.5 M Tris (pH 8.8) 4 ml - 
0.5 M Tris (pH 6.8) - 1.25 ml 
SDS (10% w/v) 150 µl 50 µl 
APS (50mg/ml) 300 µl 100 µl 
TEMED 20 µl 5 µl 
Table 2.5: SDS-PAGE running and stacking gel.  
 
2.7.2 Protein Concentration using Absorbance A280 
Protein concentration was calculated using the Beer-Lambert law, (Equation. 
1). (A) = Absorbance at a given wavelength, (ε) = molar extinction coefficient, (c) = 
protein concentration, (l) = the path length fixed (1 cm). Spectrum measurements 
were taken between 200-800 nm.  
A=εcl  Equation 1 
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2.7.3 Protein Concentration using BCATM Assay (PIERCE) 
  Bicinchoninic acid (BCA) (Fig. 2.3) assay is a colorimetric technique used to 
obtain protein concentration. The assay detects the presence of Cu
1+ 





 using a bicinchoninic reagent in an alkaline environment
160
. 
The chelation of two BCA molecules with one Cu
1+ 
molecule produces a purple 
coloured complex with an absorbance of 562 nm. Protein concentrations were 
determined with reference to a standard bovine serum albumin (BSA). Working 
reagent was prepared (50:1 ratio of reagent A: reagent B) and added (1 mL) to 
protein sample (50 μl). The mixtures in the cuvettes were mixed my inverting. These 
were covered with foil and incubated for 30 minutes at 37 °C. The standard curve 
concentrations are shown (Table 2.6). Concentrations were measured at 562 nm. 
 
Figure 2.3: Bicinchonic Acid 
 
2.7.4 Protein Concentration using Bradford Assay 
The Bradford assay used for protein determination involves binding of 
Coomassie Brilliant Blue G-250 dye to proteins
161
. When the dye is on it’s own it is 
in its cationic form (Absmax=470 nm), however when it binds to protein it is 
converted to its stable unprotonated blue form (Absmax=595 nm). This particular 
method of protein concentration analysis is better for proteins containing basic 
residues. Protein concentrations were determined with reference to a standard BSA, 
as with the BCA assay above. Coomassie Brilliant Blue G-250 (1 mL) was added to 
protein sample (50 μl). The mixtures in the cuvettes were mixed by inverting. The 
standard curve concentrations are shown (Table 2.6). Protein concentration was 












Table 2.6: BSA standard concentrations 
 
2.8 Protein Analysis 
All UV-visible spectra were obtained on a Cary 50 UV-visible 
spectrophotometer (Varian) and analysed with Cary WinUV software (Varian). All 
samples were measured in 0.5 mL quartz cuvettes with 1 cm path length and made 
up to 500 μl. 
 
2.8.1 Spectroscopic Methods 
Prior to all UV-visible spectroscopy and assays, SPT was dialysed against fresh 
buffers containing 250 µM PLP to ensure the enzyme was in the PLP bound, holo-
form. Excess PLP was removed on a PD-10 (Sephadex G-25M) desalting column 
(GE Healthcare). For UV-visible assays the concentration of enzyme was 20 µM and 
the spectrophotometer was blanked with 20 mM KPhos (pH 7.5) containing 150 mM 
NaCl at 25 °C. Quartz cuvettes from NSG Precision Cells, Type 18-BM with a 
lightpath of 10 mm and a sample volume of 500 µl were used and the spectra were 
collected from 800 nm to 200 nm. The release of CoASH from C16-CoASH during 
KDS formation was used to measure SPT activity as previously described
46
 (Fig, 
2.4). SPT (0.25 μM for a typical assay) was incubated with x2 assay buffer (100 mM 
HEPES, 0.4 mM DTNB
131
) with increasing concentrations of L-serine (0.1-40 mM). 
The reaction was initiated by the addition of the second substrate, palmitoyl CoA 









. This was a typical experiment to 
calculate kcat and Km values from Michaelis-Menten plots using Sigma Plot software. 
 
Figure 2.4: Reaction of free thiol from CoASH with DTNB to produce the TNB thiolate 
chromophore and mixed disulphide. 
 
For measuring relative activity rates were normalised to 100% relative activity. 
Activity assays were carried out in duplicate and the error bars are the standard error 
of the mean (SEM) values for each separate experiment. Assays were also performed 
on a 200 µL scale on a 96-well format in a Biotek Synergy HT plate reader. Kinetic 
constants were calculated using Michaelis-Menten kinetics and using Sigma Plot 
software. 
 
2.8.2 Bacterial SPT enzyme assay by Measuring KDS Formation 
SPT activity was also monitored by incorporation of [
14
C] L-serine into [
14
C]-
KDS by a modification of a published method
46
. A final enzyme concentration of 
25µM SPT (in 20 mM potassium phosphate buffer, pH 7.5, 150 mM NaCl) was 
incubated with 20 mM U-
14
C L-serine (7400 Bq, 0.2 µCi, PerkinElmer) and 250 µM 
palmitoyl-CoA in a final volume of 1 mL. The reaction was incubated at 37 °C for 
20 minutes and then the reaction was quenched by the addition of NH4OH (final 
concentration 0.4 M). This was then extracted with an equal volume of 
CHCl3:CH3OH (2:1, v:v). The sample was centrifuged at 13,000 rpm for 5 minutes 
and the aqueous phase was discarded. The organic phase was left to evaporate at 50 
°C. The resulting lipid residue was re-suspended in 15 µl of CHCl3:CH3OH (2:1, v:v) 
and spotted onto a Silica Gel 60 F254 TLC plate. Separation was carried out with a 
mobile phase of CHCl3:CH3OH (2:1, v:v). The TLC plate was scanned with an AR-
 
 70 
2000TM imaging scanner and [
14
C]-labelled products quantified using the Laura 4 
software (LabLogic). 
 
2.8.3 Determination of dissociation constants, substrate and product 
quinonoid 
Binding assays typically contained 20 µM enzyme in 20 mM potassium 
phosphate (pH 7.5). Varying amounts of L-serine (0-40 mM) was added and after 
addition of the substrate, the reaction mixture was allowed to equilibrate for 15 min 
at 25 °C. The Kd values were calculated from plots of ∆425 versus L-serine 





where ∆Aobs represents the observed change in absorbance at 425 nm, and ∆Amax is 
the maximal absorbance change, [serine] represents L-serine concentration, and the 
Kd is the dissociation constant. To form the substrate quinonoid, 50 mM L-serine 
and 1.5 mM S-(2-oxoheptadecyl)-CoA (Fig. 2.5) was added to the enzyme. After 
addition, the reactants were mixed and allowed to equilibrate for 15 min at 25 °C. To 
form the product quinonoid, 25 µM KDS was added to the enzyme and allowed to 
equilibrate for 15 min at 25 °C. 
 








2.8.4 1D 1H NMR 
1D 
1
H NMR was obtained with help from Mr. Haris Bangaos working 
alongside Dr Dusan Uhrin at The University of Edinburgh. Samples were loaded 
onto an 800Hz Advance (Bruker) NMR Spectrometer equipped with a z-gradient 
triple-resonance TCI cryoprobe at 298 ˚K. The samples contained: 210 μM ACP 
(520 μL), DH2O (40 μL) and Buffer G (40 μL). 
 
2.9 Protein chemistry 
2.9.1 Enzymatic protein digests 
Trypsin digests were carried out following the available PIERCE protocol. The 
reaction mixture consisted of, SPT (10 µg), ultra pure water, 5x digestion buffer (500 
mM ammonium bicarbonate pH 8.0), DTT (10 mM) and was incubated for 45 
minutes at 60 ºC. The volume was adjusted to 100 µl with ultrapure water and 
trypsin was added for a final 1:20 (enzyme: protein) ratio. The reaction mixture was 
incubated at 37 ºC for 16-24 hours. 
 
2.9.2 Conversion of Apo-ACP to Holo-ACP (or acyl ACP) 
Apo-ACP was converted into its holo-form by incubation with AcpS or Sfp 
(PPTase). ACP (60 μM) was added to reaction buffer (50 mM ammonium acetate pH 
7.5), with the specific PPTase (1 μM), 1 mM MgCl2, 1 mM free CoASH in a final 
volume of 250 μL. This reaction mixture was incubated overnight at 37 °C
44
. This 
reaction also worked for small chain acylations. To convert holo-ACP to (C8-C16 
ACP) it was incubated with AasS. Holo-ACP (25 μM) was added to reaction buffer 
(100 mM ammonium acetate pH 7.5), with AasS (1 μM), MgSO4 (10 μM), ATP (10 
μM), DTT (5 mM), required sodium salt (250 μM) in a final volume of 200 μL. The 




2.10 Mass Spectrometry analysis 
Liquid Chromatography Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometry (LC-FT-ICR) 
On-line liquid chromatography was performed using an Ultimate 3000 HPLC 
system (Dionex) equipped with a monolithic PS-DVB (500 μm х 50 mm) reverse-
phase analytical column (Dionex) coupled to electrospray ionization (nESI). Protein 
digests (5 pmoles) were loaded onto the column (maintained at 60°C) followed by a 
30 min linear gradient from 2 to 70% acetonitrile (flow rate 20 μl/min). All mass 
spectra were recorded on SolariX FT-ICR mass spectrometer equipped with a 12 
Tesla superconducting magnet (Bruker Daltonics). Transient data size was set to 
1Mword for each acquisition.  
 
 
Native mass spectrometry 
Data was acquired on a SolariX FT-ICR mass spectrometer, as described 
above. Samples, typically 2 µM, were treated with 0.5% para-nitrobenzoic acid prior 
to analysis; and ESI ionisation was employed using a syringe pump operating at a 
flow of 500 µl/lh
-1
 RF frequencies used in all ion-transmission regions were the 
lowest available value: multipole 1 (2 MHz), quadrupole (1.4 MHz) and transfer line 
(1 MHz). Ion-funnel and skimmer voltages were 200 V (funnel 1), 130 V (skimmer 
1), 8 V (funnel 2) and 3V (skimmer 2).The collision voltage for the collision cell was 
varied between 10 and 20 V, to produce optimal signal. Ions were accumulated for 
400 ms in the RF-hexapole ion trap before being transmitted to the infinity ICR trap 
and detected between m/z 1000 and 5000 to yield a broadband 1 M time-domain 
transient. Typically, each spectrum was the sum of 100 mass analyses. Mass spectra 
were externally calibrated using ES tuning mix (Agilent). The resulting spectra were 
analysed using DataAnalysis software (Bruker Daltonics); spectra were smoothed 
using the Gaussian algorithm and a smooth width of 0.15 m/z, before maximum 




Online Tandem Mass Spectrometry  
Online tandem MS was performed on the SolariX FT-ICR Instrument. After 
the initial LC-MS run specific peptides of interest were selected for fragmentation. 
The protein digest was separated using an identical gradient to the above. However, 
the mass resolving quadrupole was set to select for a specific m/z throughout the LC-
MS run and MS/MS was performed using collision-induced dissociation (CID). All 
spectra were externally calibrated using ES tuning mix (Agilent Technologies) and 
analyzed using DataAnalysis software (Bruker Daltonics), as above. For analysis of 
the tryptic digest, the SNAP 2.0 algorithm was used for automated peak picking in 
order to create a list of peptide masses. For CID experiments, fragment lists were 
created (using SNAP 2.0) and the resulting mass lists were searched against the 
relevant primary sequences using Prosight PTM software. Error tolerances were set 
to 10ppm. Isotope distributions of specific charge states were predicted from 
theoretical empirical formulas. These were overlaid upon the recorded experimental 
data as scatter plots, with the theoretical apex of each isotope peak designated by a 
circle. 
 
2.11 Nano-electrospray Ion Mobility Mass Spectrometry  
IM-MS was acquired on a waters quadrupole time of flight (Q-ToF) mass 
spectrometer that was modified in house to obtain drift time ion mobility data
163
. IM-
MS separates ions that have different mobilities but have the same m/z due to the 
addition of a drift tube (Fig. 2.6). Ions are generated by nano-electrospray ionisation 
(nESI) which is a soft ionization method allowing the protein structure to remain 
intact. These ions are then directed to a drift tube (Fig.2.6) which is filled with an 
inert buffer gas and an electric potential is applied. The drift tube separations are 
performed using a weak electrostatic field and high gas number density to allow the 




Figure 2.6: Diagram of drift cell
164
 
Nano-electrospray tips were pulled from borosilicate glass capillaries into tips using 
a Micropipette puller (Flaming/Brown). The capillary tips were loaded with 15µL of 
standards and samples to be analysed. A platinum wire was inserted into the capillary 
containing the sample and then inserted into the modified QToF mass spectrometer. 
A voltage of 1.32-2.42 mV was applied to the platinum wire and a voltage of 60-84 
V was applied to the cone. The instruments conditions were tuned in its mass 
spectrum mode to obtain the optimum shot to shot resolution. These conditions were 
a series of voltages; the capillary voltage, cone voltage, top hat lens (TH1), hexapole 
1 (H1), pre-cell ring electrode (L1), steering lens (L2), focuses beam into cell (L3), 
post–cell ring electrode (L4). After conditions were optimised, the machine was 
switched into IM mode and run at a range of drift voltages from 60 V to 20 V for a 
run of approximately 15 scans at each voltage.  
 
Data Analysis 
Mass lynx was used to modify and import the mass spectrum obtained. The 
voltage (V) is varied across the drift cell (60-20V) and pressure (P) and temperature 
(T) are recorded. The arrival time (ta) is plotted as a function of P/V, (Fig. 2.7).  
 
Figure 2.7: Arrival time (ta) vs. P/V 
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The intercept corresponds to the instrument ‘dead time’ (to) and the slope is inversely 
proportional to the mobility (K). Measurements using a drift cell can be combined 
with calculations based on kinetic theory to determine ion-neutral collisional cross 
section (CCS)
164
. From the time it takes for an ion to pass through the cell, the dead 
time (td) can be calculated from equation 3, assuming ion-neutral collisions are 
treated as elastic. The collisional cross secion (CCS) is inversely proportional to the 
mobility (K) (Equation. 4) and can be calculated from equation 5. The acquired data 
was the processed using Microsoft Excel and Origin 7.5 (OriginLab). 
 
















































3.1 Sphingomonas paucimobilis SPT 
3.1.1 Expression, Purification and Mass Spectrometry Analysis 
The S. paucimobilis SPT construct with a C-terminal hexahistidine (His6) tag 
in a pET-28a vector was available at the start of this project. Expression and 
purification was previously optimized
46
 and repeated throughout this study as 
described in section 2.61. Briefly, SPT was isolated from the cell free extract (CFE) 
by nickel affinity chromatography followed by size exclusion chromatography. The 
purified protein eluted from size exclusion chromatography with a retention time 
corresponding to homodimeric SPT of ~90 kDa (Fig. 3.1-A) and SDS-page analysis 
indicated a monomer molecular weight of ~45 kDa (Fig. 3.1-B).  
 
Figure 3.1: (A) Elution profile of size exclusion column at A280 nm. (B) SDS- PAGE analysis 
of SPT. Lane 1: low molecular weight (LMW). Lane 2: purified SPT after size exclusion 
chromatography. 
 
After purification, in order to capture the PLP-bound to lysine of SPT, irreversible 
chemical reduction of the SPT:PLP-imine using sodium borohydride, (Fig. 3.2-A) 
followed by mass spectrometry indicated a monomer molecular weight of 46,205.2 
Da (Fig. 3.2-B). This is consistent with the predicted mass of the recombinant SPT 
monomer with PLP bound (46, 104 Da + 232 Da), minus the N-terminal methionine 




Figure 3.2: (A) Irreversible chemical reduction of the SPT:PLP-imine. (B) Intact mass 
spectrometry analysis of holo-SPT. Mass is calculated by deconvolution. 
 
Enzymatic tryptic digest described in section 2.9.1 and mass spectrometry confirmed 
the sequence of the peptide with the reduced PLP modification on Lys
265
 (Fig. 3.3-A) 
with a measured peptide mass of 3, 941.84 Da (Fig 3.3-B) consistent with the 
predicted peptide mass of 3, 941 Da.  
 
Figure 3.3: (A) Lys
265
 containing SPT peptide (B) FT-ICR mass spectrum of holo-SPT 
peptide.  Insert, the isotopic distribution of the [M+6H]
6+
 consistent with predicted mass. 
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3.2  Amino Acid substrate specificity analysis of Sp SPT 
PLP is the natural form of vitamin B6. It has a characteristic yellow colour 
giving rise to a unique UV-profile with absorbance maximum at 335 nm and 390 nm 
(Fig. 3.4). Formation and breakdown of many of the intermediates within the SPT 
mechanism can be monitored by UV-visible spectroscopy due to the yellow colour of 








Figure 3.4: UV-visible spectrum of free PLP. 50 µM PLP in 25 mM KPhos buffer, pH 7.5. 
Insert, picture of purified PLP-bound enzyme showing yellow colour characteristics and 
chemical structure of PLP. 
 
In holo-SPT, the PLP cofactor is bound to a catalytic Lys
265 
via an internal 
aldimine/Schiff’s base. Typically for PLP-dependent enzymes, the internal aldimine 
exists in two tautomeric forms; an enolimine (i) when the oxygen is protonated and a 
ketoenamine (ii) when the imine nitrogen is protonated. Equilibrium is formed 
between the enolimine and the ketoenamine which can be shifted by binding of the 
amino acid substrate L-Serine via a transaldimation reaction, forming an external 
aldimine. The formation of the PLP:L-ser:external aldimine is thought to occur via a 
geminal diamine intermediate
89





 Figure 3.5: Reaction mechanism of internal aldimine displacement by L-serine to form the 
external aldimine via a gem-diamine intermediate.  
 
Since sphingolipids are L-serine derived, it is important that these enzymes are 
exclusively specific for this amino acid (Fig. 3.6). SPT appears to have specifically 
evolved to select for L-serine which is imperative, as relaxed amino acid selectivity 
results in elevated levels of toxic deoxysphingolipids resulting from the condensation 
of L-alanine and glycine with palmitoyl-CoA. Despite the high structural and 
sequence homology between members of the AOS family, each AOS member 
displays amino acid specificity; KBL and ALAS select for glycine, whereas AONS 
selects for L-alanine. Analysis of the crystal structures of each of the above AOS 
members, gives no full explanation for the highly specific substrate selection for each 
enzyme. To understand the impact of amino acid promiscuity on SPT, several amino 
acids were tested as substrates for SPT. (Fig. 3.6). 
 




Since the active form of the external aldimine is the ketoenamine species, an 
apparent dissociation constant (Kd
L-Ser
) was calculated for the binding of the L-serine 
amino acid substrate by monitoring absorbance change at 425 nm with various L-
serine concentrations. The wild-type Sp SPT has a calculated (Kd
L-Ser
) of 1.1 ± 0.1 
mM, (Fig. 3.7), in good agreement with that reported by Raman et al (1.1 mM)
46
 and 




Figure 3.7: UV-visible spectra of (A) L-serine external aldimine formation. The solid line is 
the holo-form of the enzyme (20 µM SPT, 20mM KPhos buffer (pH 7.5), 150mM NaCl, 25 
°C). Increasing concentrations of L-serine were added (0, 0.1, 0.5, 1, 2, 5, 10, 20, and 40 
mM; dotted and dashed lines), and the spectrum was recorded after 15 min. and (B) Kd 
binding curve. Dissociation constants were measured at 425 nm (see chapter 2.8.3). 
 
L-Alanine and Glycine 
We are able to explore the substrate specificity of SPT by its ability to form 
external aldimines, monitoring an increase in absorbance at 425 nm. As previously 
mentioned, a small shift in amino acid specificity from L-serine to L-alanine or 
glycine (Fig. 3.6) leads to the build-up of deoxysphingolipids, which have recently 
been shown to be toxic to mammalian cells
60
. Such L-alanine and glycine derived 
deoxysphingolipids are generated by mutant forms of human SPT enzyme and result 
in HSAN1, which is a rare disorder characterised by sensory loss as discussed in 
chapter 1.3. It is therefore essential that SPT selects only for the L-serine substrate. 
Extremely high concentrations of both L-alanine and glycine are needed to saturate 
bacterial Sp SPT and a have a calculated Km
L-Ala
 ~1 M, Km
Gly
 ~2 M (Raman, PhD 
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thesis, The University of Edinburgh, 2010). This work only accentuates that these 
amino acids are very poor substrates for bacterial SPT.  
 
L-Threonine 
 Addition of L-threonine (Fig. 3.6), which has an additional methyl group on 
Cβ, compared to L-serine, to holo Sp SPT allows the formation of an external 
aldimine at 425 nm (Fig. 3.8-A). Increasing concentrations of this allowed the 
calculation of a dissociation constant of 3.8 mM, (Fig. 3.8-B). However, despite SPT 
being able to bind L-threonine, we assume by forming an external aldimine, it is 
unable to proceed to the correct “Dunathan intermediate” by deprotonation of the 
Cα-H, forming the substrate quinonoid which we can monitor using the C16-CoA 
thioether analogue, S-(2-oxoheptadecyl)-CoA (see section 2.8.3), which has also 
previously been observed (Raman PhD thesis, 2010). This analogue can bind the 
SPT:L-serine external aldimine but cannot form the condensation product. 
Furthermore, no activity was observed using a continuous assay that monitors the 
rate of formation of the coenzyme A thiolate released during the C-C condensation 
reaction. This suggests that addition of L-threonine to SPT results in the enzyme 
remaining predominantly in the external aldimine form, unable to condense with the 
second substrate. Inspection of the SPT:PLP:L-serine external aldimine gave no 
clues as to why L-threonine should not be able to bind to SPT. Indeed, this is in good 
agreement to what we observe by UV-spectroscopy, albeit with a higher dissociation 
constant of 3.8mM. However, since the structure of SPT with its second substrate 
bound has not been solved we are unable to comprehend any residues that would 
prevent Cα rotation on the external aldimine, to bring the proton in the correct 
orientation for deprotonation by Lys
265
. Structural models of the putative SPT:L-
serine quinonoid intermediate were generated by Raman and Lowther (unpublished) 
in attempt to find possible residues which could be preventing Cα bond rotation. 
Ser
102
 was identified as a possible residue that could be involved in spatially 
restraining the Cα rotation of the SPT:L-threonine external aldimine and therefore 
play some role in selecting amino acid substrates. However, mutation of this serine 
residue to an alanine residue did not allow the acceptance of L-threonine as a 
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substrate for S102A SPT (Lowther, unpublished). Future experiments on mutating 
this serine residue to a glycine (no side chain) should be investigated in order to find 
out if Ser
102
 plays a role in controlling substrate specificity. It is also possible that the 
addition of the methyl group of threonine is clashing with SPT residues, thus 
preventing the correct formation of the ‘Dunathan intermediate’ and stopping the 
mechanism from proceeding any further than the external aldimine form. A structure 
of SPT:PLP:L-threonine external aldimine would provide further insight into this 
hypothesis. Several efforts at crystallizing the SPT:PLP: S-(2-oxoheptadecyl)-CoA 
complex and the SPT:PLP:L-threonine external aldimine have been attempted in 
collaboration with Prof. Jim Naismith at the University of St Andrews, but 
unfortunately have proven unsuccessful.  
 
Figure 3.8: UV-visible spectra of (A) L-threonine external aldimine formation. The solid line 
is the holo-form of the enzyme (40 µM SPT, 20mM KPhos buffer (pH 7.5), 150 mM NaCl, 25 
°C). Increasing concentrations of L-threonine were added (0, 0.1, 0.5, 1, 2, 5, 10, 20, and 40 
mM; dotted and dashed lines), and the spectrum was recorded after 15 min. and (B) Kd 









β-Chloro-L-Alanine (β-CA ) is an L-serine analogue that has previously been 
used as an SPT inhibitor to decrease lipids in intacts cells
53, 54
 and the mechanism of 
inhibition has been studied by Ikushiro
53
 (Fig. 3.9). Addition of β-CA (Fig. 3.6) to 
SPT results in the time dependent increase of a species observed at 335 nm, which is 
thought to be an inactivating species (see Fig 3.9). The absorbance change at 335 nm 
was measured after 20 minutes with increasing β-CA concentrations (Fig. 3.10-A) 
showing that increasing β-CA concentration also increased the amount of 
inactivating species formed. To investigate β-CA as a potential SPT inhibitor, 
enzyme activity was assayed following incubation of SPT with 5 differing β-CA 
concentrations after 20 minutes at 25 °C (Fig 3.10-B). Activity assays used here 
monitor the release of enzyme-produced CoASH in the presence of the disulfide 
reagent DTNB as described in section 2.8.1. Activities are presented as % activity 
relative to an enzyme sample in the absence of β-CA. Addition of >10 mM β-CA 
resulted in a completely inactive enzyme. 
 




Figure 3.10: (A) 40 µM SPT (20 mM KPhos buffer (pH 7.5), 150 mM NaCl) after addition of 
differing β-CA concentrations (0, 0.5, 1, 2.5, 5, 10, 20, 25, 50 mM), 25 °C. Absorbance 
change was monitored at 335 nm after 20 minutes. (B) Bar chart showing % relative activity 
of SPT before and after addition of β-CA.  
The formation of the species at 335 nm is thought to be the development of an 
inactivating compound (Fig. 3.9). To confirm the species formed at 335 nm, native 
mass spectrometry analysis of the SPT:PLP:β- CA complex that developed over 20 
minutes (Fig 3.11-A) resulted in the appearance of two species (Fig 3.11-B). The 
observed average mass of each of these species were 45, 975 Da corresponding to the 
apo-SPT monomer minus the N-terminal methionine and 46, 294 Da corresponding 
to the formation of the inactive species shown in (Fig. 3.9), all in good agreement 
with predicted masses. 
 
Figure 3.11: (A) UV-visible spectra of 40 µM SPT, (20mM KPhos buffer (pH 7.5), 150 mM 
NaCl, 25 °C, solid line) after addition of 5 mM β-CA (dotted and dashed lines). The spectrum 
was recorded every minute for 20 minutes. (B) Native mass spectrometry showing the mass 




L-Cysteine and L-Penicillamine 
Substrate binding to SPT was also monitored using the amino-containing 
substrates cysteine (Cys) and penicillamine (Pen). Cys contains a thiol side chain in 
comparison to the L-serine hydroxyl and addition of L-Cys to SPT results in a 
different UV-profile from that observed when L-serine, L-threonine, L-alanine and 
glycine are used. In contrast, we observed a time-dependent decrease and broadening 
of the 420 nm peak with a concomitant appearance of a new species at 333 nm (Fig. 
3.12-A). L-cysteine was also added to a 50 µM free PLP control and again observed 
a decrease at 390 nm and the formation of a new peak at 333 nm (Fig 3.12-B).  
 
Figure 3.12: UV-visible spectra of thiazolidine formation (A) 20 µM holo-SPT (solid line) after 
the addition of 10 mM L- Cys over 30 minutes (dotted and dashed lines). (B) 50 µM free PLP 
(solid line) after the addition of 10 mM L-Cys to over 20 minutes (dotted and dashed lines). 
All experiments carried out in 20 mM KPhos buffer pH 7.5. 
The condensation of both L- and D-Cys with PLP has been previously studied by 
Terzuoli et al. who suggested that such reactions produce thiazolidine compounds
165
. 
These results suggest that the new species at 333 nm is the formation of a 




Figure 3.13: Mechanism of PLP:TA formation after the addition of L-Cys to holo-SPT. 
 
The thiol group in L-Cys is more nucleophilic than the hydroxyl counterpart in L-
serine. Therefore, L-Cys contains, along with the nucleophilic amine, two functional 
groups that could possibly react with the electrophilic aldehyde carbon in free PLP. 
To ensure that the SPT:PLP:thiazolidine adduct was formed via a Schiff base 
intermediate rather than a thiohemiacetal, N-acetyl-L-cysteine (nitrogen is blocked 
off as an amide) was added to free PLP. A small decrease at 390 nm was observed 
due to a dilution factor and no new species was observed at 333 nm (Fig. 3.14) 
suggesting that the thiazolidine adduct is formed via an SPT:PLP:L-Cys external 
aldimine rather than a thiohemiacetal.  
 
Figure 3.14: UV-visible absorbance spectra of 50 µM PLP in 20 mM KPhos buffer pH 7.5 




To further investigate the mechanism and binding of other amino thiols, Pen was also 
tested. Pen is a degradation product of all penicillins following hydrolysis of the β-
lactam ring
166
 and can also be used therapeutically as an efficient copper chelator in 
Wilson’s disease
167, 168
 since it is not degraded by humans. The naturally occurring 
isomer of Pen is the D-configuration; the L-configuration is toxic. Both L-Pen and 
D-Pen are able to interact with the vitamin cofactor PLP. Addition of L-Pen to SPT 
resulted in what we suggest to be PLP:thiazolidine (PLP:TA) formation, that reached 
completion (Fig. 3.15-A) after 30 minutes in comparison to L-cysteine. This time 
difference is likely to be due to the gem-dimethyl group through a kinetic Thorpe-
Ingold effect favouring the cyclic form of the penicillamine
169
. This suggests that the 
peak at 333 nm observed after the addition of both L-Cys and L-Pen to SPT 
represents the formation of a PLP:TA adduct at the enzyme active site, identical to 
the one formed in the model studies between L-Cys and free PLP. The PLP:TA 
adduct was removed by dialysis against 20 mM KPhos buffer indicating it was bound 
as non-covalently in the enzyme active site. Analysis of the filtrate following 
immediate filtration of the L-Pen inactived SPT sample through a 5000 MWC 
membrane confirmed that the adduct was in the low molecular weight fraction, (Fig. 
3.15-B).  
 
Figure 3.15: UV-visible spectra of SPT:PLP:TA formation (A) 20 µM holo-SPT (solid line) 
after addition of 10 mM L-Pen (dotted and dashed lines) over 30 minutes. (B) A portion of the 
L-Pen derived PLP:TA in SPT (solid line) was removed from the enzyme following filtration 




Given that transamination at Lys
265
 occurs when SPT binds its natural substrate L-
serine and no thiazolidine is formed after the addition of N-acetyl-L-cysteine to free 
PLP, it was predicted that thiazolidine formation in SPT occurs via a PLP:L-Cys 
product in the presence of L-Cys and a PLP:L-Pen external aldimine, when incubated 
with L-Pen (Fig. 3.16).  
 
Figure 3.16: Mechanism of PLP:TA formation after the addition of (A) L-Cys, (B) L-Pen to 
holo-SPT 
 
Mass spectrometry analysis was also used to confirm thiazolidine formation in SPT 
under native conditions. Prior to analysis 0.5% para-nitrobenzoic acid (pNBA) was 
used to aid charging of the protein complex in the gas phase. The spectrum of 
inactivated SPT displayed a charge state distribution from [M + 21H]
21+
 to [M + 
27H]
27+
 (Fig. 3.17-A). Maximum entropy deconvolution of the spectra revealed three 
signals corresponding to three individual enzyme species (Fig. 3.17-B). The observed 
average masses of each of these species were (i) 92, 408.5 (ii) 92, 559.5 and (iii) 92, 
707.5 Da. These masses are in good agreement with calculated average masses of (i) 
the holo-SPT homodimer with PLP bound via a Schiff base to Lys
265 
in each active 
site (calculated average mass 92 409 Da), (ii) the holo-PLP:TA-SPT homodimer with 
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PLP:TA adduct bound in each active site (calculated average mass 92 707 Da) (Fig. 
3.17-C). 
 
Figure 3.17: (A) ESI mass spectrum of holo-SPT inactivated with L-Pen under native 
conditions. (B) Deconvolution of the ESI mass spectrum revealed three species depicted in 
the cartoon representation. (C) cartoon of (i) holo-SPT mixed homodimer with PLP bound in 
each active site (ii) SPT homodimer with PLP bound in one subunit and PLP:TA adduct in 
the other. (iii) SPT homodimer with a PLP:TA adduct in each subunit.  
 
Formation of the L-Cys PLP:TA model adduct in Tris buffer also resulted in 
a characteristic peak at 333 nm. However, after prolonged incubation the 333 nm 
peak decreased and the 420 nm peak was regenerated, indicating the thiazolidine 
formation is reversible (Fig. 3.18); a similar observation was reported previously by 
Terzuoli et al.
165
 with free PLP and L-Cys. In contrast reversibility was not observed 
in an identical experiment carried out with a KPhos buffer (not shown). Reversibility 
of thiazolidine formation has been reported previously, a characteristic utilised 







Figure 3.18: PLP:TA adduct is reversible in the presence of the primary amine, Tris (A) UV-
vis spectra of 50 μM PLP in 50 mM Tris.HCl buffer (pH 7.5) (solid line) and after the addition 
of 1 mM L-Cys at 1, 30 and 60 minute intervals (dashed lines). (B) UV-vis spectra of 50 μM 
PLP in 50 mM Tris.HCl buffer (pH 7.5).The L-Cys derived PLP:thiazolidine adduct at 60 
minutes (dashed line) and 24 hours (pink line) are shown. 
 
To investigate L-Pen and D-Pen as potential SPT inhibitors, enzyme activity 
was assayed following incubation of SPT with 5 mM aminothiol (L-Pen or D-Pen) 
for 30 minutes at 25 °C. Reaction of the DTNB reagent with the penicillamine and 
cysteine free thiol in inactivated enzyme samples resulted in high background 
absorbances that prevented a full kinetic evaluation. Because of this all samples in 
Fig. 3.19 were dialysed to remove excess inhibitor prior to activity measurements. 
Activities are presented as % activity relative to an enzyme sample in the absence of 
inhibitor (Fig. 3.19). SPT activity was reduced to 3% following incubation with 5 
mM L-Pen but inhibition with D-Pen reduced SPT activity to 34% indicating 
specificity for the L-Pen enantiomer. Similar enantioselectivity was observed for 
inactivation of SPT by cycloserine, inhibition being 15-fold greater with L-
cycloserine compared to the D-cycloserine enantiomer
55
. In contrast inhibition by L-
Cys and D-Cys reduced SPT activity to 24% and 22%, respectively. This not only 
shows that L-Pen is a more potent SPT inhibitor than Cys but there appears to be no 
stereospecificity for the Cys inhibitor. Interestingly previous work using L-[3H]-
serine substrate showed that D-serine inhibited the eukaryotic SPT complex as 
effectively as unlabelled L-serine
33
. SPT samples inactivated with either L-Pen or D-
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Pen were restored to 80% and 57% activity, respectively, following dialysis against 
buffer containing 50 μM PLP. Enzyme activity was regenerated to 83% and 76% for 
SPT samples inactivated with L-Cys and D-Cys, respectively. This suggests that the 
inhibition is reversible to a large extent and that the mechanism of SPT inactivation 
by Pen occurs by disabling the PLP cofactor. 
 
Figure 3.19: Enzyme activity of Pen- and Cys- inactivated SPT is regenerated by dialysis 
against PLP buffer. All enzyme samples contained 20 µM SPT and were incubated for 30 
minutes with the above labelled amino thiols. Enzymatic rates were measured using a DTNB 
assay and plotted as % relative activity compared to an enzyme sample with no inhibitor. 
 
As well as L-Pen acting as a mechanism based inhibitor of SPT, it can also be 
used as a tool for gently removing the PLP cofactor from SPT, producing the apo-
form. Methods for removing PLP from other PLP-dependent enzymes have been 





harsher methods resulted in precipitation of SPT in my hands, therefore, addition of 
L-Pen can be used as an alternative method for removing the PLP cofactor from SPT. 
This work was published in MedChemComm, Lowther et al.
25





3.3  Probing the role of the phosphate group in PLP 
The PLP cofactor (Fig. 3.20-A) contains four functional groups of interest; 
aldehyde, hydroxyl, pyridine and a phosphate discussed in depth in chapter 1.4. 
Recently, the role of the pyridine nitrogen was studied by the synthesis of the 
carbocyclic analogue of PLP, 1-deazapyridoxal 5’phosphate (deazaPLP)
106
, (Fig. 
3.20-B) By replacement of the natural cofactor with deaza PLP it was demonstrated 
that in fact not all PLP dependent enzymes require the protonated pyridine nitrogen 
to stabilise carbanion formation of the PLP-substrate aldimine
105
. This work 
challenges the dogma that all PLP-dependent enzymes require the electron sink 
properties of the pyridine nitrogen of PLP. Surprisingly, the role of the phosphate 
group in PLP, has been less studied throughout the literature. Older studies 
established by Snell in 1972 had looked at whether a sulfate at the 5’-position of 
pyridoxal (Fig 3.20-C) could replace the phosphate of arginine decarboxylase, 
tryptophanase and D-serine dehydratase
111
. Of the three enzymes tested, only 
arginine decarboxylase was active with this modified cofactor (23% activity 
compared with the PLP-containing enzyme) which initially emphasised an 
importance for the 5’phosphate in catalysis. However, effects of replacing the 
phosphate group seemed to show no general pattern from one enzyme to another. 
 
Figure 3.20: Structure of (A) Pyridoxal 5’-Phosphate (PLP), (B)1-Deazapyridoxal 




 Interest in the phosphate group of PLP arose when we observed an unexpected 
H-bond interaction between the L-serine and 5’-phosphate in the X-ray crystal 
structure of the SPT:PLP:L-serine external aldimine complex (PDB code: 2W8J)
46
. 
As well as this H-bond the phosphate has a number of interactions with the SPT that 
together make up a “phosphate binding cup” (Fig. 3.21). The concept of the “cup” 
was proposed by Denesyuk et al. after analysis of the X-ray crystal structures from 
five different PLP enzyme fold types
109, 110
. In SPT the cup is formed by a 
constellation of residues and an ordered water molecule that bind the oxygen atoms, 
but there appears to be little conservation amongst the PLP-superfamily. However, 
within the AOS family (which display overall sequence homology of 30-40%) the 
phosphate binding ligands are well conserved. In the Sp SPT:PLP internal aldimine 
structure the seven cup-forming ligands are provided by side-chains and backbones 
from both subunits and a water molecule. In forming the key Sp SPT:PLP:L-serine 
external aldimine intermediate all of those interactions are retained and the only 
difference is the additional H-bond from the L-serine (Fig. 3.21B). 
 
Figure 3.21: (A) Structure of the PLP:L-serine external aldimine intermediate of Sp SPT 
(PDB code: 2W8J) generated using PyMol software
172
 (B) Phosphate binding cup diagram, 
(a) T294* (b) Y135 (c) G134 (d) water (e) T262; (f) S264 (g) A295* (h) L-serine-hydroxyl 
interaction (*) indicates residue from opposite subunit). 
 
 Ikushiro et al
173
 published another SPT:L-serine external aldimine structure 
from the bacterium Sphingobacterium multivorum (Sm). The overall structures of the 
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S. paucimobilis and S. multivorum SPTs are fairly similar with only subtle 
differences found by comparing the sequence from both proteins and UV-visible 
analysis, which shows Sm SPT to lack the enolimine form of both the internal and 
external aldimne. Analysis of the crystal structure of Sm SPT (PDB code: 3A2B) 
interestingly, also reveals a H-bond interaction between the L-serine and 5’-
phosphate of PLP (Appendix 1). To probe the function of this H-bond interaction the 
PLP co-factor in Sp SPT was replaced with the dephosphorylated form, pyridoxal 
(PL) (Fig.3.20-D).  
As described previously (section 3.2) L-Pen incubation can be used as a tool to 
gently and efficiently remove the natural PLP cofactor by forming a non-covalent 
PLP:thiazolidine adduct which absorbs at 333 nm (Fig. 3.22-A). Upon dialysis the 
resultant apo-enzyme was prone to precipitation, and the holo-enzyme could not be 
recovered in high yield by simple addition of PLP or dialysis against PLP-containing 
buffers. Therefore, both regenerated SPT:PLP and SPT:PL were produced by this 
exchange process (Fig. 3.22-B). This exchange process involved dialysis of the 
SPT:PLP:TA adduct directly into a PLP/no PLP or PL buffer. The SPT:PL displayed 
absorbance maxima at 320 and 420 nm which are shifted ~20 nm compared with 
SPT:PLP. It is also interesting to note that the 320 nm peak is the most dominant, 
indicating that a different tautomer predominates in the SPT:PL complex.  
Figure 3.22: (A) UV-vis spectra of SPT:PLP (solid line) and after incubation with L-Pen to 
remove the PLP (dashed line). (B) UV-vis spectra of apo-SPT (dotted line), SPT:PLP formed 
by incubation of apo-SPT with PLP (solid line), and SPT:PL (dashed line). Conditions: 20 
mM Tris.HCl, pH 7.5 and 40 µM enzyme. 
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In order to ensure that the PL was bound to the same active site residue Lys
265 
as 
PLP, chemical reduction of the SPT:PL-imine, followed by enzymatic digest and 
mass spectrometry confirmed the sequence of the peptide (Fig. 3.23). Indeed, there 
was no promiscuous binding of PL to the SPT enzyme.  
 
Figure 3.23: Peptide mass fingerprinting of SPT:PL confirms that PL binds to Lys265.  
(A) Sequence coverage achieved when analysing the trypsin digest of SPT:PL. Amino acids 
highlighted in bold were observed in the peptide mass fingerprint (total coverage - 55%). 
Lys
265
, the PLP-bound SPT active site residue is highlighted in red. A singles species, with 
monoisotopic neutral mass 3859.94 Da, displayed a mass consistent with the tryptic peptide 
G245-K280 with the covalent addition of PL (underlined). 
(B) The observed mass spectrum of the trypsin digest of PL-modified SPT (left) and the 
observed isotope distribution of the species consistent with PL-modified G245-K280 peptide 
(right). The species was observed in the [M+4H]
4+
 charge state at monoisotopic m/z 
965.9813. The theoretical isotopic distribution is overlaid on the experimental data as red 
circles ([C168H257N43O52 + C8H9NO2 + 4H]
4+;
 calculated monoisotopic m/z 965.9928 (4+); 
error 11 ppm).  
(C) Collision induced dissociation fragmentation map of the PL-modified G245-K280 peptide. 
The resulting b and y ion fragments (data not shown) represented in red ticks, were mapped 
onto the peptide sequence of SPT using ProSight-PTM. Fragmentation allowed the 






Addition of L-serine to SPT:PL led to the formation of a peak at 425 nm suggesting 
that the absence of the 5′-phosphate did not prevent the formation of the SPT:PL:L-
serine external aldimine intermediate (Fig. 3.24-A). A Kd
L-Ser
 of 12.7 mM ± 0.3 
mM was obtained for the SPT:PL complex (Fig. 3.24-B) after addition of increasing 
concentrations of L-serine. This is an 8-fold increase when compared with the Kd
L-Ser
 
for SPT:PLP (1.1 mM). This is evidence that removing the phosphate from the 
cofactor impacts on serine binding and SPT:PLP:L-serine external aldimine 
formation and suggests that the H-bond between the serine and phosphate may 
indeed play a role in substrate specificity.  
 
Figure 3.24: UV-visible spectra of SPT:PL:L-serine external aldimine formation (A). The 
solid line is the PL:holo-form of the enzyme (40 µM SPT, 20 mM Tris.HCl buffer (pH 7.5), 
150 mM NaCl, 25 °C). Increasing concentrations of L-serine were added (0, 1, 2, 5, 10, 20, 
40, and 60 mM; dotted and dashed lines), and the spectrum was recorded after 15 min. and 
(B) Kd binding curve derived from (A). Dissociation constant was determined using the 
absorbance change at 425 nm. 
The relative enzyme activity was measured using a continuous assay that monitors 
the rate of formation of the coenzyme A thiolate released during the C–C 
condensation reaction. The apo-SPT displayed a much reduced enzymatic activity of 
3% and the regenerated SPT:PLP displayed 83% activity (Fig. 3.25). In contrast, the 
regenerated SPT:PL complex displayed only 6% activity showing that catalysis in 




Figure 3.25: Activity of SPT regenerated with PLP and PL. Activity values are relative to the 
as-purified enzyme (SPT:PLP). All enzyme samples contained 20 µM SPT in 20 mM 
Tris.HCl buffer, pH 7.5. 
Using Michaelis–Menten analysis, kinetic constants were obtained for the 
regenerated SPT:PL enzyme (Table. 3.1). For as purified SPT,the Km values for L-
serine and palmitoyl-CoA (1.6 mM and 35.6 μM, respectively) and the kcat of 1.54 
s
−1




 for L-serine are all in good agreement with published 
data
46
. Similarly, the SPT:PLP regenerated enzyme displayed similar Km and kcat 
values to the as-purified SPT, with only a small increase in the Km for L-serine (2.7 
mM). In contrast, the Km for L-serine increased to 5 mM for the SPT:PL enzyme. 
The Km for palmitoyl-CoA was unaffected (33 μM) but we observed significantly 
lower L-serine kcat (0.13 s
−1




) values for the SPT:PL which 
are 12 and 37-fold lower compared with the as-purified SPT. The removal of the 
PLP phosphate has had a combined impact by weakening L-serine binding (but not 
palmitoyl-CoA binding) and severely reducing the catalytic rate of the SPT:PL 
enzyme. These data support our hypothesis that the L-serine:phosphate interaction 




Table 3.1: SPT:PLP and SPT:PL kinetic analysis table 
In addition, KDS formation was monitored directly using a stopped 
radiochemical assay based on a method previously published
24, 46
. SPT was incubated 
with 20 mM 
14
C L-serine and 250 µM palmitoyl-CoA at 37 °C for 20 minutes and 
then the reaction was quenched by the addition of NH4OH. This was then extracted 
with an equal volume of CHCl3:CH3OH (2:1, v:v). The organic phase was left to 
evaporate at 50 °C and the resulting lipid residue was re-suspended in 
CHCl3:CH3OH (2:1, v:v) and separated by TLC with a mobile phase of 
CHCl3:CH3OH (2:1, v:v). The TLC was later visualised using an imaging scanner. 
To confirm the radioactive product was KDS, Rf values were compared to a 
commercial standard analysed by TLC and detected with ninhydrin (Fig. 3.26). No 
KDS was produced by the apo-SPT but the SPT regenerated with PLP and the PL-
regenerated enzyme produced 46% and 13% KDS relative to the as-purified enzyme. 
This analysis provides further evidence that the removal of the phosphate impairs the 
catalytic activity of the SPT. 
 
Figure 3.26: TLC plate sprayed with ninhydrin. (1) KDS standard. (2) Formation of KDS by 
SPT catalysed conversion of L-serine and palmitoyl-CoA. Insert, chromatogram showing 
scan of TLC plate. 
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The increased Kd for L-serine cannot, by itself, account for the dramatic reduction in 
activity. Therefore it was also investigated if the SPT:PL:L-serine intermediate could 
be deprotonated by removal of the L-serine Cα-H. This step generates the key 
carbanion/quinonoid species (Fig 3.27-B (intermediate III)) which reacts with the 
incoming acyl-CoA thioester. Using the C16-CoA thioether analogue, S-(2-
oxoheptadecyl)-CoA (Fig 3.27-A) which has been shown to bind to the SPT:PLP:L-




Figure 3.27: (A) Structure of palmitoyl-CoA thioether analogue, S-(2-oxoheptadecyl)-CoA. 
(B) Proposed SPT mechanism showing observed intermediates and the H-bond between the 
5’-phosphate and serine hydroxyl in aldimine II. 
 
Addition of the analogue to the L-serine external aldimine form of SPT:PLP led to 
the appearance of a peak at 495 nm (Fig. 3.28-A) which is thought to be the substrate 
PLP:L-serine quinonoid (Figure 3.27-B (intermediate III)). In contrast, the PL-
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reloaded enzyme forms a broad shoulder at 495 nm under the same conditions (Fig. 
3.28-B). These results suggest that the PL cofactor may sit in a potentially ‘non-
native’ environment due to the lack of the 5′-phosphate. It can still produce the 
external aldimine (Fig. 3.27-B (intermediate II)) with reduced affinity but crucially, 
it is severely compromised in its ability to form and/or stabilise the key quinonoid 
species (Fig. 3.27-B (intermediate III)). 
 
Figure 3.28: (A) UV-vis spectra of SPT:PLP (solid line), after addition of 40 mM L-serine 
(dashed line), after addition of 1.5 mM S-(2-oxoheptadecyl)-CoA (dotted line). (B) UV-vis 
spectra of SPT:PL (solid line), after addition of 40 mM L-serine (dashed line), after addition 
of 1.5 mM S-(2-oxoheptadecyl)-CoA (dotted line). Conditions: 20 mM Tris.HCl, pH 7.5 and 
40 µM SPT. 
Upon addition of the product KDS to the SPT:PLP enzyme there were 
observed changes at 335 and 420 nm, and the appearance of a peak at 505 nm (Fig. 
3.29-A) which is thought to be the SPT:PLP:KDS product quinonoid. In contrast, the 
SPT:PL enzyme did not form the 505 nm peak (Fig. 3.29-B). Instead, a broad signal 
between 330 nm and 500 nm with a shoulder at 400 nm was observed which suggests 
the product binds but the PL:KDS aldimine then adopts an unusual conformation. 
These combined results are evidence that the PL-containing enzyme cannot 
efficiently catalyse the formation of the key substrate quinonoid. Therefore, it 
appears that the interaction between the 5′-phosphate of PLP and the L-serine 
hydroxyl group is crucial for the formation of key intermediates in the catalytic 
mechanism and in controlling the optimal orientation of the reactive 
quinonoid/carbanion that attacks the acyl-CoA thioester. This explanation lends 
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further weight to the “Dunathan hypothesis” which was put forward over 40 years 
ago
92
 to explain the stereoelectronic control that the cofactor provides during PLP-
dependent catalysis as discussed in chapter 1.4.2.  
Figure 3.29: (A) UV-vis spectra of SPT:PLP (solid line), after addition of 25 µM KDS (dashed 
line) (B) UV- vis spectra of SPT:PL (solid line), after addition of 25 µM KDS (dashed line). 
Conditions: 20 mM Tris.HCl, pH 7.5 and 40 µM enzyme. 
SPT:PLP has been reported to have extremely poor affinity for L-phosphoserine with 
a Kd > 100 mM 
53
. Experiments were also carried out with this substrate analogue in 
hope that we could re-introduce the critical phosphate:H-bond interaction using L-
phosphoserine as a substrate for the SPT:PL enzyme. However, no substrate binding, 
nor detectable activity was observed, suggesting that the key phosphate-hydroxyl 
interaction cannot be formed in this complex (data not shown). This reiterates the 
essential role of the hydroxyl group of L-serine.  
In our lab, the crystal structure of Sp SPT with a C-terminal His-Tag (Fig. 
3.31-A) was solved in 2009
46
. In a separate study by fellow PhD student, John 
Wadsworth, the crystal structure of a new Sp SPT construct with a 12 amino acid 
linker followed by an N-terminal His-Tag was recently solved with myriocin bound
56
 
(Fig. 3.31-B). As discussed in chapter 1.2.6 myriocin is the most widely used 
inhibitor of SPT and notably the Schiff’s base external aldimine formed between 
PLP and myriocin is analogous to that formed between PLP and a known but weak 
inhibitor, D-serine. Since myriocin has a D-configuration it was discovered that it 
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acts as a dual mode inhibitor of SPT by initially binding to the enzyme active site 
before it is broken down to generate a reactive aldehyde (Fig. 3.30). 
 
Figure 3.30: Myriocin dual mode of action on SPT. Myriocin reacts with PLP in the active 
site to form the inhibitory PLP-myriocin aldimine , this species is stable for greater than 1 h 
with inhibition being reversible upon addition of excess PLP (right). Left: PLP-myriocin 
aldimine decomposes over 16 h, to produce a long chain aldehyde that reacts with the active 
site lysine to form an imine, thus rendering the enzyme inactive. This covalent modification 
can be classed as suicide inhibition. This figure was adapted from reference 
56
. 
This aldehyde then acts as a suicide inhibitor by covalently modifying the 
active site lysine residue in all SPTs. Mutating this fundamental lysine residue to an 
alanine forming the catalytically inactive K265A mutant has allowed us to capture a 
PLP:decarboxymyriocin external aldimine in the active site. A comparison of the 
wild-type PLP:L-serine external aldimine with the K265A PLP:decarboxymyriocin 









 are all within the same relative positions within 
the active site. More importantly, the hydroxyl group at position C2 of myriocin 
interacts with the 5’-phosphate of PLP mimicking the PLP L-serine external 
aldimine. Despite the opposite stereochemistry of myriocin at the Cα position 
compared with L-serine, the hydroxyl still hydrogen bonds to the 5’-phosphate of 
PLP (Fig. 3.31-B). These interactions on the SPT:myriocin complex not only 
rationalise the competitive inhibition of L-serine that myriocin displays, but stresses 
the significance of the hydroxyl-PLP phosphate interaction. 
 
Figure 3.31: Phosphate binding cup analysis using the PyMol Software
172
 (A) Structure of 
the PLP:L-serine external aldimine intermediate of Sp SPT (PDB code: 2W8J) (B) Structure 
of the PLP:decarboxymyriocin aldimine of Sp SPT (PDB code: 4BMK). Residues from 
monomer A are shown in green and monomer B are show in blue. The ordered water 
molecule is shown in red and in sphere format. 
Since SPT is the first enzyme in SL biosynthesis it should be highly specific for L-
serine as a substrate and not accept L-alanine or glycine which would generate 
downstream deoxySL products. This work provides evidence that amino acid 
substrate specificity is not only controlled by active site residues from SPT but also 
by an interaction between the phosphate of the PLP cofactor and the L-serine side-
chain. L-serine is used as a substrate by other PLP-dependent enzymes such as serine 
racemase, serine dehydratase and serine hydroxymethyltransferase so it will be 
interesting to investigate whether the 5′-phosphate also plays a catalytic role in these 
important metabolic proteins.  
 
 105 
3.3.1 Analysis of PLP phosphate cup binding of other AOS members 
Analysis of the phosphate ‘cup’ of the Sp SPT:L-serine external aldimine 
initiated an interest in appreciating the residues involved in securing the phosphate of 
other PLP:amino acid external aldimines. There are very few PLP:L-serine:external 
aldimine structures deposited in the PDB, therefore other AOS amino 
acid:PLP:external aldimines were investigated in order to gain some insight into the 
origin of specificity of the superfamily. A captivating observation was made when 
comparing the crystal structure of the SPT:PLP:L-serine external aldimine (PDB 
code: 2W8J, 1.5Å) with the ALAS:PLP:glycine external aldimine (PDB code: 
2BWP, 2.7Å), (Fig. 3.32). 
 
Figure 3.32: (A) Structure of the PLP:L-serine external aldimine intermediate of Sp SPT 
(PDB code: 2W8J) generated using the PyMol software
172
. The ordered water molecule is 
shown in red and in sphere format. Phosphate binding cup diagram is shown below where, 
(a) S264 (b) A295* (c) T294* (d) Y135 (e) G134 (f) Water (g) T262 (h) L-serine-hydroxyl 
interaction. (B) Structure of the PLP:glycine external aldimine intermediate of ALAS (PDB 
code: 2BWP) generated using PyMol software
172
. Phosphate binding cup diagram is shown 
below where, (a) L248 (b) T278 (c) T278 (d) S277* (e) Y116 (f) A115 (g) T245. Where, (*) 
indicates residue from the opposite subunit.  
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It is interesting to note that an ordered water molecule is involved in 
anchoring the PLP in the SPT:L-serine external aldimine, whereas only residues are 
involved in the phosphate binding cup of the ALAS:glycine external aldimine. As a 
result, one would expect that SPT should be more flexible than ALAS that lack the 
water molecule. This is observed in the hyperthermophile Thermotoga maritima, an 
enzyme that has three water molecules in the PLP binding site, resulting in a flexible 
binding pocket that is thought to play a role in the temperature dependence on the 
activity of the enzyme
110
. 
Fig. 3.32A shows the additional interaction (h) that SPT makes with the 
hydroxyl of substrate L-serine. This is the followed by an interaction with the amide 
backbone of Ala
295
*(b) from the second subunit. In the ALAS:PLP:glycine external 
aldimine there is of course no hydroxyl present on the substrate amino acid to allow 
for the same interaction as SPT. Interestingly Thr
278
* (b) of ALAS (Fig. 3.32-B) 
plays a dual role, making two interactions with the phosphate oxygens of PLP; a 
side-chain hydroxyl and an amide backbone interaction. This threonine residue in 
ALAS could be providing the necessary hydroxyl interaction with the phosphate of 
PLP, as demonstrated in the SPT:L-serine external aldmine. Sequence alignment of 
other members of the AOS family show that Ala
295
 is replaced with a threonine 
residue in not only ALAS but also AONS (Fig 3.33). AONS uses L-Ala as a 
substrate, which also lacks a hydroxyl group. This suggests the question, if Ala
295
 in 
SPT is replaced with a threonine residue, would this residue then provide the 
phosphate – hydroxyl interaction that is needed for optimum activity and shift 
substrate specificity from L-serine to alanine or glycine? Thus, our aim was to 





Figure 3.33: Sequence analysis of the AOS family of PLP dependent enzymes; SPT, 
(Uniprot code: Q93UV0, PDB: 2W8J); AONS, E. coli (P12998, PDB:1DJ9); KBL, E. coli 
(P0AB77, PDB: 1FC4), ALAS, R. capsulatus (P18079, PDB: 2BWP). The sequence 
alignment was generated using CLUSTALW2. Conserved residues are shown in yellow, 
residues involved in PLP binding are in green and residues involved in the phosphate 
binding cup are shown in cyan. 
3.3.2 Sp SPT A295T mutant 
3.3.2.1 Cloning 
The A295T mutation was introduced into the SPT gene by site directed 
mutegenesis (Stratagene) using the pET-28a/SPT WT plasmid as a template. After 
transformation in C2987 cells and DNA purification the mutant was confirmed by 




3.3.2.2 Expression and Purification 
Expression was initially optimised by varying temperature, induction time 
and IPTG concentration in a small scale induction. The optimum expression was 
with 0.1 mM IPTG at 30 °C for 4 hours in BL21 (DE3) competent cells. Large scale 
induction was carried out and a 3g cell pellet was initially used for a single 
purification. The cell free extract was harvested by sonication and centrifugation. 
The C-terminal hexa-histidine SPT A295T mutant was purified by Ni-NTA agarose 
affinity chromatography. SDS-PAGE analysis gave rise to a band at ~45 kDa and 
size exclusion chromatography indicated a dimer (~90 kDa), identical to WT SPT 
(data not shown). 
 
3.3.3 Spectroscopic properties and substrate specificity 
From the SPT:L-serine external aldimine structure it was observed that Ala
295
 
played an important role in anchoring the PLP cofactor. It is possible that mutating 
alanine to a threonine could completely perturb PLP binding, containing not only a 
hydroxyl group but also a bulky methyl group. Binding of the PLP cofactor was 
barely affected by this mutation, still displaying maximum absorbance values similar 
to WT SPT (335 nm and 420 nm, Fig. 3.34-A), conversely the enolamine (335 nm) 
peak is observed as the most prominant (Fig. 3.34-B). The ability for the mutant to 
bind SPTs natural substrate L-serine, forming an external aldimine species was 
studied with increasing substrate concentrations. Addition of L-serine to the A295T 
mutant resulted in an increase in absorbance at 425 nm as observed in the WT 
enzyme. However, the ΔAbs was less for the mutant in comparison to the WT SPT. 
This result demonstrates that SPT residue 295 plays a role in substrate binding. Next, 
the ability of the mutant form of SPT to bind L-alanine and glycine was investigated 
in comparison to the WT enzyme. Both WT SPT and A295T SPT were unable to 
accept glycine as a substrate. After addition of varying concentrations of L-alanine 
the ΔAbs was less for the WT enzyme (Fig. 3.34-C) in comparison to the A295T 
mutant (Fig 3.34-D). These results are very subtle, but an encouraging idea is that 
one point mutation can cause a delicate shift in substrate selectivity. This is 
preliminary data and scope for a new project. A larger range of substrate 
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concentrations must be used to confidently calculate Kd values. It would be 
interesting to check the enzyme activity of the A295T mutant with L-alanine using 
the continuous DTNB assay. Making an A295S mutant would also be thought-
provoking. A serine residue would still provide the hydroxyl interaction needed 
without the methyl bulk of threonine. Mutating alanine to a serine could result in 
acceptance of glycine as well as L-alanine. Similarly, it would also be interesting to 
prepare a T278A ALAS mutant and investigate if it’s specificity had been switched 
from glycine to L-serine. These are promising premilinary results that should be 
taken forward in a new project. The reconstitution of SPT with pyridoxal was 
published in ChemComm
174
 (see publications section) and the myriocin PBC analysis 
was incorporated into a JACS paper by Wadsworth et al.
56






Figure 3.34: UV-analysis of WT SPT and A295T mutant. (A) WT SPT (B) A295T SPT. The 
solid line in each spectrum is the holo-form of the enzyme. Increasing concentrations of L-
serine were added (0, 0.1, 0.5, 1, 2, 5, 10, 20, 40 mM dotted and dashed lines). (C) A295T 
SPT. The solid line in each spectrum is the holo-form of the enzyme. Increasing 
concentrations of glycine were added (0, 2, 5, 10, 20, 40, 60, 80, 100 mM dotted and dashed 
lines). (D) A295T SPT. The solid line in each spectrum is the holo-form of the enzyme. 
Increasing concentrations of L-alanine were added (0, 2, 5, 10, 20, 40, 60, 80, 100 mM 
dotted and dashed lines).  
 
3.3.4  Conclusion 
In view of the hydrogen bond interaction observed in Sp SPT between the 
hydroxyl L-serine substrate with the phosphate moiety of PLP, it was fascinating to 
determine this contact to be fundamental for substrate specificity and catalytic 
activity of the enzyme. The natural PLP cofactor was gently and efficiently removed 
by forming a PLP:thiazolidine adduct after addition of L-Pen. Regeneration of SPT 
with the dephosphorylated form of PLP, PL, resulted in the formation of a SPT:PL 
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holo form with an altered UV absorbance maxima of the enolimine and ketoenamine 
forms showing peaks at 335 nm and 420 nm. The dissociation constant of L-serine 
increased 8-fold and the environment of this external aldimine seems to be affected. 
Crucially, when the second acyl-CoA substrate is added, the enzyme is severely 
compromised in forming the key carbanion/quinonoid species. These results confirm 
that the interaction observed between the 5’-phosphate of PLP and the L-serine 
hydroxyl plays an important role in quinonoid stabilization. It is plausible that the PL 
cofactor is sitting in a ‘non-native’ environment which is disrupting Cα rotation and 
therefore control of the optimal orientation of the quinonoid intermediate to allow for 
subsequent deprotonation. This supports the ‘Dunathan hypothesis’ for the stereo 
control of PLP enzymes, that bond being broken must be in a plane perpendicular to 
the   orbitals of the PLP electron sink92.  
The residues involved in anchoring the 5’-phosphate of PLP in the active site 
of members of the AOS family have been described in terms of a ‘phosphate binding 
cup’. Analysis of the phosphate binding cup of the ALAS:glycine external aldimine 
revealed an important residue that could possibly be involved in determining 
substrate specificity of these enzymes. In SPT, the Ala
295 
residue is replaced with a 
threonine in ALAS and AONS. The threonine residue has a hydroxyl available to 
interact with the phosphate of PLP and both ALAS and AONS cannot form this H-
bond contact with their respective amino acid substrate (glycine and L-alanine). This 
A295T mutation has been incorporated into SPT and the mutant was expressed and 
purified. Preliminary studies suggest this mutant has a binding preference for L-
alanine over L-serine. Further investigation on activity is required to confirm if 
providing a hydroxyl interaction from threonine to PLP provides scope for shifting 
substrate specificity from L-serine to L-alanine and glycine. Another idea would be 
using site-directed mutagenesis to make the A295S SPT mutant and T278A ALAS 







3.4 Hereditary sensory and autonomic neuropathy type 1 SPT 
mutants 
Previous studies on human SPT have shown that mutations in the first subunit 
hLCB1 have been associated with HSAN1. Like other HSAN1 mutations, in human 
SPT the substrate specificity shifts from L-serine to L-alanine and glycine producing 
known neurotoxic sphingolipid metabolites 1-deoxy-SLs. The heterodimeric human 
SPT displays many difficulties to work with as both subunits are thought to be 
situated in the membrane of the endoplasmic reticulum (ER). In a previous study by 
Campopiano and colleagues the crystal structure of the PLP-bound, holo-form 
homodimeric Sp SPT was used to map the C113W/C113Y human HSAN1 mutations 
to residue N100 on the bacterial enzyme
46
. The bacterial enzyme is a good model for 
the human enzyme due to the high sequence homology shared between them. Both 
bacterial mimics of the HSAN1 mutations, SP SPT N100W and N100Y, were shown 
to significantly reduce SPT enzyme activity and cause perturbations of the PLP 
biding site. Crystal structures for both mutations have been solved and show a 
hindrance of movement of a catalytically important residue Arg
378
. These were the 
first data to provide information on how HSAN1 mutations may lead to defects in 
enzyme activity. Recent screens identified three heterozygous missense mutations in 
the second human SPT subunit hLCB2 that show a significant loss in SPT activity. 
The three human SPT mutations V359M, G382V and I504F were mapped onto the 
bacterial SP SPT as V246M, G268V and G385F (Fig. 3.35). A focus of this project 
was to prepare these mutation mimics in the bacterial enzyme and characterise their 




Figure 3.35: Structure of the hLCB2 HSAN1 mutations that were mapped onto Sp SPT 
enzyme showing the change in amino acid structure. 
 
3.4.1 Cloning of pET28a/SPT V246M, G268V and G385F 
HSAN1 mutant mimics were incorporated into the SPT gene by site directed 
mutegenesis (Stratagene) using the pET-28a/SPT WT plasmid as a template. After 
transformation in C2987 cells and DNA purification the mutant sequence was 
confirmed by Big Dye sequencing. 
 
3.4.2 Expression and purification of HSAN1 SPT2 mutant mimics.  
The three mutant proteins were expressed using established protocols
46
. Two 
of the three mutants (Sp SPT V246M and G385F) were soluble. In contrast, the 
G268V mutant was found to be insoluble and several attempts were made to improve 
the solubility of the protein (such as changing expression cell lines, induction at 
lower temperature and different IPTG concentrations (data not shown)); however the 
majority of the protein remained in the cell pellet suggesting this particular HSAN1 
hLCB2 mutation leads to substantial protein miss-folding of the bacterial mimic. The 
other two mutants (Sp SPT V246M and G385F) were obtained in milligram 
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quantities and purified via nickel affinity chromatography as previously described for 
the wild-type SPT
46
. Both V246M and G385F behaved as dimers by size exclusion 
chromatography (molecular weights ~90kDa) and displayed elution profiles similar 
to wild-type SPT (data not shown). 
 
3.4.3 Spectroscopic properties of WT SPT and HSAN1 mutant mimics.  
Initial analysis of the Sp SPT V246M (Fig. 3.36-B) and G385F (Fig. 3.36-C) 
by UV-vis spectroscopy revealed that both HSAN1 mutants display spectra similar to 
wild-type SPT(Fig. 3.36-A), which has two absorbance maxima at around 335 and 
420 nm. These peaks are characteristic of the holo, PLP-bound internal aldimine 
form of the enzyme, arising from the two tautomeric forms of PLP. These results 
confirm that both mutants were purified with the PLP cofactor covalently bound in 
the enzyme active site as an imine to Lys
265
. However, on closer inspection it is clear 
that there are subtle differences in the spectral profile of SPT G385F compared with 
the wild type enzyme. In contrast to the wild type SPT, the UV-visible spectrum of 
SPT G385F shows a significant blue shift with maximum absorbance values of 330 
nm and 410 nm (Fig. 3.36-B). This suggests that mutation at position 385 has had an 
impact on the way the PLP co-factor binds at the active site of SPT.  
Analysis of the wild-type SPT and both mutants led to the determination of 
the apparent L-serine dissociation constants (Kd
L-ser
, Table 3.2). L-serine was able to 
form the external aldimine in wild type and both mutant forms of SPT. Wild-type 
SPT binds L-serine with a Kd
L-ser 




of 1.5 mM was 
obtained for the V246M mutant. This analysis supports the initial observation (based 
on UV-vis data) that PLP is bound in the same environment as that of the wild-type 
enzyme. In contrast, a Kd
L-ser 
of 4.7 mM was obtained for mutant G385F, a ~4 fold 
increase in comparison to the WT SPT and suggesting that this mutation has had 
some impact on both PLP and substrate binding. We have shown previously that the 
wild-type bacterial SPT is unable to use glycine or L-alanine as substrates to allow 
formation of deoxy-SLs to appreciable levels and neither the V246M and G385F 




Figure 3.36: UV-Vis spectral analysis of Sp SPT wild-type and mutant mimics. Absorbance 
spectra of (A) Sp SPT wild-type (B) SPT V246M and (C) SPT G385F and the Kd derived 
from this data. In the wild-type spectrum (A), the enolimine (335 nm) and ketoenamine (420 
nm) forms of the external aldimine are shown. The solid line in each spectrum is the holo-
form of the enzyme (40 µM SPT, 20 mM potassium phosphate buffer (pH 7.5), 150 mM 
NaCl, 25 °C). Increasing concentrations of L-serine were added (0, 0.5, 1, 2, 5, 10, 20, 40 




3.4.4 Kinetic analysis and KDS formation of SPT WT and HSAN1 
mutant mimics. 
In order to ascertain the effect that each of the HSAN1 SPT2 mutant mimics 
has on enzyme catalysis, Michaelis–Menten kinetic analyses were performed for the 
wild-type, V246M and G385F enzymes using a DTNB assay that monitors formation 
of the CoASH product. The wild-type SPT bound L-serine and palmitoyl-CoA (C16-
CoA) with Km values of 1.6 mM and 35.6 µM, respectively (Table 3.2). The enzyme 
turned over with a kcat of 1.14 s
-1









for the acyl-CoA – all in good agreement with published values 
46
. 




 for L-serine 
 
(4- and 5- fold) 




 for C16-CoA (9- and 4-fold lower) for the V246M and 
G385F mutants, respectively were obtained (Table 3.2). In addition KDS formation 
directly using incorporation of 
14
C L-serine was monitored directly. Both mutants 
were less active and displayed 84% (V246M mutant) and 15% (G385F) KDS 
production relative to the wild-type SPT enzyme. 
 
 
Table 3.2: Kinetic parameters for the wild-type Sp SPT and HSAN1 mutations (V246M, 
G385F and G268V) showing Km, kcat and Kd values. 
 
3.4.5 Modelling the structural impact of HSAN-1 mutations 
Unfortunately, neither of the Sp SPT V246M and G385F HSAN1 mutant 
mimics crystallised (under the same conditions as wild-type
46
 or by screening for 
new conditions). Therefore, to rationalise the impact that each of the HSAN1 hLCB2 
mutations has on the structures of these altered enzymes, modelling was carried out 
based upon the crystal structure of holo-SPT (PDB: 2JG2) and the SPT:PLP-L-serine 
external aldimine complex (PDB: 2W8J). It is worth noting that the PLP-binding site 
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is at the subunit interface between the two monomers and the active site is formed by 
residues from both subunits. Using the “mutagenesis” tool within PyMol
172
 to 
replace the wild-type side-chain with each mutant side-chain and applied the default 
conformational constraints was used to produce a structural model (Fig. 3.37 and Fig. 
3.38). Interactions that were within 5 Å of each mutant residue of interest are 
highlighted (Fig. 3.37 and Fig. 3.38). The amide backbone of G268 makes polar 
contacts with the side-chain of S97 and the backbone of F263 and most importantly 
the backbone of the crucial K265 residue involved in PLP binding (Fig. 3.37-A). The 
model predicts that these polar contacts to S97 and F263 are maintained after 
inclusion of the isopropyl side-chain of the G268V mutant; however, it loses the 
polar contact with the K265 residue (Fig. 3.37-B). The most interesting/important of 
these is the additional contact made with the backbone of M78 (from the same 
subunit) that leads to a severe steric clash with the side-chain of V268 (Fig. 3.37-B). 
This interaction is not present in the WT structure (Fig. 3.37-A) and suggests that the 
bulky hydrophobic valine residue cannot be accommodated at this position. This 
structural change may well be the cause of the observed detrimental effect on protein 
solubility. 
 
Figure 3.37: Structural models of the HSAN-1 mutant mimic Sp SPT G268V using the Sp 
SPT PLP-L-serine external aldimine structure (PDB:2W8J). (A) Wild type Sp SPT 
highlighting interactions within 5 Å of G268 (B) Mutated residue Val 268 showing new 






The side chain of residue V246 is in a hydrophobic pocket in close proximity to F239 
and V204 and the amide backbone makes polar contacts with the side chain of E232 
and the backbone amides of A249 and Q250 (Fig. 3.38-A). In the model, mutation of 
this residue to a methionine does not cause any severe alterations or clashes and the 
M246 side chain is accommodated in the same pocket (Fig. 3.38-B). Nevertheless, 
this mutation does have some impact on the palmitoyl-CoA binding by reducing the 
Km ~4 fold and (kcat/Km
PCoA




Figure 3.38: Structural models of Sp SPT V246M mutation using the Sp SPT L-serine 
external aldimine structure (PDB:2W8J) (A) Wild-type SPT with V246 (B) Model of SPT 





Position G385 is shown to be on the surface of SPT and solvent exposed. Mutation 
of this residue to F385 may result in this hydrophobic side chain preferring a buried 




 that is known to undergo conformational change during the 
catalytic cycle. Residue R378 is known to bind the carboxylate of the L-serine 
substrate in the PLP-L-serine external aldimine complex and to do so undergoes 
large movement brought about by the structural changes of the PPATP loop
46
. 
Mutation of R378 impacts both substrate binding and catalysis; our model suggests 
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that the introduction of F385 would alter the conformational flexibility of the enzyme 
(Fig. 3.39). This is indeed the case since we observed a ~5 fold decrease in efficiency 
(kcat/Km
L-ser
) of the G385F mutant compared with wild type (Table 3.2). 
 
 
Figure 3.39: Structural models of the Sp SPT G385F mutant mimic based on (A) Sp SPT 
holo structure (PDB: 2JG2) and (B) the L-serine external aldimine structure (PDB:2W8J). 
Residues from monomer one are shown in white, residues from monomer two are shown in 
teal, the PLP co-factor is shown in green, and the mutated glycine to phenylalanine residue 





Two of the three recently-discovered human hLCB2a HSAN1 causing 
mutations (V359M and G382V) are found at residues that are strictly conserved in 
the LCB2s from human, mouse, fly, rat, zebra fish, yeast and bacterial SPT
70
. The 
third, I504, is less highly conserved; in fly (Drosophila melanogaster) it is a 
methionine and in bacterial Sp SPT enzyme it is a glycine. The HSAN1 causing 
mutations in hLCB2a (V359M, G382V and I504F) correspond to bacterial Sp SPT 
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mutations V246M, G268V and G385F respectively). G268 is three residues away 
from the essential active site residue K265 and in the 3D structure makes contacts 
with the backbone of this residue. It was not surprising that introduction of G268V 
into Sp SPT resulted in a drastic reduction in protein solubility, presumably due to 
misfolding during recombinant expression. Modelling studies reveal that this residue 
is also near to the side chain of residue N100 from the opposite subunit of the 
homodimer as previously discussed. In mutating G268 to valine, polar contacts to the 
K265 residue are lost. A plausible explanation for the misfolding of the G268V 
mutant is that it disrupts the polar contacts with the key lysine residue. The global 
fold of the protein could also be adversely affected by an apparent steric clash 
between the side-chain of valine in position 268 and the backbone of Met
78
. The 
G268V model predicts that this H-bond is lost and is therefore not surprising that this 
mutation causes such detrimental effects of the bacterial enzyme. 
 In contrast to the G268V, both V246M and G385F mutant were soluble. 
Modelling studies do not give a clear insight as to the structural basis for the HSAN1 
phenotype in the V246M or G385F mutants. These mutations appear to be more 
subtle. However, analysis of the PLP cofactor binding and enzyme kinetics of these 
two mutant mimics does provide some clue as to why these changes would cause 
alterations of the hLCB2a subunit that would lead to the HSAN1 phenotype. For 
V246M The apparent Kd
L-ser 
is unchanged by the incorporation of the HSAN1 
mutation, suggesting that, in this case, the key PLP:L-serine external aldimine 
intermediate can also form as it would in native SPT. The V246M mutant mimic also 
displays a significantly higher Km for the acyl-CoA thioester substrate, suggesting 
that binding of this substrate is compromised, at least subtly in this mutant. This is 
useful information about a residue potentially involved in binding the second 
substrate since, to date, we still do not have a structure of the Sp SPT PLP complex 
with palmitoyl-CoA bound. For the G385F mutant it is plausible that swapping the 
large hydrophobic phenylalanine residue from glycine may lead to it adopting an 
alternative conformation. This has the potential to substantially affect the architecture 




 loop which 





 Without any crystal structures of the HSAN1 mutant mimics it is impossible 
to confidently propose any effect these mutation have on specific residues and 
overall structure of the protein. To improve the PyMol models made throughout this 
study, Molecular Dynamic simulations around a 15Å radius of the active site could 
be used to gain further insight into these single point mutations. This computational 
method would provide detailed information on the fluctuations and conformational 
change of the protein by calculating the time dependent behaviour of the molecular 
system. Minimisations could also be carried out, and information could be gained 
from resulting increased or decreased B-factors which would indicate the true static 
or dynamic mobility of an atom. It would be beneficial to transfer these mutations 
into a different SPT construct, namely ‘American Sp SPT’ that has recently been 
crystallised in our group with myriocin bound
56
. It would be advantageous to be able 
to compare the crystal structures to the hypothetical models. Since bacterial mimics 
are unable to shift substrate specificity, they are unable to provide any more 
information to support the hypothesis that HSAN1 is caused by a build-up of L-
alanine and glycine derived ‘deoxy-SL’s’. From the SPT crystal structures available 
there is no indication of residues that could be preventing the selection of L-alanine 
and glycine. However, the work described in section 3.3 involving the importance of 
the interaction of the hydroxyl of the L-serine substrate with the phosphate group of 
PLP may shed some light onto the origin of specificity of SPT. In a collaborative 
effect we combined our data with that from Prof. Teresa Dunn’s lab (Uniformed 
Services University of the Health Sciences, Washington DC) and this work was 
published in Biomed Res Int
175
 (see publications section).  
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3.5 Probing the Sphingomonas wittichii SPT:ACP complex 
Sphingomonas wittichii (Sw) is a sphingolipid producing organism; therefore 
contains a gene encoding an SPT homologue. It was previously discussed that other 
members of the AOS family are expressed with an accompanying acyl carrier protein 







). The entire Sw genome has been 
sequenced
176
 and interestingly a gene encoding a small ACP was found immediately 
upstream from the SPT gene (Fig. 3.40). Since the two ACP/SPT genes are linked a 
curious hypothesis is that Sw SPT utilises a C16-ACP substrate instead of C16-CoA 
The expression, purification and characterisation of Sw SPT and Sw ACP was first 
described by Raman et al.
44
. Subtle differences between Sw SPT and its homologue 
Sp SPT were observed
44
. The X-ray crystal structure of Sw SPT gave insight into 
slight differences between the two forms of SPT (Sw and Sp) and it was illustrated 
that the entrance to the active site at the “top” of the protein surfaces was notably 
wider than that observed in Sp SPT. Furthermore, Sw SPT displayed the same UV-
visible profile as Sp SPT and was also enzymatically active; however, a kinetic study 
revealed it was ten-fold slower than Sp SPT. Previous attempts to transfer a 
palmitoyl group (C16) on to Sw ACP were unsuccessful and have therefore been 
unable to prove or disprove this hypothesis. Further attempts were made in this work 










3.5.1 Expression and Purification of S. wittichii ACP and SPT 
A pET-28a plasmid containing ACP-SPT was available at the start of this 
project and expression and purification was optimised and described by Raman et 
al.
44
. It is interesting to note that the ACP could not be expressed alone and required 
co-expression with the SPT gene. The co-expression of ACP-SPT in pET-28a was 
used to transform BL21 (DE3) competent cells and protein expression was induced 
with 0.1 mM IPTG in LB broth for 5 hours. SPT contains a C-terminus 6 histidine 
tag which enabled purification of the protein by nickel affinity chromatography. It 
was initially hoped that untagged ACP would co-elute with SPT by forming an ACP-
SPT complex. However, SPT bound to the Ni resin, whereas ACP remained in the 
CFE. This result suggested one of two things; there were only weak/no interactions 
between both proteins or the ACP was purified in its inactive apo-form. SPT was 
further purified by gel filtration chromatography, confirming it was a dimer (Fig. 
3.41-A). It possessed the same spectroscopic properties as that reported by Raman et 
al
44
. The holo-protein was analysed by native mass spectrometry to allow the capture 
of the dimer form of the protein with PLP bound. A mass of 89, 430 Da was 
observed in good agreement with the calculated mass. 
 
Figure 3.41: (A) Elution profile of the size exclusion column monitored at A280 nm. (B) ESI 
mass spectrum of holo-SPT inactivated with L-Pen under native conditions. 
 
The Sw ACP was further purified by anion exchange chromatography. Sw ACP 
eluted at roughly 0.3M KCl confirmed by SDS-PAGE. Fractions containing the 
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protein of interest were pooled, concentrated and loaded onto a gel filtration size 
exclusion column, eluting pure, monomeric Sw ACP (Fig. 3.42). 
 
Figure 3.42: (A) SDS-PAGE, Lane 1: LMW marker, lane 2-5: size exclusion fractions. (B) 
Elution profile of S75 size exclusion column (A280 nm). 
 
3.5.2 Characterisation of SW ACP 
Purified Sw ACP was analysed by LC-ESI-MS to determine its post-
translational status. It has a measured mass of 8784 Da, (Fig. 3.43) which is in 
agreement with the theoretical mass (M+H)
+
 of the apo-ACP lacking the N-terminal 
methionine. This result gave a valid explanation as to why ACP and SPT did not co-
elute during purification - the ACP is in its inactive form. This result also suggests 
that the ACP is not modified to its active form by the endogeneous acyl-carrier 




Figure 3.43: The FT ESI-MS of the apo-ACP. The top panel is the ion envelope of the 9+ to 
5+ charge states of the ACP. The bottom panel shows the theoretical isotope envelope (in 
red dots) of the 7+ charge state of the apo-ACP based on its empirical formula. 
 
3.5.3 Modification of SW ACP with PPTase 
To become catalytically active apo-ACP must be post-translationally modified 
to its active holo-form by the transfer of a phosphopantetheine arm (4’-PP). This 
reaction is catalysed by a specific PPTase, converting the serine side chain hydroxyl 
into a thiol (see section 1.6.3). Numerous studies have shown some promiscuous 
PPTases have been able to directly transfer an acyl chain in addition to the 4’-PP 
group from an acyl-CoA in one step. Previously, several PPTases were used to study 
acyl transfer to Sw ACP by Raman et al.
44
; S. coelicolor AcpS, B. subtilis Sfp and S. 
verticillus Svp. The results confirmed only Sfp could transfer short acyl chains, 
however, failed to transfer the C16 chain. Sequence alignment of several FAS II 
ACPs revealed an unusual bulky tryptophan residue directly before the DSL motif. 
Raman et al. produced models of the Sw ACP against ACP from E .coli (Fig. 3.44). 
These models show the tryptophan residue (W37) in a position that could possibly be 




hypothesis is that this tryptophan residue could be blocking the transfer of longer 
acyl chains. If this residue plays a role in modification to the holo-form then 
mutating the tryptophan to an alanine may produce the ACP in the active holo-form. 
Furthermore, if it plays a role in acylation then this mutation may allow the transfer 
of longer acyl chain lengths, namely C16. Sequence alignment of Sw ACP against 
other members of both the FAS and PKS family (Appendix 2) reveal extremely low 
sequence homology, suggesting this ACP is unique. Directly before the possibly 
problematic tryptophan, Sw ACP contains a glutamic acid residue which is replaced 
for a glycine in almost all other ACPs. A double mutation was therefore made 
(E36G/W37A) to mimic most ACPs in hope that this would allow for the acylation 
of Sw ACP. 
 
 





generated Sw ACP 3D-model. The Sw ACP Swiss-model, coloured cyan and the Sw ACP 
JIGSAW-model is coloured green. Trp37 is shown in stick form. (B) Overlay of E. coli acyl-
ACP structure (PDB: 1LOH) and Sw ACP model shown in green with Trp37 residue shown 











3.5.4  Cloning of pET 28a/ACP-SPT E36G/W37A plasmids 
The double ACP mutation (E36G/W37A) was introduced into the SPT gene by 
site-directed mutagenesis (Stratagene) using the plasmid pET28a/ACP-SPT as a 
template. After transformation into C2987 cells and purification of DNA samples the 
mutations were confirmed by Big Dye sequencing.  
 
3.5.5  Expression and Purification and Mass Spectrometry analysis 
Expression was optimised in BL21 (DE3) competent cells for 5 hours at 30 °C 
with 0.1 mM IPTG. The same purification protocol was carried out as with the WT 
clone. Unfortunately, the SPT and ACP E36G/W37A did not co-elute. The mutated 
ACP was further purified by anion exchange, eluting at the same salt concentration 
as that for WT. Fractions were pooled, concentrated and loaded onto a S75 gel 
filtration size exclusion column. The protein could not be detected by absorbance at 
280 nm due to not possessing any aromatic residues, therefore all fractions were 
analysed by SDS-PAGE. Purified Sw ACP E36G/W37A was also analysed by LC-
ESI-MS. A mass of 8597 Da was measured, (Fig. 3.45). This corresponds the 
theoretical mass (M+H) of the apo-ACP lacking the N-terminal methionine. The 
mutant ACP had a 187 Da difference in mass from the WT ACP accounting for the 
two mutations made. Unfortunately, this result confirms that the mutated ACP is still 
not modified to its active form by the FAS II machinery in E. coli. This result also 
suggests the tryptophan residue doesn’t play a role in the activation of ACP. 
However, further studies into the acylation of E36G/W37A ACP and the differences 






Figure 3.45: FT ESI-MS of the Sw ACP E36G/W37A mutant apo-form. The top panel is the 
ion envelope of the 9+ to 5+ charge states of the ACP. The bottom panel shows the 





H NMR of the E36G/W37A ACP gave an indication of how the protein was 
folded in comparison to the wild-type Sw ACP (Fig. 3.46). No striking difference in 
NMR data confirms both the WT and the mutant ACP are folded. Dispersed peaks in 
the alphatic region (0 ppm-4 ppm) indicate methyl groups in amino acid side chains 
are buried in the hydrophobic core of a folded protein. The amide signal dispersion 
(6 ppm-10 ppm) supports the existence of secondary structure and confirms both 






















































































3.5.6 Post translational modification of apo-ACP  
Both WT and E36G/W37A Sw ACP require post-translational modification to 
produce the active form. Conditions were optimized by incubation of ACP with a 
specific PPTase, free CoASH/palmitoyl CoA in reaction buffer in attempt to transfer 
‘4-PP arm/C16 chain. In this particular study, B. subtilis Sfp was expressed and 
purified as Raman et al. found this to be the only PPTase that could transfer short 
acyl chains
44
. Additionally, a gene encoding a putative AcpS protein was found in 
the Sw genome. This plasmid was already available prior to the project and also used 
to determine how effective it was at catalysing the post-translational modification of 
apo-ACP.  
 
3.5.7 Expression and Purification of B. subtilis Sfp and S. wittichii 
AcpS 
Expression conditions were optimized in BL21 (DE3) competent cells for 5 
hours at 30 °C with 0.1mM IPTG. Sw AcpS (Mr = 15448 Da) and Bs Sfp (Mr = 
28373 Da) were C/N-terminally His6 tagged respectively and were purified by nickel 
affinity chromatography and analysed using SDS-PAGE (Fig. 3.47-A). Sw AcpS was 
further purified by gel filtration confirming it eluted in the void volume as 
aggregated protein (Fig. 3.47-B). 
 
Figure 3.47: (A) SDS-PAGE, Lane 1: LMW marker, lane 2: Sw AcpS, lane 3: Sw Sfp. (B) 




3.5.8 Modification of ACP 
Both the WT and E36G/W37A apo-ACP were incubated in reaction buffer 
with a PPTase (Sw AcpS or Bs Sfp), MgCl2 and CoASH/palmitoyl-CoA at 37 °C 
overnight. A range of PPTase concentrations and temperatures were used until 
optimum conditions were obtained. The modification was measured using ESI FT-
ICR. Sfp converted only E36G/W37A apo ACP to the holo-form, but could not 
transfer the C16 chain for both WT and the E36G/W37A mutant. Sw AcpS converted 
both wild-type apo ACP and E36G/W37A mutant to the holo form (Fig. 3.48), but 
also could not transfer the C16 chain. To this end it can be concluded that removal of 
the tryptophan residue of Sw ACP did not allow the conversion of apo- to C16-ACP.  
During this work, the crystal structure of ACP from Geobacter metallireducens 
(Gm) was published (PDB: 2KWM)
179
. This was interesting to this particular study 
as it also had a tryptophan residue directly before the DSL motif; however; no role 
for the tryptophan residue was discussed. Modelling studies of Sw ACP using Gm 
ACP as a template were carried out (Fig. 3.49). However, sequence alignments 
showed that Sw ACP only had 16% identity and 31% similarity with Gm ACP. It 
should be noted, that a good model would produce ~ 30% identitiy. It is important to 
appreciate the significance for the need of high sequence identity between proteins to 
understand how accurate a model is being produced. Ideally, Ramachandran plots 
should be used in conjunction to modelling as a way to assess and validate the 
quality of the model. This plot would give an indication of the empirical distribution 
of datapoints observed in a structure and the residues that cluster in regions of 
secondary structure to therefore give an insight into the overall conformation of the 
protein. Gm ACP is shown to be a poor model for Sw ACP with very low identity 
and therefore Ramachandran plot analysis was not carried out. However, Gm ACP is 
the only other ACP observed with a tryptophan directly before the DSL motif and 
thefore it was essential to carry out this sequence identity comparison. The crystal 
structure of Gm ACP shows a large hydrophobic cavity, which could bind bulkier 
acyl intermediates, and the location of the helices were found to be more similar to 
other acyl-ACPs with medium and long chains rather than other apo-ACP and holo-
ACP structures. Even though Gm ACP contains a tryptophan residue directly before 
the DSL motif, due to low sequence homology, this is shown to be a poor model for 
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Sw ACP; modelling programmes built the model by aligning α-helix II. Gm ACP is 
suggested to be involved in lipid A acylation, wherease Sw ACP is hypothesised to 
be invloved in sphingolipid biosynthesis, this may be a reason for Gm ACP being a 
weak model for Sw ACP. Even though both ACP’s have an unusual tryptophan 
residues before the DSL motif, no role has been assigned to this side chain. This 
analysis also implied that this tryptophan residue of Sw ACP had no specific role and 






Figure 3.48: ESI FT-ICR MS data A: 7+ charge state of apo-ACP with Sfp and Sw AcpS, 
inset shows the HPLC trace. B: The 7+ charge state of mutant apo-ACP with Sfp (~10% 





Figure 3.49: 3D model of Sw ACP using Swiss 3D model software
177
. Sw ACP was 
templated against Gm ACP (PDB: 2LML). The tryptophan residue next to the DSL motif is 
highlighted in red in a stick form. 
 
3.5.9  Analysis of Sw AcpS 
It is interesting to note that Sw AcpS purifies as an aggregated protein. 
However, it is still able to convert apo-ACP to holo-ACP yet cannot transfer any acyl 
chains from acyl-CoAs. This is the only AcpS gene in the Sw genome and its closest 
homologue is E.coli AcpS with 36% identity. Purifications of other AcpS enzymes 
(Streptomyces coelicolor AcpS) and a literature search presents information on the 
common trimer structure of AcpS from different organisms. By studying the resolved 
crystal structure of AcpS from B. subtilis (PDB: 1F80)
157
 and S. pneumonia (PDB: 
1FTE)
180
 it was deduced that the C-terminal His6-tag on the Sw AcpS may interfere 
with the protein folding into the expected trimeric structure. The structure of the 
AcpS trimer from S. pneumonia shows the C-termini of the AcpS monomers clash at 
the protein interface (Fig. 3.50). By comparing sequences of AcpS from several 
different organisms it is suggested that it is more common to follow a cloning 
strategy where the His6-tag is positioned at the N-terminus of the gene instead of the 
C-terminus. The mis-folding of the Sw AcpS could be resulting in the problematic 




Figure 3.50: The structure of Streptococcus pneumoniae AcpS (PDB 1FTE)
180
: each 
monomer is shown in a different colour (green, red, and yellow). The C-terminus of each 





3.5.10  Cloning of pET28a- S. wittichii AcpS 
A synthetic Sw AcpS gene was designed with NdeI and BamHI restriction sites 
and ordered from GenScript. The synthetic AcpS gene was ligated into a pET28a 
plasmid available in the lab. The AcpS gene was supplied in a pUC57 plasmid and 
was cut with the appropriate restriction sites. The pET28a plasmid contained a 
bcam2034 gene (1404 bp) that was cloned into the vector using NdeI and BamHI 
restriction sites. A restriction double digest was performed on both the 
pET28a/UGD2034 and pUC57 Sw AcpS plasmids. The reaction mixture was 
analysed by enzymatic restriction and the bands of interest, cut pET28a vector (5333 
bp) and cut Sw AcpS gene insert (411 bp) were gel extracted and ligated to construct 





Figure 3.51: Restriction enzyme analysis of Sw AcpS-pET28a using BamHI and NdeI. Lane 
1: hyperladder, lane 2-5: Sw AcpS-pET28a + BamHI + NdeI. Two bands are present in lanes 
2-5 corresponding to the Sw ACPS gene (411bp) and cut pET28a vector (5333bp). 
 
3.5.11 Expression and Purification of Sw AcpS 
The pET-28a Sw AcpS plasmid was used to transform BL21 (DE3) cells and a 
small-scale test expression was carried out in order to determine the optimum 
expression conditions using a range of IPTG concentrations, temperatures and 
incubation times. Induction with 0.1 mM IPTG and incubation at 20 °C for 5 hours 
was found to be the optimum expression conditions for Sw AcpS. Purification was 
carried out using a HisTrap (5 mL) column followed by gel filtration. Size exclusion 
purification resulted in the isolation of a broad and asymmetric peak corresponding 
to the expected mass of a trimer (~45kDa) (Fig. 3.52). Unfortunately, each 
purification lead to protein aggregation and after altering buffer composition was 
unable to produce protein that didn’t precipitate or present a symmetrical trimeric 
peak from gel filtration. This protein was active in converting apo- ACP to its holo-




Figure 3.52: Elution profile of Sw AcpS from S75 size exclusion column (A280 nm). 
 
3.5.12 Conclusion 
There were several failed attempts to acylate the apo Sw ACP with longer acyl 
chain lengths (C4-C16) and only extremely poor quantities were obtained with 
smaller chain lengths after utilizing several promiscuous PPTases (Bs Sfp and Sw 
AcpS) and optimizing conditions. Removal of a tryptophan residue (W37) located 
near the DSL motif of Sw ACP resulted in the purification of apo-protein, showing 
this mutant form of ACP also was not acylated to its active holo form by E. coli FAS 
machinery. Both Bs Sfp and Sw AcpS were able to modify the E36G/W37A mutant 
form of apo ACP to its holo-form but could not transfer a palmitoyl group (C16). It 
was thought that this was possibly unsuccessful due to a recognition problem 
between the ACP and the PPTase. Analysis of the Sw AcpS led to the hypothesis that 
the C-terminal His6-tag may be affecting the protein folding and resulting in 
aggregated protein. The Sw AcpS was re-cloned with an N-terminal His6-tag in 
attempt to express the protein in its expected trimeric form and thus, aid the C16 
acylation of the ACP. After optimisation of purification conditions Sw AcpS purified 
from size exclusion as a broad trimeric peak. However, each purification lead to 
protein aggregation and after altering buffer composition was unable to produce 
protein that didn’t precipitate or present a symmetrical trimeric peak from gel 
filtration. A future project could be to optimize these purification conditions in hope 
to purify stable trimeric protein. This would open the doors to having a better 
understanding of the Sw ACP:AcpS complex, possibly through a crystal structure. 
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Unfortunately, no further evidence has been provided to support the hypothesis that 
C16-Sw ACP is a substrate for SPT. 
This Sw ACP is difficult to characterize displaying only 28% as the highest 
sequence similarity to FAS type II M. tuberculosis ACP and 13% highest sequence 
similarity to PKS S. coelicolor ACP (Appendix 2). Attempts to acylate the well 
characterized E.coli ACP have been successful with chain lengths as high as C16 
(see section 3.7). There seems to be something unusual about the Sw ACP that is 
preventing acylation with longer chain lengths. After analysis of the S. wittichii 
genome it was observed that there are another two ACPs - A and B (Fig 3.53-A and 
3.53-B) in addition to the one discussed, (Fig 3.53-C). Both of these ACPs (A and B) 
have a 58% sequence identity against each other. However, analysis of both these 
sequences against the unusual Sw ACP (C) reveal an extremely low sequence 
identity of 21% and 24% with ACP A and B respectively (Appendix 3). Both of 
these Sw ACPs (A and B) also have a high sequence homology of 59% and 68% 
respectively against E.coli type II ACP in comparison to 25% observed with Sw 
ACP-C. It would be interesting and scope for a new project to clone, express and 
purify these ACPs to determine their post translational state. It would be interesting 
to try and acylate these with higher chain lengths (C16) and test them as a substrate 
for SPT with L-serine. This would further emphasise the unusual properties of the Sw 





Figure 3.53: S. wittichii genome annotation of other ACPs. (A) ACP-A annotated in red (B) 




3.6 Structural and Functional Analysis of Acyl Carrier Proteins 
 
The Sw ACP has proven to be unusual, with the highest sequence similarity of only 
27% after alignments against several members of type II FAS and 13% similarity 
after alignments against several members of PKS. Limited structural information is 
available for Sw ACP at present and the only successful analysis has been on the apo-
form using high resolution mass spectrometry techniques coupled with ID 
1
H NMR. 
Due to difficulties in acylating this particular ACP, other ACPs (E. coli, S. coelicolor 
and V. harveyi) have been successfully acylated and characterized using a novel Ion 
Mobility (IM) method to separate the different conformational forms (conformers) of 
the ACP. Ion mobility data allows us to calculate the rotationally averaged collision 
cross section (CCS) for each charge state of the intact ACP protein. Thus, by 
comparision of the CCS for different modified forms of ACP (ACP proteoforms), we 
can gain insight into how varying the acyl chain influences the overall structure of 
the protein. Work carried out by Rafferty et al, has shown the X-ray crystal structure 
of E.coli ACP in its apo-, holo- and acylated forms
150
. The acylated 
phosphopantetheinyl moiety (4’PP) is located within the hydrophobic cavity, formed 
by the four α-helical domains of the ACP. It is thought that the acyl chain growns 
inside a hydrophobic cavity and flips out using a ‘switch-blade’ mechanism to be 
extended by two carbon units by the enzymes of the FAS complex. Comparison of 
the hexanoyl-, heptanoyl-, and decanoyl- ACP structures reveal the volume of the 
protein increases as the length of the aliphatic chain increases, suggesting that the 
hydrophobic cavity increases in volume in order to accommodate the growing acyl 
chain 
150
. It is hypothesised that when the acyl chain reaches a critical length it can 
not be accommodated inside the hydrophobic cavity and the acyl chain will leave the 
cavity, becoming exposed, thus, causing a conformational change. A different 
concept has been proposed by Cronan. Instead of the “switchblade” which suggest 
energy input, Cronan prefers an “acyl flip” mechanism, where hydrophobic 
interaction governs the dynamics of the process (Cronan, personal communication). 
IM is an established technique for analysis of the shape and conformation of 
molecules. This technique can be coupled to mass spectrometry (MS) giving rise to 
analysis of both the mass to charge (m/z) and molecular shape of the species known 
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as a collision cross section (CCS). Along with using IM-MS, fragmentation 
techniques are also used here to understand if/how the acyl chain effects 
fragmentation of the protein and overall structure. 
 
3.6.1 Expression and purification of E.coli ACP 
The E.coli ACP cloned into pET22b with contains a C-terminus 6 histidine tag 
was kindly sent from Prof. Mike Burkhart (University of California, San Diego). The 
gene was amplified by PCR, analysed by agarose gel electrophoresis (Fig. 3.54-A) 
and sequenced. E.coli ACP was expressed in BL21 (DE3) cells and a small scale test 
expression was carried out to determine the optimum expression conditions. 
Expression was induced with 0.1 mM IPTG with incubation at 32 °C for three hours. 
Although the structures of ACPs from various organisms are highly conserved they 
all have very different properties and appear to run differently on SDS-PAGE (Fig. 
3.54-B). E.coli ACP was purified by nickel affinity chromatography followed by gel 
filtration. .  
 
Figure 3.54: (A) Agarose gel analysis of ACP constructs. Lane 1: hyperladder, lane 2-4: 
amplified E. coli ACP DNA product. (B) SDS-PAGE analysis of ACP purification, Lane 1: 
LMW marker, lane 2-6: fractions of non-monomeric peaks from size exclusion 





The post-translational status of the protein was analysed by direct infusion ESI-MS 
using “native” conditions (20 mM ammonium acetate buffer) in positive (Fig. 3.55-
A) and negative mode (Fig. 3.55-B). A mass of 9575.5 Da was measured 
corresponding to the theoretical mass (M+H)
+
 of the apo-ACP lacking the N-terminal 
methionine.  
 
Figure 3.55: ESI-MS of E. coli ACP in positive and negative mode (A) 70 µM Apo ACP in 20 
mM ammonium acetate pH 7.5, sprayed in positive mode, cone 65 V, capillary 1.6 mV. (B) 
70 µM ACP in 20 mM Ammonium Acetate pH 7.5, sprayed in negative mode, cone -65V, 
capillary -1.6 mV 
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 indicating there are two species present in the 
sample. The m/z of these peaks are similar to the expected m/z of acetyl-ACP (C2) 
with the same charge states as the apo ACP, suggesting a certain amount of ACP is 
modified in vivo by the E.coli endogenous machinery. The same sample was then 
analysed in negative mode (Fig. 3. 55-B). Due to the large number of acidic residues 
resulting in the low pI of the protein (4.1), the ACP sample sprayed more easily. 
 
3.6.2 Expression and purification of S. coelicolor AcpS and V. harveyi 
acyl-acyl carrier protein synthetase (AasS) 
S. coelicolor AcpS cloned into a pET15b plasmid and V. harveyi AasS cloned 
into a pET16b plasmid were used to transform BL21 (DE3) competent cells. 
Expression of Sc AcpS was induced with 0.1 mM IPTG and incubated at 30 °C for 5 
hours. Express of Vh AasS was induced with 0.1 mM IPTG and incubated at 30 °C 
for 3 hours. Sc AcpS (Mw = 14, 729) and Vh AasS (Mw = 60, 414) were purified by 
nickel affinity chromatography and analysed by SDS-PAGE (Fig. 3.56-A). Sc AcpS 
was further purified by gel filtration eluting as a trimer (Fig. 3.56-B). 
 
 
Figure 3.56: (A) SDS-PAGE analysis of Sc AcpS and Vh AasS, Lane 1: LMW marker, lane 





3.6.3 Modification of E.coli ACP 
For modification of apo-ACP with shorter acyl chain lengths (C4-C6) 
previously described methods
44
 were used. ACP was incubated with Sc AcpS, 
MgCl2, DTT, CoASH/C2-C6 CoA in 50 mM mmonium acetate reaction buffer at 37 
°C overnight. For the modification with longer chains (C8-C16), holo-ACP was 
incubated in 100 mM ammonium acetate reaction buffer, AasS, ATP, MgSO4, DTT 
and sodium myristate/palmitate (C14/C16). Concentrations of enzymes and reactants 
were varied until these optimum conditions were achieved. Acylation states were 
initially confirmed by MALDI MS (data not shown) and ESI-MS (Fig. 3.57) before 
IM experiments were carried out. All experimental and expected masses are 
tabulated in appendix 4. The spectrum of the C14 acylated ACP indicates that almost 
all the protein was converted to its acylated form using AasS. However, only 50% of 









Figure 3.57: ESI-MS of 50 µM ACP in 10 mM ammonium actetate buffer pH 7.5. (A) Holo-







3.7 Ion Mobility Mass Spectrometry of E. coli ACP 
IM-MS is a recent development in biophysical structural analysis that allows 
for the separation in two dimensions: on the basis of structure and ion neutral CCS 
and also on molecular mass which allows for differentiation between isobaric 
species
181, 182
. IM-MS data was collected on a modified quadrupole time-of-flight 
(MoQToF) mass spectrometer containing an additional 5.1 cm drift cell. Ion arrival 
time distributions were recorded at a drift voltage (DV), by synchronising the release 
of ions into the drift cell together with mass spectral acquirement. Ions are generated 
by soft ionisation nESI and then directed onto the ion drift cell (Fig. 3.58). The drift 
cell is formed by a stack of ring electrodes connected via resistors in series forming a 
voltage divider (see section 2.11 of materials and methods). This generates a uniform 
electrostatic field. The incorporation of a drift cell allows the separation of 
aggromers and isobaric conformer’s within corresponding m/z species. Ions of larger 
surface area experience more collisions with the neutral gas than smaller ions and 
therefore elute more slowly
164
. All IM-MS data were obtained by Eleanor Dickson 
and Leonora Fane-Saunders in a collaborative project with Dr. Perdita Barran. The 
acquired data was then processed using Microsoft Excel and Origin 7.5 (OriginLab). 
 
 
Figure 3.58: A block diagram of the primary components of biological IM–MS 
instrumentation. 
 
The ion arrival time distribution for each m/z was analysed by fitting Gaussian 
curves to the distribution in order to determine the number of different conformers 
present within each ion peak. The CCS from the different conformers was 
determined from a plot of the arrival time (ta) versus P/V, (see section 2.11 of 
materials and methods). The conditions under which each form of ACP was analysed 
are recorded in table 3.3. The CCS distribution was corrected for the intensity of the 
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peak allowing for a more accurate interpretation of the CCS distributions. The apo, 
holo and C8 acylated ACPs were analysed at different concentrations to understand 
if the concentration of the protein affected the charge state distribution. However, 




charge states suggesting 
the concentration of ACP has little effect on CCS (data not shown). 
 






















50 µM Apo ACP in 
10 mM Ammonium 
Acetate 




50 µM Holo ACP in 
10 mM Ammonium 
Acetate 




50 µM C4 ACP in 10 
mM Ammonium 
Acetate 




50 µM C6 ACP in 10 
mM Ammonium 
Acetate 




50 µM C8 ACP in 10 
mM Ammonium 
Acetate 




50 µM C14 ACP in 
10 mM Ammonium 
Acetate 




50 µM C16 ACP in 
10 mM Ammonium 
Acetate 




Table 3.3: Conditions under which each of the ACP samples were analysed using IM-MS  
 
All samples were analysed under native conditions using ammonium actetate 
pH 7.5 to try and preserve solution phase structure in the gas phase. From the charge 
state distributions of all forms of the E. coli ACP it can be confirmed the 6
+
 charge 
state is the most prominent and two different conformers exist within each ion peak. 
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Evaluation of the CCS of all three charge states are shown in appendix 5. 
Comparison of the CCS of all forms of ACP in the 6
+
 and charge state is shown in 
figure 3.54. Using 2-dimensional NMR data, it has been hypothesised that two 





 has also theorised that E. coli ACP exists in two conformers; 
a solvent-shielded conformation and a solvent-exposed conformation. The prosthetic 
linker containing the Ser-O-4’PP is known to be flexible, adopting different 
conformations which have been shown to be important in the mobility of the acyl 
chain attached to the ACP
152
. Figure 3.59 shows that all forms of the ACP, with the 
exception of apo-ACP seem to favour the more extended conformer (Fig. 3.59-(b)). 
However, as the chain length increases from C4 to C16 the amount of the compact 
conformation (Fig. 3.59-(a)) also increases. We interpret these results as the extended 
conformation, where the acyl chain is held inside the hydrophobic cavity and the 
compact conformer is where the acyl chain is outside the hydrophobic cavity. In the 
apo form the hydrophobic cavity is not filled with the prosthetic linker or an acyl 
chain and therefore collapses into a compact conformation. When the 4’PP arm is 
attached on Ser
36
 of the protein and acyl chains are added, the ACP can exist in two 
conformations; where the acyl chain is solvent exposed and where the acyl chain is 
buried inside the hydrophobic cavity. These results suggest that as the chain length 
increases from the holo-form to the C16-form, the acyl chain increasingly spends 
more time outside the hydrophobic cavity as it becomes more difficult to bury deep 
inside the cavity which shields from exposure to solvent. Indeed, it has been 
suggested by molecular dynamics that when the acyl chain is not buried inside the 
hydrophobic cavity it associates with one of the loops linking helices
152
. These 
results are particularly encouraging for using IM-MS as a method to probe the 
different acylation states of ACPs. The results show that the growing acyl chain 
affects the equilibrium between the two conformers of the ACP. There does not 
appear to be a critical chain length whereby the acyl chain is fully solvent exposed, 
instead it has an effect upon how deeply the acyl chain can be buried into the 
hydrophobic cavity. These conclusions support the fact that as the acyl chain length 




Figure 3.59: Intensity adjusted CCS distributions of the 6
+
 charge states of the apo, holo and 
C4/C6/C8/C14/C16 acyalted forms of E.coli ACP. The Y axis is intensity but in the IM-MS 
convention is not shown. 
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3.8 Fragmentation of E. coli ACP 
Mass spectrometry fragmentation is a technique used to gain information on 
the structural analysis of proteins in their native conformation. Electron capture 
dissociation (ECD) involves electron capture neutralization of a charge site on a 
multiple-charge ion resulting in formation of a radical cation forming c and z product 
ions (Equation. 6). Fragment ions retaining the positive charge at the amino terminus 
are named a-, b-, or c-type ions and fragment ions retaining the positive charge on 




 + e– → [M+nH]
+(n-1)• 
→ c and z product ions 
Equation 6 
 
ECD is used in conjunction with FT-ICR and allows for the determination of the 
location of post-translational modifications (PTMs) whilst conserving the overall 
fold of the protein in the gas phase. This is an excellent technique to use on ACPs as 
the process maintains the secondary structure whilst probing and identifying the 
dynamic regions in the protein. To date, this technique has been used to successfully, 
map ligand binding
183, 184
 and probe overall intact protein flexibility
132
. Rigid 
structural regions of the protein such as the 4 α- helix bundle should undergo little 
fragmentation due to a large amount of H-bonding. In contrast, unstructured regions, 
such as the flexible loops before and after the α- helix should undergo more 
fragmentation. Cleavage sites can then be mapped onto a fragmentation map of the 
known amino acid sequence and also to the previously determined X-ray crystal 
structure. Using this technique on apo-, holo- and acylated forms of ACP would give 
insight into how the growing acyl chain effect the dynamic regions of the protein. 
Preliminary data is displayed on fragmentation of apo (Fig. 3.60-A) and holo ACP 
(Fig. 3.60-B) using pNBA as a supercharging reagent. Different concentrations of 
ACP and pNBA were initially tested to obtain optimum fragmentation conditions. 
ECD of apo-ACP (Fig. 3.60-A(i)) looking at the isolated m/z: 1368, shows a 
fragmentation that can be mapped onto the unstructured loops of the E. coli ACP 
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crystal structure (Fig. 3.60-A(ii)). Fragmentation occurs at the conserved DSL motif 
located at the end of the highly structured helix II. Observing the isolated m/z: 1417 
of holo ACP (Fig. 3.60-B(i)) locates the serine reside (circled green) as the site of 
PTM. Fewer fragmentations are observed with holo ACP in comparison to the apo 
form suggesting the phosphopantetheine linker is in a location masking residues of 
the protein. Interestingly, no fragmentation occurs around the DSL motif after this 
serine residue has been modified. Now the conditions have been optimized, 
comparison of the fragmentation maps of the apo-, holo- and acylated forms of ACP 
should be carried out in order to understand and determine how larger acyl chains 








Figure 3.60: ECD fragmentation map and crystal structure of (A) apo E. coli ACP and (B) 





Even though the structures of various ACPs have been determined by NMR 
and X-ray crystallography, IM-MS offers an attractive complementary strategy for 
the native and dynamic structural analysis of these proteins. E.coli ACP was 
successfully expressed, purified and characterized in its apo-form. Successful 
expression and purification of Sc AcpS and Vh AasS allowed for the modification of 
apo E. coli ACP to its holo and acylated forms monitored by mass spectrometry. 
Using soft ionization nESI allowed for the tertiary structure of all forms E. coli ACP 
to be maintained. The charge state distribution showed little change between the 
different forms of the ACP suggesting that the different acylation states have a small 
effect on the structured nature of the protein and how conformationally flexible it is. 
Previous work based upon the structural analysis of the acylated forms of E. coli 
ACP have shown the growing acyl chain to be located in a hydrophobic cavity that 
expands in order to accommodate the developing acyl chain. Using IM-MS, arrival 
time distributions at a range of drift voltages were obtained for the different forms of 
ACP. These were then converted to CCS distributions showing that the ACP exists in 
equilibrium between two conformations, supported by molecular dynamics and 
fitting of NMR data. Apo-ACP favours the more compact conformation, when the 
hydrophobic cavity is empty it causes the 4-helix bundle to collapse. Addition of the 
4’PP linker and growing acyl chains result in the observation of both the compact as 
well as an expanded conformation. The presence of the acyl chain stabilizes the 
hydrophobic cavity and therefore prevents its collapse. We interpret this that the acyl 
chain spends most of its time inside the hydrophobic cavity and some of its time 
outside. As the acyl chain length increases it becomes more difficult to accommodate 
the acyl chain deep inside the cavity explaining why the compact conformer 
increases with chain length. Whether the acyl chain lies on a hydrophobic groove on 
the ACP surface or in an extended conformation is unclear. These experiments 
should ideally be repeated on a construct where the His6-tag has been removed from 
the ACP ensuring the results are more biologically relevent. The His-tag could have 
a possible effect on the CCS distribution. The construct has already been designed, 
expressed and purified (Appendix 6) laying the foundation for future analysis. ECD 
on apo and holo forms of E. coli ACP have shown the addition of the 
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phosphopantetheine linker effects the fragmentation of the protein. Conditions have 
been optimised and future work on the acylated forms of the ACP should be carried 
out. 
3.9 Overall Conclusions  
Working with the PLP-dependent enzyme serine palmitoyltransferase (SPT) 
has opened the doors to many exciting questions and projects. This work 
encompasses insights into the substrate specificity and inhibition of SPT from S. 
paucimobilis (Sp) together with probing the role of the essential PLP cofactor. Even 
though SPT and other members of the AOS family are extremely well characterised, 
little information from the crystal structures point to conceivable explanations for the 
exclusive substrate selectivity observed. Binding to SPT was studied by addition of 
the following amino acids: L-serine, L-alanine, glycine, L-threonine, β-chloro-L-
alanine, L-cysteine and L-penicillamine. Both aminothiols L-cysteine and L-
penicillamine that mimic L-serine are shown to be mechanism-based inhibitors of 
SPT. Inactivation was found to occur by disabling the PLP cofactor by forming a 
PLP:thiazolidine (TA) adduct. Interestingly, the PLP:TA adduct was stable in 
contrast to the adduct formed by the mechanism based inhibitor L-cycloserine
55
. 
Since, L-cysteine and L-penicillamine give rise to unsubstituted and substituted 
thiazolidines, respectively, that are tolerated in the active site there is now scope for 
structure-activity relationships investigating thiazolidines as potential inhibitors of 
SPT and other PLP-dependent enzymes involved in sphingolipid metabolism. This 
work also resulted in the development of a more gentle and efficient method to 
reversebly remove the PLP cofactor from SPT. This project tied in nicely with the 
hypothesis that an unexpected hydrogen bond interaction observed in Sp SPT 
between the hydroxyl L-serine substrate with the phosphate moiety of PLP could be 
playing a key role in substrate specificity and/or catalytic activity. SPT was 
regenerated with the dephosphorylated form of PLP, pyridoxal (PL) and a full kinetic 
and spectroscopic analysis was carried out. The results presented herein confirm that 
the contact observed between the 5’-phosphate of PLP and the L-serine hydroxyl 
plays an important role in quinonoid stabilization. The PL bound enzymes caused a 
negative effct on Cα rotation and therefore control of the optimum orientation of the 
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quinonoid intermediate to allow for subsequent deprotonation. This elucidation lends 
further weight on the ‘Dunathan hypothesis’ that bond being broken must be in a 
plane perpendicular to the   orbitals of the PLP electron sink.  
The residues interacting with the 5’-phosphate of PLP in the active site of 
members of the AOS family have been described in terms of a ‘phosphate binding 
cup’. Analysis of the phosphate binding cup of the ALAS:PLP:glycine external 
aldimine complex suggested that the SPT residue (Ala
295
) could possibly be 
responsible for the substrate specificity of this enzyme. In this work a single point 
mutation (A295T) has been incorporated into the SPT gene and has been expressed 
and purified. Preliminary studies suggest this mutant could be vital for substrate 
selectivity of SPT and emphasises the need for the PLP-phosphate, L-serine hydroxyl 
interaction in SPT. This work is a starting point that may help with the development 
of AOS enzymes with more relaxed substrate specificity. These preliminary results 
have paved the way for a full kinetic, spectroscopic and structural analysis that 
should be the start of an exciting new project. The PLP cup also proved useful in 
studying myriocin and revealed that the hydroxyl group of myriocin an position C2 
makes an important interaction with the 5’phosphate of PLP mimicking the PLP:L-
serine external aldimine. 
Three recently-discovered HSAN1 causing hLCB2 mutants have been 
mapped onto the soluble homodimeric bacterial SPT enzyme and successfully 
cloned. The impact of these mutations on PLP binding, SPT structure and activity 
were explored with reults ranging from; subtle alterations to how PLP sits within the 
SPT active site to lowering of substrate binding and catalytic activity through to a 
complete loss of solubility all brought about by a single change. Future studies on re-
cloning these mutations into a different plasmid to aid crystallization would lead to a 
better understanding on their structural impact. Exactly how these HSAN1 mutations 
cause the human hLCB1/hLCB2/ssSPT complex to lose its exquisite specificity for 
L-serine and also accept L-alanine and glycine to form deoxySLs will require in 
depth analysis of the human enzyme. Working with the membrane associated human 
enzyme has resulted in several difficulties that’s complexity has been added to by the 
elaborate organization of the protein. Although we are still far from solving the 
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crystal structure of the human enzyme, recent development into the improvement of 
the purification of of membrane bound proteins are evolving. 
SPT is not only an extremely important enzyme to understand but remarkably 
interesting. Work on SPT from S. wittichii (Sw) led to the hypothesis that an unsual, 
co-expressed C16-ACP could possibly be its substrate rather than C16-CoA. 
Unfortunately, Sw C16-ACP could not be tested as a substrate for SPT due to the 
many difficulties presented when trying to acylate the protein with several PPTases 
that were expressed and purified. It was thought that these difficulties could be 
arising due to either a) an unsual tryptophan residue located before the conserved 
DSL motif that could be blocking the transfer of a palmitoyl group or b) the C-
terminal His6-tag of Sw AcpS could be causing the protein to aggregate and therefore 
cause difficulties in ACP:AcpS recognition. The trypophan residue before the DSL 
motif was successfully mutated by site directed mutagenisis however this 
E36G/W37A mutant unfortunately didn’t solve the problem of transferring the 
palmitoyl chain onto the ACP. In another an attempt to unravel the Sw ACP mystery, 
the Sw AcpS was re-cloned with an N-terminal His6-tag in an attempt to express the 
protein in its expected trimeric form and thus, aid the C16 acylation of the ACP. 
Future work could be based upon optimising these purification conditions in hope to 
purify the stable trimeric protein. Furthermore, there are two other ACPs in the S. 
wittichii genome that should ideally be cloned, expressed and compared to this 
unusal ACP located directly before the SPT gene. 
 Finally, E.coli ACP was expressed, purified and characterized in its inactive 
apo-form, then successfully modified to its active holo and acylated forms by Sc 
AcpS and Vh AasS. A novel technique, IM-MS has been used to gain structural 
insight into the different forms of ACP. CCS distributions were calculated for 
different acylated states showing that the ACP exists in equilibrium between two 
states: a compact and an extended conformation. Apo-ACP favours the more 
compact conformation, whilst addition of the phosphopantetheine linker and growing 
acyl chains result in the compact conformation as well and an expanded 
conformation. This is an exciting and powerful strategy for structural analysis of 
proteins. As mentioned previously type II FAS and type I PKS have been shown to 
sequester the growing acyl chain on the outside of the protein instead of buried inside 
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the hydrophobic cavity like E. coli ACP. Purification of both rat ACP (type II FAS) 
and Streptomyces coelicolor ACP (type I PKS) has already been carried out, 
Appendix 7 and 8. This work paves the way for a comparison of ACPs of different 
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Figure A1: (A) Structure of the PLP:L-serine external aldimine intermediate of 
Sphingobacterium multivorum SPT (PDB code: 3A2B) (B) Phosphate binding cup diagram, 
(a) S273 (b) F114 (c) G113 (d) water (e) water (f) S243* (g) A274* (h) L-serine-hydroxyl 








Figure A2: Sequence alignments of Sw ACP against type I FAS (A) Conserved residues are 
coloured cyan and the DSL motif is coloured grey and PKS (B) Conserved residues are 






Figure A3: Sequence alignment of ACP’s in wittichii. ACP_1 and ACP_2 correspond to the 
other ACPs found in the wittichii genome, not cloned in this project. ACP_3 corresponds to 
the ACP expressed and purified throughout this study. Conserved residues are coloured 
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Figure A5: (A) Agarose gel analysis of XhoI/NdeI double digest of non his-tagged E.coli 
ACP/pET22b. Lane 1: hyperladder, lane 2-4: E. coli ACP/pET22b plasmid digested with XhoI 
and NdeI. (B) SDS-PAGE analysis, Lane 1: LMW marker, lane 2-3: fractions of non-
monomeric peaks from size exclusion chromatography, lane 4-7: E. coli ACP, fractions of 







Figure A6: (A) Small scale induction of S. coelicolor ACP (A) Lane 1: LMW marker,  
2:before IPTG induction, 3: 0.1 mM IPTG after 2h, 4: 0.25 mM IPTG after 2h, 5: 0.5 mM 
IPTG after 2h, 6: 1 mM IPTG after 2h, 7: 0.1 mM IPTG after 3h, 8:  0.25 mM IPTG after 3h, 
9: 0.5 mM IPTG after 3h, 10: 1 mM IPTG after 3h (B) SDS-PAGE analysis after size 
exclusion chromatography Lane 1: LMW marker, lane 2: fraction loaded onto the column 
lane 3-7: fractions of monomeric peak from size exclusion chromatography. 
 
 181 



























































































































































































































































Figure A8: (A) Agarose gel analysis of NcoI/BamHI double digest of rat ACP/pET28a. Lane 
1: hyperladder, lane 2-4: rat ACP/pET28a plasmid digested with NcoI and BamHI. (B) SDS-
PAGE analysis, Lane 1: LMW marker, lane 2-6: rat ACP fractions from anion exchange 
chromatography. 
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